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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
1.1 Background 
 
History 
Even half a century after their introduction β-lactam drugs are still the most widely 
prescribed antibiotics in medicine. Although anti-bacterial effects of molds had been 
reported and even investigated at least several times, the history of this class of 
drugs really began with their serendipitous discovery by Alexander Fleming (1881-
1955) in 1928 (Figure 1).[1],[2] Returning to his laboratory at St. Mary's Hospital in 
London after a short vacation, he observed a blue mold growing in a Petri-dish 
which originally had been overgrown with colonies of staphylococci. Around the 
mold there was a halo within which no bacterial colonies were growing. The mold 
evidently had produced a lethal substance, which diffused outward through the 
culture media, thereby killing bacteria wherever they were present. Fleming learned 
that the medium containing the anti-bacterial substance, which he named penicillin 
after the mold Penicillium notatum, was not toxic to laboratory animals.[1],[3] 
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Alexander Fleming (1881-1955). 
Figure 1. 
 
The priority of other duties at the hospital prevented further scrutiny of his 
observations. Moreover, the advent of sulfa drugs led to a general disinterest in 
Fleming's first disclosure. It was not until 1938 that penicillin came under renewed 
investigation by Walter Florey and Ernst Boris Chain at Oxford University.[4] They 
confirmed Fleming's results and succeeded in the isolation of an impure material 
with unique potent killing power towards certain germs in test animals. In 1942, 
Chain produced penicillin G (1), a yellow powder, which was successfully used by 
Fleming against meningitis (Figure 2). By that time, Florey had visited the United 
States where plans were set up for the industrial production of penicillin by Merck, 
Pfizer, and Squibb, supported by the federal government.[5] This heavily subsidized 
research and production in a relatively short time, led to the large-scale manufacture 
of penicillin. Sufficient large quantities of penicillin became available for 
administering to wounded soldiers on the battlefields. In 1943, a British radio 
broadcast on the invention of a remarkable medicine aroused the attention of 
researchers at Gist-brocades (at that time named "Nederlandsche Gist- en 
Spiritusfabriek"). This news, in combination with information from scarcely 
available literature was the start of a research program which led to the development 
of several penicillin-derived drugs and intermediates.[6] After World War II, it 
became clear that an astonishing 95% of soldiers with infection injuries had survived 
thanks to medication with penicillin. In 1945, Fleming, Chain, and Florey were 
jointly awarded the Nobel Prize in physiology and medicine for their discovery of 
penicillin G. 
 
Introduction 
 
 
3  
N
S
O
N
H
O
CO2H
O
N
S
O
N
H
O
CO2H
penicillin G penicillin V1 2  
Figure 2. 
 
In this early period of penicillin, considerable effort was devoted to fundamental 
aspects of the chemistry of penicillin G. Studies in Britain and the United States soon 
revealed the existence of more compounds with penicillin activity. In 1949, when the 
structure of penicillin G (1) was finally elucidated by Dorothy Crowfoot-Hodgkin,[7] 
it was found that these compounds had the same general structure as penicillin but 
with different side chains. It soon became apparent that these penicillins could not 
be easily synthesized on a large scale. However, the use of various biosynthetic 
procedures in a well-considered way gave access to a large variety of penicillins. In 
1957, after nine years of scrutinizing work, John C. Sheehan and K.R. Henry-Logan 
completed the total synthesis of penicillin V (2) (Figure 2).[8] The isolation of 6-
amino-penicillanic acid, the β-lactam nucleus of both penicillin V and G, by scientists 
from Beecham in 1957, was a major contribution to the development and production 
of semi-synthetic penicillins.[9]  
 
Another important milestone in the search for new β-lactam antibiotics has been the 
discovery by Abraham and Newton[10] at Oxford in 1953 that a fungus of the genus 
Cephalosporium produces a number of potent antibiotics, among which cephalosporin 
C (3) (Table 1). Great interest arose when it appeared that this antibiotic showed 
broad-spectrum activity. It was active against both Gram-positive and Gram-
negative bacteria, it was inert towards hydrolysis by certain penicillinases, and it 
had a similar low toxicity as the penicillins.[11] The discovery of the cephalosporins 
opened a new field of research aimed at the search for and exploration of more 
active and different anti-bacterial compounds. As the penicillins and cephalosporins 
are chemically sensitive compounds, chemical progress in this field of antibiotics has 
depended heavily on the use of modern analytical and purification techniques and 
on the development of more selective reagents and protecting groups. A 
considerable boost to the chemical morale of synthetic chemists working in this field 
was given by Woodward's total synthesis of cephalosporin C (3).[12]  
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Table 1. Important early cephalosporins. 
R: R': name: nr.: year of discovery: 
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CH2OAc cephalosporin C 3 (1953) 
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CH2OAc cephalotin 4 (1962) 
     
O
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CH3 cephalexin 
 
5 (1967) 
     
O
NH2
 
Cl cefaclor 6 (1974) 
 
 
Modern large-scale fermentation methods have enabled penicillin production to 
reach a level of more than four thousand tons annually. As a consequence, 
penicillins can now be regarded as a commercially available synthetic bulk 
intermediate for other, more sophisticated β-lactam antibiotics. Since the 
cephalosporins are generally more expensive to produce than the penicillins, 
numerous chemical studies have been performed to achieve economical conversion 
of penicillins into the cephalosporins. Such transformation requires an oxidation of 
one of the methyl groups of penicillin and a ring expansion of the thiazolidine 
moiety. These stringent requirements were eventually fulfilled in a novel process 
originally described by Morin et al..[13] After this breakthrough, the chemistry of 
cephalosporins developed rapidly and very soon a large variety of cephalosporins 
became available on an industrial scale.  
 
In 1962, combined synthetic efforts led to the first semi-synthetic cephalosporin 
cephalotin (4), which was remarkably active against penicillin-resistant 
Staphylococcus. Further developments within the cephalosporin family resulted in 
orally active formulations, e.g. cephalexin (5) and cefaclor (6) (Table 1). The synthesis 
of the latter compound is a brilliant tour de force in synthetic organic chemistry. 
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Mode of action and mechanism of resistance of penicillin-type antibiotics 
The cell-wall of bacteria partly consists of peptidoglycan, which is essential for the 
stability of the cell-wall. The final step in the cell-wall synthesis in bacteria is the 
formation of peptide cross-links between adjacent glycan chains (formation of 
peptidoglycan). The formation of the peptide cross-links involves an unusual type of 
peptide formation, called transpeptidation. This transpeptidation is inhibited by β-
lactam antibiotics, and thus an imperfect, weakened peptidoglycan is formed 
leading to death of the growing bacteria (Figure 3). When the formation of the cell-
wall, catalyzed by autolysins, continues, further weakening of the cell wall damage 
leads to osmotic lysis, followed by death.[14] 
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Figure 3. Transpeptidase inhibition by a penicillin molecule.. 
 
In spite of the therapeutic success of the early β-lactam antibiotics, the anti-bacterial 
activity of the first-generation drugs against certain Gram-negative "problem germs" 
was not sufficient. Already a few years after the second world war, strains of 
Staphylococcus aurus had emerged that were immune to penicillin.[15] Since then, 
bacterial resistance towards antibiotics has spread and has become a serious threat to 
humanity. Bacteria have developed several creative mechanisms for protection 
against antibiotics and are even capable of passing the genes responsible for the 
resistance to other bacteria.[15] A defense mechanism active against β-lactam 
antibiotics utilizes β-lactamases, which are enzymes that hydrolyze the β-lactam ring 
of the antibiotic.[16] As the β-lactam ring is the bioactiphore of both penicillins and 
cephalosporins, these antibiotics become inactive.  
 
The methicillin-resistant Staphylococcus aurus (MRSA) is a notorious example of a 
highly dangerous bacteria strain.[17] This strain is resistant to all β-lactam antibiotics 
due to the presence of an additional penicillin-binding protein (PBP2a) for which β-
lactams have a high affinity.[18] Vancomycin[19] and Synercid[20] are the only 
marketed drugs that are effective against MRSA infections. In addition to the 
complications caused by the restricted options for treatment, vancomycin-resistant 
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MRSA[21] has recently been detected in hospitals in Japan[22] and the USA.[23] 
Furthermore, the hospital setting is no longer the exclusive domain of MRSA 
infections. Recently, there have been alarming reports of its spread in nursing 
homes, extended-care facilities, and a day care center.[24] The problem of resistance is 
dramatically enhanced by inappropriate and uncritical prescription by medical 
doctors, incorrect usage of the antibiotics by patients, and the excessive use of 
penicillins in animal feeding.  
 
Possible solutions for the resistance problem 
A provisional solution for the β-lactamase problem is using a combination of the 
antibiotic and the potassium salt of clavulanic acid (9) (Figure 4). Although 
clavulanic acid is not very effective as an antibiotic, it inhibits the activity of β-
lactamases. In combination with β-lactamase-sensitive penicillins and 
cephalosporins, clavulanic acid therefore causes a distinct increase in the activity of 
these antibiotics. It can be expected, however, that bacteria also will adapt rapidly to 
this combination drug as well.  
 
Another conceivable solution to the problem of persistent resistance can be the 
responsible prescription for the use of antibiotics. Bacterial which have developed a 
resistance towards certain antibiotics, also have acquired a more complex 
metabolism. Due to the extra genetic luggage inherent to the additional metabolism, 
resistant bacteria will loose their resistance to an antibiotic when they are no longer 
exposed to it. This process is essentially the same as the evolutionary process that 
made them resistant. Therefore, the abovementioned tools are important to solve the 
resistance problem to an extent that many antibiotics will continue to serve as life-
saving drugs during the 21st century.  
 
Many companies are looking for novel classes of anti-bacterial agents. An effective 
strategy to discover compounds with activity against resistant organisms involves 
synthetic modulation of a known class of anti-bacterial agents with pronounced 
activity.[25] Since cephalosporins have an excellent safety profile and are synthetically 
accessible from commercial sources, the development of new derivatives of these 
compounds is a very promising avenue for the identification of anti-MRSA agents. 
Recent numbers on drug prescription in US show that β-lactam antibiotics are still 
widely used in medicine. Therefore, the search for new cephalosporin antibiotics 
remains a profitable issue for the pharmaceutical industry (Figure 4). The 
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combination of combinatorial chemistry, chemistry on the solid support, and high 
throughput screening catalyzes this search for new pharmaceuticals.[26] 
 
Figure 4: β-Lactam antibiotics in the top 200 prescriptions in the US.[27] 
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As is evident from the top 200 prescriptions in the United States (Figure 4), the first 
generation antibiotics (e.g. penicillin V (7), amoxicillin (8), cephalexin (5)) as well as 
the second and third generation cephalosporins (e.g. cefaclor (6), cefixime (11), 
cefprozil (8)) are still very important antibacterial pharmaceuticals. 
 
Since an ideal antibiotic will probably never be found, the war against infectious 
diseases goes on, in which new chemical entities will be thrown into the fray. New 
anti-bacterial agents need to be cheap, effective, and non-toxic. Although in recent 
years the worldwide incidence of antibiotic resistance among Gram-positive 
bacteria, e.g. Staphylococcus, Streptococcus and Enterococcus species, has increased, 
major interest is still focused on the development of novel cephalosporin antibiotics 
in order to improve anti-bacterial activity against resistant bacterial strains.[28] In this 
respect, it should be emphasized that also the development of new synthetic 
methodologies and new reactions in the field of penicillin and cephalosporin 
chemistry is of extreme importance, to enable the synthesis of new entities in this 
field.  
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1.2 Aim of the research and outline of the thesis 
 
In 1994, DSM Research and Gist-brocades started the joint-venture Chemferm, which 
in 1996 initiated the so-called Cluster Project "Fine-Chemistry", a cooperation 
between four universities and Chemferm. One of the main objectives of this project 
was to develop improved, or alternative clean, (bio)catalytic, efficient routes for 
cephalosporin β-lactam antibiotics.  
 
The research described in this thesis is focused on the chemical modification of β-
lactam nuclei. In the first phase of the project, most attention was paid to the search 
for new (green) syntheses or shortcuts for 7-ACCA, the β-lactam core of cefaclor (6) 
(Figure 4), from readily available fermentation products. As a consequence of new 
insights and developments, as well as of different views of industrial importance, the 
aims were adjusted to a focus on the chemistry of 3-formylcephalosporins as a 
versatile class of β-lactam nuclei.  
 
Nature itself is capable of synthesizing 3-formylcephalosporins as part of the 
metabolism of Cephalosporium acremonium (see Chapter 2, Section 2.2). In principle, 
by blocking or changing the sequel steps by molecular pathway engineering, 
isolation of 3-formylcephalosporins in large quantities can be envisaged. By means 
of this environmentally benign bio-approach, a green process for the production of 
3-formylcephalosporins might be an opportunity in the future. In view of these 
"green" prospects of 3-formylcephalosporins, its chemistry fits well in the objectives 
of the cluster project (vide supra). Until now, the 3-formylcephalosporins are only 
accessible using complicated, multi-step procedures (Chapter 2). The above-sketched 
green future prospects are a clear stimulus for the development of new chemistry on 
the basis of 3-formylcephalosporins as the key-intermediates, as is described in this 
thesis.  
 
Three main objectives can be recognized for this part of the project. 
 
• Finding short, high yielding synthetic routes towards the key-intermediates, 
3-formylcephalosporins, from readily available and cheap β-lactam nuclei. 
• Exploring the chemistry of 3-formylcephalosporins in order to find 
alternative, more economical synthetic routes to antibiotics, which have 
already been commercialized. Special attention is paid to the use of Barton's 
radical decarboxylation methodology in the cephalosporin system.  
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• Using the acquired knowledge of cephalosporins for the synthesis of new and 
interesting β-lactam antibiotics. 
 
In Chapter 2, an overview of the syntheses of 3-formylcephalosporins and their use 
as advanced intermediates in the syntheses of building blocks for β-lactam 
antibiotics will be given. In Chapter 3, a new synthetic methodology is described for 
the preparation of 3-formylcephalosporins from starting materials readily available 
by fermentation, viz. 7-aminodesacetylcephalosporanic acid (7-ADCA), 7-
aminocephalosporanic acid (7-ACA), and cephalolactone. In Chapter 4, a synthetic 
study concerning the preparation of 3-norcephalosporins from 3-
carboxycephalosporins, employing Barton's radical decarboxylation reaction, is 
presented. The application of a halo-decarboxylation reaction at C4, using the model 
substrates 7-phenylacetyl-ADCA and 7-phenylacetyl-ACA, is discussed in detail. In 
Chapter 5, 3-formylcephalosporins are converted into the corresponding 3-
carboxycephalosporins via a new procedure. These 3-carboxycephalosporins are then 
subjected to Barton's radical decarboxylation reaction to produce the corresponding 
3-norcephalosporins, applying the optimum conditions established with the model 
compounds as described in Chapter 4. The results of the radical decarboxylation 
reactions for both the model compounds (carboxylate at C4) and the C3-carboxylates 
are evaluated in terms of structural differences. One of the objectives was the 
synthesis of 7-ACCA, the nucleus of cefaclor. This compound could indeed be 
synthesized from 3-carboxycephalosporins employing Barton's radical 
decarboxylation procedure. In Chapter 6, the behavior of 3-formylcephalosporins in 
Wittig-type olefinations is investigated. Chapter 7 is devoted to the 
diastereoselective Barbier-type organozinc additions to 3-formylcephalosporins, 
yielding new advanced and promising intermediates for the synthesis of novel β-
lactam antibiotics. 
 
Summaries in English and Dutch conclude this thesis. 
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SYNTHESIS AND APPLICATIONS OF 
3-FORMYLCEPHALOSPORINS:  
AN OVERVIEW OF THE RELEVANT LITERATURE 
 
 
 
 
 
 
 
 
 
 
2.1 Introduction 
 
This chapter contains a literature overview relevant for the research described in the 
following chapters. The formyl group at the 3-position of the cephalosporin nucleus 
is highly instrumental in the synthesis of a large variety of cephalosporins with 
structural modifications at C3 (Figure 1). In this review, various aspects of the 
chemistry of these key-intermediates are covered. First, all reported syntheses of 3-
formylcephalosporins are described. The second part deals with applications and 
reactions of 3-formylcephalosporins. Especially the chemistry of the 3-formylgroup 
is discussed. In general, protection-deprotection steps are only mentioned when 
important. 
S
N
O
R'HN
CO2R
CHO
3-formylcephalosporins
1
2
3
4
7
 
Figure 1. 
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2.2 Synthesis of 3-formylcephalosporins  
 
In the late 60s the first synthesis of a 3-formylcephalosporin has been reported.[1],[2] 
In the famous total synthesis of cephalosporin C by Woodward et al.[1] 3-
formylcephalosporin 4 constitutes an important intermediate. In this synthesis, β-
lactam 1 was condensed with dialdehyde 2 to afford adduct 3, which, on treatment 
with trifluoroacetic acid was transformed to aminoaldehyde 4 (Scheme 1).  
S
N
O
NH2
CO2CCl3
CHO
N
O
CO2CCl3
SRN
O
H
O
R = Boc
OO
HH
OH CO2CCl3
+
NH
O
SRN
1 2 3 4
a b
 
a) n-octane, 80°C; b) TFA. 
Scheme 1. 
 
The authors wrote: "this sensitive intermediate (aldehyde 4) was used in subsequent 
reactions without extensive purification". This was the start of numerous studies 
aimed to use these sensitive 3-formylcephalosporins for the syntheses of novel types 
of β-lactam antibiotics with other or better anti-bacterial properties. 
 
Most reported syntheses involve, at the same stage, deacetylation of the acetoxy 
group at C3 (e.g. of 5) using citrus acetylesterase (Scheme 2).[3] Cautious acidification, 
followed by extraction into an organic solvent and subsequent treatment with 
diazomethane, leads to methyl ester 6, which was contaminated with some lactone, 
in 65-75% yield.[2] 
S S
N
O
N
H
CH2OAc
O
CO2Na
S S
N
O
N
H
CH2OH
O
CO2Me
S S
N
O
N
H
O
CO2Me
CHO
O
O
S S
N
O
N
H
O
CO2Me
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a,b c
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a) citrus acetylesterase; b) CH2N2; c) MnO2; d) ethylene glycol, acid. 
Scheme 2. 
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Oxidation of the hydroxymethyl group with manganese(IV) oxide gave aldehyde 7 
in only 17% yield, which was converted directly into the ethylene acetal 8. Attempts 
to hydrolyze aldehyde 7 to the free acid were unsuccessful. The corresponding 
thioketal was synthesized from 7 by reaction with dimercapto ethane in 86% yield.[4] 
 
An alternative synthesis of 3-formylcephalosporins by Peter et al.[5] is outlined in 
Scheme 3. The synthesis starts from the 3-substituted hydroxymethyl compounds 9 
or 10, which can be obtained by a route similar to that depicted in Scheme 2. 
Attempts to oxidize the hydroxyl group in 10 with chromium(VI) oxide and acetic 
acid or manganese(IV) oxide in dichloromethane failed, because the diphenylmethyl 
ester was not inert under the reaction conditions. Only the Moffat oxidation 
(DMSO/acetic anhydride or DMSO/benzoic acid anhydride) successfully led to 
aldehydes 11 and 12. The yields ranged from 30 to 90%.  Depending on the substrate 
a small amount of the corresponding ∆2-isomer 13 may be formed as well.  
 
S
N
O
RHN
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CO2CHPh2
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RHN
CO2CHPh2
CHO
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N
O
RHN
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CHO
R = O
NHBoc
S
N
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RHN
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RHN
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CO2H
S
N
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RHN
CO2H
CHO
9a,b 10a,b
11a,b 12a,b
13a,b 14a,b 15a,b
a
b
c 
d
O
a
b
 
a) DDQ or CrO3, H2SO4; b) Ph2CN2; c) DMSO, Ac2O or DMSO, (PhCO)2O or CrO3, pyridine; d) TFA. 
Scheme 3. 
 
Later, it turned out that also the Collins method (chromium(VI) oxide/pyridine) 
leads to the corresponding 3-formylcephems. The formation of hydroxylactones 15 is 
a competitive reaction in the ∆3-systems 14, which are obtainable from 12. In the ∆2-
series (viz. 9 to 13) such lactonization can not occur. Good yields of 11 were obtained 
from 9 with dichlorodicyanoquinone (88%) or chromium(VI) oxide/sulfuric acid 
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(Jones oxidation; 70% yield) as the oxidizing reagents.[1] Esterification with 
diphenyldiazomethane afforded smoothly the 3-formylceph-2-ems 13 (Scheme 3). 
 
More recently, the abovementioned ∆3-alcohols 10 were efficiently oxidized with IBX 
(1-hydroxy-1,2-benziodoxol-3(1H)-one 1-oxide) in DMSO to give the corresponding 
aldehydes 12a and 12b in excellent yields of 91% and 94%, respectively.[6] 
 
Webber et al.[7] also used the Jones oxidation for the transformation of alcohol S-
oxide 16 into the corresponding aldehyde 17, in an excellent yield of 98% (Scheme 4). 
 
S
N
O
RHN
CHO
O
CO2tBu
S
N
O
RHN
O
CO2tBu
OH
O
NHBoc
R = 
16 17
a
 
a) CrO3, H2SO4. 
Scheme 4. 
 
Only one example was reported in which the well-known Swern oxidation is 
employed for the preparation of a 3-formylcephalosporin. Nagano et al.[4] obtained 
∆3-aldehyde 19 from the corresponding alcohol 18 in 73% yield (Scheme 5). This 
example is rather unique, as no other groups use the Swern oxidation for such 
transformation in the cephalosporin system. 
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N
O
N
H
OH
CO2CHPh2
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O
S
N
O
N
H
CO2CHPh2
CHO
O
O
18 19
a
 
a) oxalyl chloride, Et3N, DMSO. 
Scheme 5. 
 
Nature is also capable of synthesizing a 3-formylcephalosporin.[8] The three final 
steps in the biosynthesis of cephalosporin C (24) in Cephalosporium acremonium 
involve sequentially: (a) the oxidative ring expansion of penicillin N (20) to 
deacetoxycephalosporin C (DAOC; 21a), (b) the hydroxylation of DAOC 21a to 
deacetylcephalosporin C (DAC; 21b), followed by (c) the acetylation of DAC 21b to 
cephalosporin C (24) (Scheme 6). Fujisawa and co-workers have reported the 
generation of mutants, derived of C. acremonium ATCC 14553, in which the terminal 
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acetyl transfer was blocked. As a result, accumulation of DAC 21b was observed in 
the culture broth.[9] Eventually, a new metabolite, viz. aldehyde 23, was isolated from 
one of the mutants defective in the acetyl transfer step.[10] During the formation of 
22, the enzyme deacetoxycephalosporin C / deacetylcephalosporin C synthase 
(DAOC/DAC synthase) is apparently capable of oxidizing DAC 21b to the 3-
formylcephalosporin 22. A spontaneous non-enzymatic hydrolysis of 22 leads then 
to ring-opened aldehyde 23 (Scheme 6). 
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R
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CO2H
S
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R
CO2H
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2324
a  R' = H
b  R' = OH
a
b c
a
penicillin N,
 
a) DAOC/DAC synthase; b) DAC O-acetyltransferase; c) non-enzymatic hydrolysis. 
Scheme 6. 
 
3-Formylcephalosporins are also accessible through oxygen or air oxidation of 3-
iodomethylceph-3-ems 25a-c applying rhodium(III) chloride in a catalytic fashion in 
the presence of aluminum powder in DMF, affording 26a-c in isolated yields up to 
66% (Scheme 7).[11] The reaction can also be carried out in an autoclave under an 
oxygen atmosphere in DMF.[12] 
 
S
N
O
RHN
CO2R'
CHO
R = 
O
S
N
O
RHN
CO2R'
I
R' = a  p-MeO-benzyl
b  p-NO2-benzyl
c  CHPh2
25a-c 26a-c
a or b or c
or d or e
 
a) RhCl3, O2, Al, DMF; b) O2, DMF; c) VOSO4, VO(acac)2, O2, Al; d) NaI, MeOH, CH2Cl2; e) NMP, O2, 
phosphomolybdic acid. 
Scheme 7. 
 
When the reaction was performed with at least an equimolar amount of vanadyl 
sulfate or vanadyl acetonate, similar yields of 26 were obtained from 25.[11] Without 
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such a catalyst, but under an oxygen atmosphere in the presence of sodium iodide 
dissolved in a methanol-dichloromethane solvent mixture, the dimethyl acetal of 
aldehyde 26a was formed in 40% yield at the maximum.[13] It is assumed that the 
reaction proceeds via a hypervalent iodine species. 
 
Tanaka et al.[14] reported an aerobic oxidation of 3-iodomethylcephalosporin 25a in 
N-methyl-pyrrolidone (NMP) in the presence of phosphomolybdic acid (22 wt%). 
The corresponding 3-formyl compound 26a was obtained in a moderate yield of 
54%.  
 
Catalytic oxidation methods are of great interest for industrial applications and 
accordingly also for the syntheses of 3-formylcephalosporins. Bruno et al.[15] claim an 
effective method (>90% yield) for the oxidation of the hydroxymethyl group in 
cephalosporins e.g. 9 using TEMPO 27 as the catalyst (Scheme 8). 
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a) NaOCl, CH2Cl2, KBr. 
Scheme 8. 
 
A completely different approach, starting from the readily available cephalosporin 
lactones 28, was used to synthesize 3-formylcephalosporins 12 (Scheme 9).[16]  
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a) TMSCl, Et3N, DMF; b) Br2; c) DMSO; d) Ph2CN2. 
Scheme 9. 
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Cephalosporin C10-bromolactones 29 were prepared in good yields (73-78%) via in 
situ silylation of 28 at the C10-position, followed by bromination with molecular 
bromine. Conversion of 29 into the hydroxylactone 15 was achieved smoothly in 
quantitative yield by stirring it in a DMSO solution at room temperature. Treatment 
of the hydroxylactone 15, which is in equilibrium with its open aldehyde 14, with 
diphenyldiazomethane afforded aldehyde 12 in 81-98% yield. The hydroxylactones 
have also been synthesized directly from 3-hydroxymethyl cephalosporins, which 
possess a free carboxylate at the C4 position.[17] In this patent, the hydroxymethyl 
group is oxidized with a hexavalent chromium compound. 
 
 
2.3 Reactions with 3-formylcephalosporins   
 
2.4 Removal of the 3-formyl group  
  
Removal of the 3-formyl group in order to synthesize 3-norcephalosporins can be 
accomplished by direct decarbonylation, or by performing a Baeyer-Villiger 
oxidation. 
 
Aldehydes 11 and 12 were successfully decarbonylated with Wilkinson's catalyst 
(tris-triphenylphosphosphine rhodium chloride) in benzene at reflux temperature, 
affording the parent cephalosporin skeletons 30 and 31 in excellent yields of 80-90% 
(Scheme 10).[1] Also platinum metal complexes, capable of taking up carbon 
monoxide, were used for this purpose.[18] 
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a) Wilkinson's catalyst, benzene, reflux. 
Scheme 10. 
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A second method for removing the formyl-group at C3 involves a Baeyer-Villiger 
reaction (Scheme 11).[19] 3-Formylcephalosporins 12 was treated with a peracid and 
the resulting 3-formyloxycephem 32 was converted into 3-hydroxycephem 33 by 
hydrolysis, preferably in the presence of a basic agent.  
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CO2CHPh233b  
a) peracid; b) H2O, base. 
Scheme 11. 
 
The thus formed cephalosporin 33, in principle, can be used for the synthesis of the 
commercially important β-lactam antibiotic cefaclor. For this purpose, the hydroxyl 
group at C3 is substituted by a chlorine, e.g. with PCl5. Depending on the nature of 
the peracid, also the corresponding S-oxide has been isolated as a byproduct. 
 
 
 
2.5 Oxidation of the 3-formyl group:  
synthesis of 3-carboxycephalosporins  
 
The conversion of the 3-formyl group into the 3-carboxy group is not as 
straightforward as it seems, as the first synthesis reported involves at least four 
separate steps (Scheme 12).[20] Reaction of 3-formylcephalosporin 34 with ethylene 
glycol gave 35 in quantitative yield. Treatment of this ethylene acetal 35 with NBS 
under radical conditions gave β-bromoethyl ester 36 in 45-55% yield, which was 
converted into the corresponding β-iodoethyl ester in a reaction with sodium iodide 
in acetone in 95% yield. Finally, hydrolysis of the β-iodoethyl ester with zinc in acetic 
acid, gave 3-carboxyceph-2-em 37. 
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a) ethylene glycol, acid; b) NBS, AIBN; c) NaI, acetone; d) Zn, acid. 
Scheme 12. 
 
Substituted esters of 3-carboxycephalosporins have also been obtained directly from 
aldehyde 11 (Scheme 13).[21] Treatment of 11 with of a catalytic amount of sodium 
cyanide afforded the cyanohydrin 38. Subsequent in situ oxidation of 38 with 
manganese(IV) oxide gave intermediate 39, which in the presence of the appropriate 
alcohol released cyanide to produce esters 40a-c. Protection of the C4 carboxylic acid 
function with diphenyldiazomethane gave esters 41a-c in overall yields ranging 
from 36 to 79%. 
 
S
N
O
RHN
CHO
CO2H
R = S
N
O
RHN
CO2R'
CO2H
O
S
N
O
RHN
OH
CN
CO2H
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a) NaCN, R'OH, MnO2; b) Ph2CN2. 
Scheme 13. 
 
The bromoethyl ester 41c can be used as an advanced intermediate in the synthesis 
of 3-carboxycephems, as has been illustrated in Scheme 12 (vide supra). 
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2.6 3-Formylcephalosporins as intermediates in the synthesis of 
fluorinated compounds  
 
In the synthesis of fluorinated cephalosporins, 3-formylceph-3-em 12 has been used 
as the key-intermediate (Scheme 14).[22]  
S
N
O
N
H
CHO
CO2CHPh2
O
S
N
O
N
H
CHF2
CO2CHPh2
O
12 42
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a) piperidinosulfur trifluoride; b) diethylaminosulfur trifluoride. 
Scheme 14. 
 
Aldehyde 12 was treated with an excess of piperidinosulfur trifluoride (PST) or 
diethylaminosulfur trifluoride[23] at room temperature affording crystalline 42 in a 
moderate yield of 45%. 
 
 
2.7 Addition of amine-compounds to 3-formylcephalosporins  
 
Hydroxyl amine is one of the first amine compounds that has been used in a reaction 
with 3-formylcephalosporins. In the past, the reaction of hydroxylamine with β-
lactam antibiotics, which generally results in rapid cleavage of the β-lactam ring, was 
used as a chemical assay method.[24] Nevertheless, aldehyde 43 could be converted 
into the corresponding aldoxime 44 in 29% using hydroxylamine (Scheme 15).[25] 
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a) NH2OH; b) SOCl2. 
Scheme 15. 
 
The oxidation level of 44 was raised by simply dehydrating the oxime with thionyl 
chloride to give nitrile 45 in 30% yield. Later, this approach was applied essentially 
in the same manner to accomplish the synthesis of 3-cyanoceph-3-ems with different 
side chains (R = phenylacetyl, D-N(Boc)-phenylalanin, or 1-hydroxyethyl).[21] The 
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free acid of 45, obtainable after removal of the benzhydryl ester, undergoes facile 
hydrolytic opening of the β-lactam ring upon raising the pH above 7.8. 
 
In essentially the same manner, reaction of aldehyde 43 with aminooxyacetic acid 
hemihydrochloride produced cephem 46a in 87% yield (Scheme 16). Analogously, 
formation of oximes 46b and 46c was achieved in ca. 50% yield by condensation of 
43 with methoxyamine or benzyloxyamine, respectively.[25] With other protection 
groups at the 7-aminogroup (e.g. phenylacetyl or N(Boc)-phenylalanine) the reaction 
with methoxyamine gave similar yields.[21] 3-Formylcephalosporins containing a free 
carboxylic acid at C4, were also converted into the corresponding amino-3-
oxyiminomethyl-3-cephalosporins in good yields.[26] 
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R' = COPh
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43
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a
b
c
d
e
a
b
c
a
b
a) H2NOR; b) H2NNHR'. 
Scheme 16. 
 
Substituted hydrazines also add to 43 under carefully chosen conditions. They 
should be nucleophilic enough to react with the 3-formyl substituent and yet not too 
basic to rupture the β-lactam ring.[27] Thus, an equimolar solution of the aldehyde 
and p-tosylhydrazine in chloroform afforded p-tosylhydrazone 47a in quantitative 
yield (Scheme 16).[28] This reaction is generally applicable and cephems 47b-e have 
been prepared in 30-66% yield using the appropriate hydrazines. Analogously, 3-
formylcephalosporins with a free carboxylic acid function at C4 also react with 
substituted hydrazines to the corresponding 3-hydrazonocephalosporins.[29] 
 
Tosylhydrazone 47a was used for the preparation of 3-diazomethylcephalosporin 49. 
For this purpose, a solution of tosylhydrazone 47a in THF was brought into reaction 
with n-butyl lithium to give lithium salt 48. On slowly warming to 40°C, 3-
diazomethylcephem 49 was formed in 66% yield (Scheme 17).[28] This reactive 
cephalosporin undergoes 1,3-dipolar cycloaddition reactions with a large variety of 
alkenes. 
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a) n-BuLi, THF; b) 40°C. 
Scheme 17. 
 
Analogously, cephalosporins with a thiadiazole unit directly attached to the C4-
position have been synthesized as shown in Scheme 18.[30] 
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a) H2NNHC(S)R', DMSO; b) DDQ. 
Scheme 18. 
 
Treatment of aldehyde 43 with thiocabonylhydrazines in DMSO led to the 
corresponding thiocarbonylhydrazones 50 in quantitative yields. Subsequently, 
oxidative ring-closure by treatment with DDQ in dioxane gave the thiadiazoles 51 in 
high yields of 71-93%. The use of conventional reagents like FeCl3 or peroxides often 
led to side reactions.  
 
The use of cephem-N-methylnitrone 52 as a building block for more complex 
heterocyclic systems was studied by Spry et al.[31] The synthesis of these nitrone 
involves the use of 3-formylcephem 34 (Scheme 19). Treatment of 34 with N-
methylhydroxylamine gave the N-methylnitrone 52 in a moderate yield of 54-64%. 
Oxidation of 52 to the corresponding sulfoxide, followed by cycloaddition reactions, 
yielded more complicated tricyclic cephalosporins. 
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a) CH3NHOH, pyridine, EtOH. 
Scheme 19. 
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When aldehyde 12 or its sulfoxide was condensed with D-penicillinamine (53) in a 
methanol-chloroform solvent mixture, complex fused tetracyclic systems 54 were 
obtained, and the benzhydryl group was eliminated (Scheme 20).[32]  
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12 54
SH
HO2C
NH2
53
 
Scheme 20. 
 
When the methyl ester of D-penicillinamine (53) was used, the formyl group and the 
β-lactam ring acted as competing reacting centers in this reaction, and therefore, a 
mixture of products was obtained. This phenomenon can readily be explained by an 
enhanced nucleophilicity of the D-penicillinamine when present as the methyl ester. 
 
 
2.8 3-Formylcephalosporins in Wittig reactions  
 
3-Formylcephalosporins only reacted smoothly in Wittig olefination reactions when 
stabilized phosphoranes were used. Thus, trans methyl ester 56 was prepared in 44% 
yield by reaction of 12 with the stabilized phosphorane 55 (Scheme 21).[33]  
 
12 56
55
S
N
O
N
H
CO2CHPh2
CHO
O
S
N
O
N
H
CO2CHPh2
CO2Me
O
O
OMePh3P
 
Scheme 21. 
 
Analogously, 3-formylcephalosporin-S-oxides 17 was subjected to Wittig reactions 
with a variety of stabilized phosphorous ylides, giving the corresponding 3-
(substituted) vinyl-cephem nuclei 57a-c in reasonable yields (Scheme 22).[7] 
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a) Ph3P=CHR'. 
Scheme 22. 
 
Less stabilized phosphoranes have to be prepared in situ and were used in an 
epoxide (1,2-epoxybutane) mediated Wittig reaction with ∆2-aldehyde 58 to give γ- 
and δ-lactamyl derivatives 59 in reasonable yields (Scheme 23).[34] Under these 
conditions only minor amounts (5%) of the Z-derivatives along with small amounts 
of the corresponding ∆3-products were formed as well. The corresponding ∆3-
isomers were obtained by an oxidation-reduction sequence involving the ring sulfur 
atom. 
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a) 1,2-epoxybutane, 1,2-dichloroethane. 
Scheme 23. 
 
The same reaction has also been performed with the corresponding S-oxide of 58, 
avoiding the formation of ∆2/∆3-mixtures, which are frequently obtained in the 
Wittig olefination reaction.[35] For an anti-bacterial activity, however, reduction to the 
sulfide is always necessary.  
 
Hashimoto et al.[36] used stable phosphorane 61 in THF at a temperature below 0°C in 
a Wittig reaction with aldehyde 60 to produce alkene 62 (Scheme 24).  
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Higher temperatures caused a significant drop in yield of the olefination products. 
This Wittig reaction has also been used for the synthesis of other complicated 
substituted 3-vinylcephalosporins.[37] 
 
Cephalosporins with a dihalovinyl group at the 3-position have been synthesized in 
a Wittig-like reaction with aldehyde 13 in poor yields (Scheme 25).[38] The fluorine 
63a derivative was prepared in 10% yield using hexamethylphosphorous triamide as 
the solvent, zinc powder and dibromodifluoromethane.  
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a) hexamethylphosphorous triamide, Zn, CBr2F2; b) CCl4, Ph3P, Zn; c) CBr4, Ph3P, Zn. 
Scheme 25. 
 
Carbon tetrachloride or carbon tetrabromide, triphenylphosphine and zinc powder 
gave in a similar reaction the corresponding chlorine- 63b or bromine-derivative 63c 
in 13% and 33% isolated yield, respectively. 
 
Alkenylsulfoxides 65 can act as enzyme inhibitors, especially of transpeptidase and 
β-lactamase (Scheme 26).[39] These antibacterial agents have been synthesized from 3-
formylcephalosporins (e.g. 43) by reaction with dimethyl-p-nitrobenzylphosphonate 
64 and n-butyl lithium in a Wittig-type reaction involving a phosphorous ylide as the 
reactive species. Simultaneously, the thioether was oxidized to the corresponding 
sulfoxide in an intra-molecular fashion. 
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a) n-BuLi, THF. 
Scheme 26. 
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2.9 Grignard reactions with 3-formylcephalosporins  
 
Grignard reactions with 3-formylcephalosporins are well studied and widely used 
by many groups for the synthesis of 3-functionalized cephalosporins. For example, 
the Grignard reaction of 13 with MeMgI-LiCl in THF, followed by Jones oxidation of 
the methylcarbinol intermediate 66a afforded ketone 67a in 65% yield from aldehyde 
13 (Scheme 27).[40] Lithium chloride is necessary to obtain the carbinol 66a in high 
yield.[41] The lithium cation is very effectively coordinated to the oxygen atom of the 
carbonyl group and thus preventing lactonization. 
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a) MeMgI or EtMgI, LiCl; b) CrO3, H2SO4; c) MsCl, collidine, LiCl, DMF; d) Ph3P, CCl4. 
Scheme 27. 
 
Dehydration was performed by in situ formation of the mesylate 68a and 
subsequently elimination using lithium chloride to give the corresponding 3-
vinylcephem 69a in 38% yield.[42] Similarly, addition of ethylmagnesium iodide, 
followed by dehydration, gave the corresponding 3-(E)-1-propenyl cephem 69b in 
40% yield. The ketone group of 67a has also been converted into an α-chlorovinyl 
group by treatment with triphenylphosphine in CCl4 to give compound 70 in 15% 
yield (Scheme 27).[43] 
 
An elegant example using the Grignard reaction for the modification of the 
substituent at the C3 position was reported by Beeby et al.[44] Aldehyde 34 was 
allowed to react with an excess of vinylmagnesium chloride at -70°C to give 
vinylcarbinol 71a as a (1:1) mixture of diastereomers. Allylic substitution was 
achieved with acetic acid using a catalytic amount of p-TsOH, thereby producing 
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acetoxy derivative 72a in 44%. Similarly, treatment with 5-mercapto-1-
methyltetrazole and p-TsOH as the catalyst led to thioether 72c in 66% (Scheme 28).  
 
S
N
O
RHN
CO2CHPh2
CHO
S
O
R = 
S
N
O
RHN
CO2CHPh2
OR'
S
N
O
RHN
CO2CHPh2
X
X = OAc
X = OH
X = 
R' = H
R' = COCH3
NN
N
N
S
Me
34
71 72a
b
a
b
c
a b or c
or d
 
a) vinylmagnesium chloride; b) p-TsOH, THF, AcOH; c) 10% aqueous THF, p-TsOH; d) p-TsOH, 5-mercapto-
1-methyltetrazole. 
Scheme 28. 
 
Instead of p-TsOH, other acids such as perchloric or hydrochloric acid were found to 
be similarly effective. The corresponding acetate 71b, obtained by treating 71a with 
pyridine and acetic acid anhydride, served equally well as starting material in the 
abovementioned reactions. Isomerization of 71a to the primary alcohol 72b was 
effected in a similar way using 10% aqueous THF with p-TsOH as the catalyst. 
Conversion of the ∆2- into the ∆3-isomers is achieved either by direct equilibration 
with a trace of triethyl amine in pyridine, or by the two-step oxidation-reduction 
sequence via the sulfoxide intermediates. 
 
Valcavi et al..[45] used the Grignard reaction to synthesize novel C3-substituted 
cephalothin derivatives from aldehyde 34 (Scheme 29). The corresponding carbinols 
73a-c were acetylated with acetyl chloride in pyridine to give 74a-c in an overall 
yield of 36-47%. Ethynylmagnesium bromide was used before to synthesize C3-
propyn-1'-ol  cephalosporin 73b.[46]  
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a) R'MgBr; b) AcCl, pyridine. 
Scheme 29. 
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2.10 Barbier-type allylation reaction with 3-formylcephalosporins  
 
The behavior of aldehyde 26a in Grignard reactions was also studied by Tanaka et 
al..[47] Ethylmagnesium bromide in THF gave only 14% of the desired product 75a 
together with several by-products (Scheme 30). It should be noted that 
vinylmagnesium bromide did not give an acceptable amount of adduct 75b (R" = 
CH=CH2). In contrast, the "Barbier Type" reaction of aldehyde 26a with allyl 
bromide in a PbBr2/Al (0.03/1 equivalent)-DMF system proceeded smoothly to 
produce the desired adduct 75c in 69% yield. The formation of 75a-c can be 
reasonably understood by assuming that the addition of in situ generated allylmetal 
reagents is followed by lactonization. 
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a) R"MgBr, THF; b) allyl bromide, PbBr2/Al, DMF. 
Scheme 30. 
 
In a similar manner, the "Barbier Type" reaction of aldehyde 26a with other 
substituted allyl halides and propargyl bromide gave the corresponding 
functionalized lactones 76d-j in 33-91% yield (Scheme 31). 
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Scheme 31. 
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2.11 Concluding remarks  
 
This overview of synthesis and applications of 3-formylcephalosporins clearly 
demonstrates the usefulness of this key-intermediate in cephalosporin chemistry. 
Several research groups actively contributed to this chemistry. It should also be 
noted that many reactions have been included in patents, indicating the industrial 
relevance of the chemistry of 3-formylcephalosporins. 
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AN EVALUATION OF SYNTHETIC ROUTES 
TOWARDS 3-FORMYLCEPHALOSPORINS 
 
 
 
 
 
 
 
 
 
 
3.1 Introduction 
 
Although nature itself is capable of synthesizing 3-formylcephalosporins,[1] the first 
man-designed synthesis of a 3-formylcephalosporin (Figure 1) was reported by 
Woodward et al.[2] in 1966, who used the aldehyde as a crucial intermediate in the 
total synthesis of cephalosporin C. Ever since, many other procedures have been 
reported. Most of these routes involve a two-step process in which deacetylation of 
the 3-acetoxy group in a 7-ACA analogue is followed by oxidation of the thus 
obtained hydroxymethyl group into the aldehyde function. Some stoichiometric 
oxidations used are the Moffat oxidation,[3] the Collins oxidation,[3] and the Jones 
oxidation.[3],[4] Manganese(IV) oxide,[3],[5] and chromium(VI) oxide in acetic acid[3] 
have also been applied. In one report, the Swern oxidation has been used.[5] Recently, 
more elegant methods were published, employing 1-hydroxy-1,2-benziodoxol-3(1H)-
one 1-oxide (IBX)[6] in DMSO, and the catalytic method using TEMPO[7] in 
combination with a co-oxidant. 
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Figure 1. 
 
Other oxidations of 3-iodomethylcephalosporins, which involve oxygen- or air 
oxidation[8] either in the presence of rhodium(III) chloride or phosphomolybdic 
acid,[9] are also known. In an alternative non-oxidative approach, 3-
formylcephalosporins are synthesized from the readily available cephalosporin 
lactones.[10] A more comprehensive and detailed overview of the synthesis and 
applications of 3-formylcephalosporins has been described in chapter 2. 
 
3-Formylcephalosporins have great potential as synthetic intermediates, as they 
allow either the synthesis of a variety of new β-lactam antibiotics, or a new synthetic 
route to cephalosporins, which are already on the market for many years. The 
presence of the formyl group is essential, as it can serve as a handle for the 
introduction of numerous new functionalities. Since no general synthesis of 3-
formylcephalosporins was available at the start of this study, it was considered 
relevant to design a new synthetic route to this aldehyde, based on modern synthetic 
concepts. Such a synthetic effort is in full accordance with the objective formulated at 
the outset of the project, namely synthetic manipulation at the C3 position in 
cephalosporins in order to improve existing synthetic procedures to known 
antibiotics, and also to provide access to novel biologically promising cephalosporin 
entities. 
 
Such a new synthetic route has to fulfill three requirements. In the first place, the 
synthesis must start from readily available and cheap materials. Secondly, the 
synthetic route should be as short as possible and be high yielding as well. Finally, 
all possible isomers with respect to the position of the double bond and the oxidation 
state of the sulfur atom should be easily accessible via, at least in principle, the same 
procedure. 
 
This chapter is an evaluation of synthetic approaches to 3-formylcephalosporins 4-6 
implied in this study. Three readily available cephalosporins, viz. phenylacetyl 
protected 7-aminodesacetylcephalosporanic acid (7-phenylacetyl-ADCA) 1, 7-
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aminocephalosporanic acid (7-ACA) (2), and cephalolactone 3 were selected as 
starting materials (Scheme 1). These compounds are readily available from 
fermentation and are industrially attractive starting compounds. 
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Scheme 1. 
 
 
3.2 Results and discussion 
 
3.2.1 Synthesis of 3-formylcephalosporins from 7-ADCA 
 
7-Phenylacetyl-ADCA 1 is an interesting candidate for the synthesis of 3-
formylcephalosporins, as it is readily available in industrial quantities from 
penicillin G fermentation followed by ring-expansion (Scheme 2).  7-Phenylacetyl-
ADCA was used as such, as there is no need to deprotect the 7-amino function, 
because this unit can easily be deprotected enzymatically at a later stage.[11] For the 
required protection of the C4-carboxyl group the tert-butyl ester was chosen, because 
this environmentally benign and economically interesting group can be readily 
introduced. Moreover, the re-conversion of the esters into the corresponding 
carboxylic acids, which in general is rather problematic for these types of substrates, 
is high yielding in the case of the tert-butyl ester.[12]  
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Scheme 2. 
 
Oxidation of the sulfide to the corresponding sulfoxide and allylic bromination with 
N-bromosuccinimide under radical conditions, gave bromomethyl derivative 7 in 
good yields. The only drawback of the radical bromination step is the formation of 
by-products due to bromination at the benzylic or the allylic position adjacent to the 
sulfur atom. For this study, compound 7 was obtained from DSM Anti-Infectives.[13] 
Consultation of the literature revealed that allylic bromides can be oxidized to the 
corresponding aldehyde in only one step applying a Swern-type reaction with 
AgBF4.[14] Unfortunately, this method appeared not suitable for the synthesis of 
aldehyde 6. Subjecting 7 to this oxidation procedure afforded a product that, 
according to 1H-NMR-analysis, did not contain the β-lactam ring anymore. 
Apparently, the reaction conditions are too harsh for this sensitive molecule leading 
to complete breakdown of the cephalosporin ring system.  
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a) NaI, acetone, 5h (r.t.) and 2.5h (45°C), 97%; b) O2, RhCl3 (cat.), Al, DMF, o/n, 23%; c) CF3CO2.NH4, DMF, 
50°C, 2.5h; d) phosphate buffer pH 7.0, 32%. 
Scheme 3. 
 
As direct oxidation of bromine 7 turned out to be impossible, iodine analog 8 was 
prepared in quantitative yield from 7 using sodium iodide in acetone. It has been 
reported that such cephalosporin methyl iodides can be oxidized to the 
corresponding aldehydes reasonably efficiently applying oxygen in 
dimethylformamide and rhodium(III) chloride as the catalyst (Scheme 3).[9] When 
methyl iodide 8 was subjected to this oxidation procedure, aldehyde 6 was isolated, 
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albeit in a rather low yield of 23%. Much higher yields were obtained for related 
methyl iodides containing a p-methoxylbenzyl, p-nitrobenzyl or diphenylmethyl 
ester[9] at the C4 position instead of a tert-butyl ester as in 8. The nature of the C4-
ester substituent apparently plays a role in this direct oxidation of 3-
iodomethylcephalosporins to the corresponding aldehydes.  
 
In an alternative approach, iodide 8 was converted into the corresponding alcohol 9 
in 32% isolated yield by reaction with ammonium trifluoroacetate in DMF and work-
up with an aqueous phosphate buffer (Scheme 3).[15] The actual yield was much 
higher according to TLC- and 1H-NMR analyses. Purification by column 
chromatography caused a dramatic loss in yield, probably caused by decomposition 
at the active surface of the stationary phase. Next, hydroxy compound 9 was 
subjected to a variety of oxidation procedures in order to obtain the desired 
aldehyde 6 (vide infra). 
 
 
3.2.2 Synthesis of 3-formylcephalosporins from 7-ACA 
 
In comparison with 7-ADCA (1), 7-ACA (2) has a major advantage as the starting 
substance, because it has a higher oxidation state of the C10 carbon atom. In 
compound 2, an acetoxy group is present at C10, whereas 7-ADCA has a C3 methyl 
group. For the preparation of 3-formylcephalosporins, nearly the same strategy as 
described above in Section 3.2.1. was followed for 7-ACA as the starting material. 
The required protection of the carboxyl group at C4 was attained via a tert-butyl ester 
function, prepared in the usual way with isobutene and sulfuric acid[16] (Scheme 4). 
Subsequently, the amino function was protected with trityl chloride using triethyl 
amine as the base to give N-tritylated tert-butyl ester 10 in only 13% overall yield. 
Under these basic reaction conditions the double bond had completely isomerized 
from the ∆3- to the ∆2-position, possibly due to an increased steric interaction 
between the acetoxy substituent at the C10 position and the bulky tert-butyl ester at 
C4. This is a surprising observation, since generally mixtures of the ∆2- and ∆3-isomer 
are formed.[17],[18] Release of steric interference between the cis substituents in the 
ceph-3-em system may be invoked to explain this phenomenon.[19] 
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Scheme 4. 
 
In the next step, the acetoxymethyl group was converted into an iodomethyl group 
by reacting 10 with trimethylsilyl iodide, followed by aqueous work-up.[20] The 
resulting iodide 11 was transformed into the 3-formylcephalosporin by catalytic 
oxidation with oxygen using rhodium(III) chloride or vanadyl sulfate as the 
catalyst.[9] Unfortunately, this reaction gave aldehyde 12 only in trace amounts. In 
view of the facts that the yields in both protection steps of 7-ACA were 
disappointingly low and that the conversion of the iodomethyl group into the formyl 
moiety was also a low-yielding reaction, the synthetic strategy for the synthesis of 3-
formylcephalosporins from 7-ACA was reconsidered. 
 
In the new approach, a phenylacetyl amino protection was chosen as its usefulness 
had been proven in the 7-ADCA route to 3-formylcephalosporins (see Section 3.2.1). 
Reaction 7-ACA (2) with phenylacetyl chloride under Schotten-Baumann conditions 
afforded the desired amido compound 13 in an excellent yield of 83% yield (Scheme 
5). 
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CH2N2, Et2O, EtOAc, 70%. 
Scheme 5. 
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With the aim to obtain the corresponding alcohol 14, saponification of the acetoxy 
unit in 13 was investigated. Reaction with sodium hydroxide in methanol, followed 
by acidification and subsequent treatment with diazomethane at a constant pH, in 
order to esterify the 3-carboxylic acid function, led to a mixture of two products 
according to TLC analysis. On attempts to separate these compounds by column 
chromatography, only a single product was isolated. Both 1H-NMR spectroscopy 
and IR analysis indicated the presence of lactone 3. This exclusive formation can 
readily be rationalized by lactonization of the intermediate hydroxy methylester 14 
catalyzed by the relatively acidic silicagel used for the column chromatography. In a 
different approach, lactone 3 was evaluated as a precursor for the synthesis of 3-
formylcephalosporins (vide infra) (see also Chapter 2).  
 
In order to avoid lactonization, the C4 carboxyl group of 13 was first protected as a 
tert-butyl ester by treatment with dicyclohexyl carbodiimide and tert-butyl alcohol 
using DMAP as the catalyst. The only product obtained, after recrystallization, was 
the ∆2-isomer 15 in 88% yield (Scheme 6).  
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a) DCC, tert-BuOH, DMAP (cat.), CH2Cl2, -30°C - r.t., 88%; b) NaOH, MeOH, -20°C, 4h, 98%; c) isourea 
(DCC, tert-BuOH), CH2Cl2, r.t., 15h, 79%; d) NaOH, MeOH, -30°C, 6h, 44%, e) m-CPBA, CHCl3, 0°C, 2h, 
98%; f) NaOH, MeOH, -40°C.  
Scheme 6. 
 
The synthesis of ∆3-sulfide 18 was achieved by using the isourea derived from tert-
butyl alcohol and DCC[21] instead of the DCC/DMAP method. As no base is 
required in this procedure, only ∆3-acetoxy ester 18 is formed, and isomerization to 
the ∆2-sulfide 15 cannot take place. The corresponding ∆3-sulfoxide 17 could be 
synthesized by oxidation of the ∆2-sulfide 15 with m-CPBA in quantitative yield 
(Scheme 6). On first sight, hydrolysis of the acetoxy function seemed to be 
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straightforward, but in practice new difficulties were encountered. Saponification of 
the acetoxy group in 17 with sodium hydroxide in methanol led, immediately after 
the addition, to severe decomposition of the starting material, even at -40°C. Most 
likely, nucleophilic opening of the β-lactam ring by the hydroxide ion,[22] initiates 
this undesired process leading to a black tar in only 30 minutes. Saponification was 
more successful in the case of the corresponding sulfides 15 and 18. After 6 hours at -
30°C, about 50% of starting material 18 was still present. Addition of an extra 
equivalent of base did not increase the rate of the hydrolysis. Instead more 
decomposition of the starting material was observed. As a result hereof, ∆3-hydroxy 
compound 19 was only obtained in a moderate yield of 44%. Only for the ∆2-
compound 15 the hydrolysis of the C10 acetoxy group appeared to be facile, 
affording 16 in quantitative yield. This different behavior between 15 and 18 is not 
yet understood. The remarkable differences between 15, 17, and 18 clearly indicate 
that subtle differences in structure may have enormous consequences for the 
chemical behavior. 
 
After saponification of the acetoxy group, the primary alcohol was subjected to an 
oxidation procedure in order to obtain the corresponding aldehyde. For establishing 
the optimum reagent and reaction conditions, a large number of test reactions was 
performed with the alcohols 9, 16 and 19.  The results are collected in Table 1.  
 
The data in Table 1 reveal that the choice of oxidizing reagent is very important. 
Activated manganese(IV) oxide (entries 1 and 2) gave good results. However, the 
large excess needed to force the reaction to completion, and the sometimes lower 
isolated yield caused by sticking of the product to the manganese(IV) oxide, are 
serious disadvantages. Moreover, the quality of the manganese(IV) oxide, which is 
very essential, is not reliable. The oxidizing reagents of the chromate family[23],[24] 
(entries 3-5) did not react or showed a moderate reactivity towards the 3-
hydroxymethylcephalosporins. The Moffat oxidation[3] seemed to be successful, but 
appeared to be a very slow and therefore unpractical reaction. Although the TEMPO 
catalyzed oxidation of a cephalosporin was described in a patent,[7] the specific 
examples mentioned in the patent gave non-reproducible results when repeated. 
Minor modifications, e.g. using NCS as co-oxidant did also not lead to positive 
results.[25] Using other catalysts, e.g. platinum(IV) oxide, chromium(VI) oxide[26] and 
rhodium(III) chloride (entries 13-16) was not successful either, demonstrating the 
difficulties of the oxidation of the 3-hydroxymethylcephalosporins. Even the well-
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known Swern oxidation failed, although in literature one successful example is 
claimed.[5],[27] Only degradation of the starting material 16 was observed.  
 
Table 1: Oxidation of the 3-hydroxymethyl group to the 3-formyl group 
entry: method: alcohola: yield: (%)b 
1 activated MnO2 (40°C) 9 88 
2 activated MnO2 (40°C) 16 79 
3 benzimidazolium dichromate (BIDC), 
microwave 
9 0c 
4 pyridinium chlorochromate (PCC) 16 42 
5 isoquinolinium dichromate (IQDC) 16 19 
6 DMSO, Ac2O (Moffat) 16 n.d. 
7 TEMPO (cat.), O2 16 0c 
8 TEMPO (cat.), NaOCl 16 0c 
9 TEMPO (cat.), NCS 9 0d 
10 9 96 
11 16 81 
12 
IBX 
IBX =  
IBX   
O
I
O
O
O+ -
 19 95 
13 PtO2 (cat.), O2 9 0c 
14 PtO2 (cat.), O2 16 0c 
15 CrO3 (cat.), H5IO6 9 trace 
16 RhCl3 (cat.), NaIO4 19 n.d.e 
17 oxalyl chloride, DMSO (Swern) 16 0f 
a 9 = sulfoxide, 16 =  ∆2-sulfide, 19 = ∆3-sulfide  
b isolated yield 
c no reaction; only starting material recovered 
d chlorinated products; no aldehyde (1H-NMR) 
e aldehyde, but also over-oxidation to corresponding sulfone 
f severe decomposition 
 
Most gratifyingly, a modification of the Dess-Martin oxidation, i.e. the precursor for 
the Dess-Martin reagent i.e. 1-hydroxy-1,2-benziodoxol-3(1H)-one 1-oxide (IBX) was 
successful and gave excellent results (entries 10-12).[6] The corresponding aldehydes 
were obtained in high yields (81-96%). IBX is one of the mildest reagents available 
for the oxidation of alcohols to carbonyls. The reagent can easily be prepared on 
large scale, and it has been claimed that detonation is less probable as compared to 
the Dess-Martin reagent.[6] Moreover, only 1.5 equivalents were necessary to 
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complete the oxidation of alcohols 9, 16, and 19 in a clean and selective manner in 
short time.  
 
In summary, the experiments described above show that the conversion of 7-ACA 
into the 3-formylceph-2-em 4 only involves four steps, all of them high yielding, 
resulting in overall yields of 47-58%. The sequence of steps to this aldehyde 4 is 
depicted in Scheme 7 (left column). 
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a) tert-BuOH, DCC, DMAP (cat.), CH2Cl2, -30°C - r.t., o/n, 88%; b) MCPBA, CH2Cl2, 0°C, 1.5h, 98%; c) 
cephalosporin acetyl hydrolase (CAH), H2O pH 7.5, r.t., 4-8h; d) isourea (DCC, tert-BuOH), THF, o/n, 61%; e) 
isourea (DCC, tert-BuOH), THF, o/n, 62%; f) NaOH, MeOH, -20°C, 4h, 98%; g) IBX, DMSO/THF, r.t., 30h, 
81%; h) IBX, DMSO, r.t., 15', 96%; i) IBX, DMSO, r.t., 15', 95%.  
Scheme 7. 
 
The synthesis of the corresponding 3-formylceph-3-em 5 was approached in a 
similar manner. After protection of the amino group, the acetate at C10 was 
hydrolyzed applying an immobilized enzyme (cephalosporin acetyl hydrolase) to 
give the hydroxyacid 20 in high yield. This compound has to be handled with great 
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care to prevent lactonization under acidic conditions (Scheme 5). To avoid the 
formation of ∆2 by-products in the next protection step, the esterification of the C4 
carboxylic acid function in 20 was accomplished by treatment with the isourea 
derived from DCC and tert-butyl alcohol[21] to give the tert-butyl ester 19 in 62% 
overall yield. As no base is required in this procedure, only ∆3-hydroxy ester 19 is 
formed. Oxidation of alcohol function at C10 in 19 to the corresponding aldehyde 5 
was achieved in almost quantitative yield with IBX as the oxidizing agent.  
 
Figure 2. PLUTON drawing of the X-ray structure of aldehyde 5. 
 
The synthesis of 3-formylceph-3-em-1-oxide 6 started from sulfide 13, which was 
oxidized in quantitative yield to the sulfoxide 21 with meta-chloroperbenzoic acid 
(Scheme 7). Hydroxyacid 22 was obtained by enzymatic hydrolysis (cephalosporin 
acetyl hydrolase) of the C10 acetate in 21. The tert-butyl ester 9 was then obtained 
from 22 in an overall yield of 61% by treatment with the isourea derived from DCC 
and tert-butyl alcohol. Oxidation of the C10 hydroxy function to the corresponding 3-
formylcephalosporin 6 was accomplished, again in excellent yield, using IBX as the 
oxidant. The chemistry shown in Scheme 7 represents efficient novel routes to the 
aldehydes 4, 5, and 6, which are key-compounds for further synthetic elaboration of 
the cephalosporin nucleus at C10. 
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3.2.3 Synthesis of 3-formylcephalosporins from cephalolactone  
 
Initially, cephalosporin lactones were not of particular interest from a synthetic point 
of view. In the early 1960s, the first uncontrolled synthesis of such lactone was 
reported by Abraham et al.[28] In an attempt to deacetylate cephalosporin C (23) to 
the corresponding hydroxyacid 24 under acidic conditions, mainly the lactone 25 
was formed (Scheme 8). A more controlled synthesis by Chauvette et al.[29] involves 
the enzymatic deacetylation of 23 with orange peel acetyl esterase to give the 
hydroxyacid 24, followed by lactonization to cephalolactone 25 in the presence of 
acid or acetic anhydride. Later, Kukolja et al.[30] nicely demonstrated that 
lactonization without a separate deacetylation step was possible by simply stirring 
phenylacetyl amino-protected 7-ACA 13 in acidic aqueous acetone (Scheme 9). 
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Scheme 8. 
 
As already mentioned in the introduction (Scheme 1, for more details see Section 2.2 
in Chapter 2), 3-formylcephalosporins can be synthesized from this readily available 
cephalosporin lactone 3.[10] The literature procedures were repeated with some 
adaptations. Thus conversion of phenylacetamide protected 7-ACA 13 into 
cephalolactone 3 (89% yield) was accomplished by stirring it in aqueous acid and 
acetone.[30]  
 
Bromination of lactone 3 was performed according to the method of Sugawara et 
al.[10] Then, simply stirring of the resulting mixture of bromines 26a and 26b in a 
THF/water mixture,[32] resulted in the formation of hydroxylactone 27 in 95% yield, 
which, actually is in equilibrium with its open aldehyde form 28 (Scheme 9). 
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Scheme 9. 
 
Treatment of 27 with diazomethane in THF, using the procedure of Sugawara et 
al.,[10] gave methyl ester 29 in 97% (Scheme 10). This product was not subjected to 
purification by column chromatography on silica gel, because under the relatively 
acidic conditions at the column, reformation of hydroxylacton 27 may readily occur 
(similarly as in Scheme 5).  
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Scheme 10. 
 
In order to prevent such a lactonization, the conversion into a tert-butyl ester, which 
is much more stable toward hydroxylacton formation, would be required. 
Disappointingly, after reaction of the hydroxylacton 27 with the isourea (derived of 
tert-butyl alcohol and DCC), tert-butyl ester 5 was formed in only a trace amount. 
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Therefore, no further attention was paid to this lactone approach. Moreover, at that 
time it was found that the 7-ACA route appeared to be superior in yield and 
efficiency when compared with the lactone route. 
 
 
3.3 Concluding remarks 
 
In conclusion, starting from readily available 7-ACA (2), a convenient, high yielding 
procedure for some 3-formylcephalosporins, viz. 3-formylceph-2-em 4 and 3-
formylceph-3-em sulfide 5 and the corresponding sulfoxide 6 has been developed. 
These 3-formyl derivatives are valuable compounds for further synthetic 
elaboration. Although 7-phenylacetyl-ADCA (1) and cephalolactone (3) are suitable 
as starting material, the overall synthetic efficiency of the routes to 3-
formylcephalosporins starting from these two compounds is inferior to that using 7-
ACA (2). The higher oxidation state of the C10-substitution in 7-ACA as compared 
with 7-ADCA (1) turned out to be the decisive factor in its applicability in the 
synthesis of 3-formylcephalosporins. 
 
 
3.4 Experimental part 
 
General remarks 
100 MHz 1H-NMR spectra were recorded on a Bruker AC 100 spectrometer and 300 MHz 1H-NMR 
spectra and all 13C-NMR spectra were recorded on a Bruker AC 300 using Me4Si as internal standard. 
All coupling constants are given as 3J in Hz, unless indicated otherwise. Melting points were 
measured with a Reichert Thermopan microscope and are uncorrected. IR spectra were recorded on a 
Bio-Rad FTS-25 instrument. For mass spectra a double focusing VG7070E mass spectrometer was 
used. For some samples, High Resolution FAB was carried out using a JEOL JMS SX/SX102A four-
sector mass spectrometer (JEOL Ltd. 1-2 Musashino  3-chome, Akishima Tokyo), coupled to a MS-MP 
9021D/UPD data system (University of Amsterdam). Elemental analyses were conducted on a Carlo 
Erba Instruments CHNSO EA 1108 element analyzer. For the determination of optical rotations a 
Perkin-Elmer 241 polarimeter was used. Solvents were dried using the following methods: 
dichloromethane was distilled from P2O5; ethyl acetate was distilled from K2CO3; diethyl ether was 
distilled from NaH; hexane and heptane were distilled from CaH2; tetrahydrofuran was distilled from 
sodium just before use. All other solvents were of analytical grade. Thin layer chromatography (TLC) 
was carried out on a Merck precoated silicagel 60 F254 plates (0.25 mm). Spots were visualized with 
UV or using a molybdate spray. Flash chromatography was carried out at a pressure of ca. 1.5 bar, 
using Merck Kieselgel 60H. Column chromatography at atmospheric pressure was performed with 
ACROS silicagel (0.035-0.070 mm; pore diameter ca. 6 nm). 
An evaluation of synthetic routes towards 3-formylcephalosporins 
 49 
Systematic names were generated using the ACD/Name program provided by Advanced Chemistry 
Development Inc. (Toronto, Canada). Bromide 7 was obtained from DSM Anti-Infectives (Delft, The 
Netherlands). 
 
N1-[(5aR,6R)-1,7-dioxo-1,4,6,7-tetrahydro-3H,5aH-azeto[2,1-b]furo[3,4-d][1,3]thiazin-6-yl]-2-
phenylacetamide (3) 
Following the procedure by Kukolja et al.,[30] phenylacetyl-7ACA 13 (0.78 g; 2.0 mmol) was dissolved 
in a mixture of concentrated hydrochloric acid (4 ml), acetone (16 ml), and water (12 ml). After 
stirring for 15h at r.t., dichloromethane and saturated NaHCO3 solution were added. Extraction with 
dichloromethane (2x50 ml) and drying (MgSO4) afforded lactone 3 (0.59 g; 89%) as an off-white solid. 
Mp 208-210°C (dec.); [α]D = +170° (c = 1.0; acetone); 1H-NMR (300 MHz, CDCl3 and few drops DMSO-
d6) δ (ppm) =  3.58  and 3.65 (qAB, JAB = 14.0 Hz, 2H, PhCH2), 3.77 and 3.85 (qAB, JAB = 18.3 Hz, 2H, 
SCH2), 5.03 (s, 2H, OCH2C=), 5.12 (d, J = 5.0 Hz, 1H, NHCHCHS), 5.91 (dd, J = 5.0 Hz J = 8.5 Hz, 1H, 
NHCHCHS), 7.23-7.37 (m, 5H, PhH), 8.92 (d, J = 8.5 Hz, 1H, NH); 13C-NMR (75 MHz, CDCl3 and few 
drops DMSO-d6) δ (ppm) = 23.1 (SCH2), 42.5 (PhCH2), 58.3 (CHNH), 60.7 (CHS), 71.8 (CH2O), 124.2 
(=CCH2O), 127.1, 128.8,  129.8, and 136.6 (PhC), 142.3 (=CCO2CH2), 165.0 (C=O, lactam), 167.0 
(CO2CH2), 171.7 (PhCH2C(O)); IR (KBr): ν 3289 (broad, NH), 1790 (two peaks) (C=O, lactam and 
lactone), 1652 and 1520 (C=O, amide), 1418 (C-N), 1147 (C-O, lactone) cm-1; MS (CI+): m/z (%) = 331 (2) 
[M+H]+, 298 (16), 156 (15), 118 (19), 112 (50), 91 (100), [C7H7]+; elem. anal.: calc. (found) for 
C16H14O4N2S: C: 58.17 (58.14), H: 4.27 (4.27), N: 8.48 (8.33). 
 
tert-Butyl (4S,7R,7aR)-3-formyl-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-4H,6H-azeto[2,1-
b][1,3]thiazine-4-carboxylate (4) 
To a stirred solution of 1-hydroxy-1,2-benziodoxol-3(1H)-one 1-oxide (IBX) (1.4 g; 5.0 mmol) in DMSO 
(8 ml) was added a solution of alcohol 16 (1.0 g; 2.48 mmol) in THF (3.0 ml) over a period of 3h. The 
reaction mixture was stirred for an additional 30h at rt. Then the reaction mixture was extracted with 
ethyl acetate, the extracts washed with water (3x75 ml), brine (1x75 ml), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by column chromatography (SiO2, ethyl 
acetate / hexane 3:7) to furnish aldehyde 4 (0.81 g; 81%) as a white solid. 
Mp 146-148°C (dec.); [α]D = +679° (c = 0.30; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.44 (s, 
9H, C(CH3)3), 3.65 (s, 2H, PhCH2), 5.27 (s, 1H, CHCO2tBu), 5.30 (d, J = 3.9 Hz, 1H, NHCHCHS), 5.55 
(dd, J = 3.9 Hz J = 7.6 Hz, 1H, NHCHCHS), 6.22 (d, J = 7.6 Hz, 1H, NH), 7.26-7.40 (m, 5H, PhH), 7.43 
(s, 1H, SCH), 9.25 (s, 1H, CHO); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 27.8 (C(CH3)3), 43.1 (PhCH2), 
49.8 (CHCO2tBu) 53.9 (CHNH), 60.4 (CHS), 83.7 (C(CH3)3), 116.1 (=CCO2H), 127.7, 129.1, 129.4 and 
133.5 (PhC), 138.0 (SCH) 163.9 (C=O, lactam), 165.7 (CHCO2tBu), 167.5 (CO2H), 171.5 (PhCH2C(O)); IR 
(KBr): ν 3265 (broad, NH), 1768 (C=O, lactam), 1733 (C=O, ester), 1667 and 1544 (C=O, amide), 1369 
(C-N), 1152 (O-C, ester) cm-1; MS (FAB+, NOBA): m/z (%) = 425 (30) [M+Na]+, 403 (11) [M+H]+, 347 
[M+H–C4H8]+, 178 (100); elem. anal.: calc. (found) for C20H22O5N2S: C: 59.69 (59.73), H: 5.51 (5.59), N: 
6.96 (6.93), S: 7.97 (7.97). 
 
tert-Butyl (7R,7aR)-3-formyl-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-2H,6H-azeto[2,1-
b][1,3]thiazine-4-carboxylate (5) 
This compound was prepared from alcohol 19 (0.566 g; 1.4 mmol) in the same way as described for 
the synthesis of 3-formylceph-2-em 4 (0.552 g, 96%). An analytical sample (white crystals) was 
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obtained by column chromatography (SiO2, ethyl acetate / heptane 1:1) followed by re-crystallization 
(diethyl ether). 
Mp 146-148°C (dec.); [α]D = +152° (c = 0.51; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.56 (s, 
9H, C(CH3)3), 3.24 and 3.94 (qAB, JAB = 18.3 Hz, 2H, SCH2), 3.63 and 3.67 (qAB, JAB = 16.0 Hz, 2H, 
PhCH2), 4.99 (d, J = 5.4 Hz, 1H, NHCHCHS), 5.95 (dd, J = 5.4 Hz J = 9.2 Hz, 1H, NHCHCHS), 6.33 (d, J 
= 9.2 Hz, 1H, NH), 7.25-7.40 (m, 5H, PhH), 9.80 (s, 1H, CHO); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 
22.1 (SCH2), 27.7 (C(CH3)3), 43.2 (PhCH2), 58.9 (CHNH), 59.8 (CHS), 85.8 (C(CH3)3), 122.4 (=CCHO), 
127.7, 129.2, 129.3 and 133.5 (PhC), 140.2 (=CCO2tBu), 159.0 (CO2tBu), 164.7 (C=O, lactam), 171.1 
(PhCH2C(O)), 187.9 (-CHO); IR (KBr): ν 3334 (broad, NH), 1795 (C=O, lactam), 1705 (C=O, ester), 1668 
and 1518 (C=O, amide), 1373 (C-N), 1226 and 1161 (C-O, ester) cm-1; MS (FAB+, NOBA): m/z (%) = 425 
(18) [M+Na]+, 403 (13) [M+H]+, 347 (28) [M+H–C4H8]+, 176 (100); elem. anal.: calc. (found) for 
C20H22O5N2S: C: 59.69 (59.51), H: 5.51 (5.53), N: 6.96 (6.88), S: 7.97 (7.94). 
 
tert-Butyl (7R,7aR)-3-formyl-1,6-dioxo-7-[(2-phenylacetyl)amino]-1,6,7,7a-tetrahydro-2H-1λ4- 
azeto[2,1-b][1,3]thiazine-4-carboxylate (6) 
This compound was prepared from alcohol 9 (0.421 g; 1.0 mmol) in the same way as described for the 
synthesis of 3-formylceph-2-em 4. Purification by chromatography (SiO2, ethyl acetate / heptane 2:1) 
afforded 6 as a white solid (0.398 g; 95%). 
Mp 175-176°C (dec.); [α]D = -153° (c = 0.48; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.58 (s, 9H, 
C(CH3)3), 2.85 (dd, J = 18.4 Hz 4J = 1.6 Hz, 1H, SCH2), 3.63 (s, 2H, PhCH2), 4.40 (d, J = 18.4 Hz, 1H, 
SCH2), 4.47 (dd, J = 5.2 Hz 4J = 1.6 Hz, 1H, NHCHCHS), 6.16 (dd, J = 5.2 Hz J = 9.9 Hz, 1H, 
NHCHCHS), 6.91 (d, J = 9.9 Hz, 1H, NH), 7.25-7.37 (m, 5H, PhH), 9.97 (s, 1H, CHO); 13C-NMR (75 
MHz, CDCl3) δ (ppm) = 27.7 (C(CH3)3), 41.4 (SCH2), 43.1 (PhCH2), 60.0 (CHNH), 67.6 (CHS), 86.3 
(C(CH3)3), 116.5 (=CCHO), 127.6, 129.0, 129.3 and 133.6 (PhC), 139.9 (=CCO2tBu), 158.2 (CO2tBu), 164.5 
(C=O, lactam), 171.3 (PhCH2C(O)), 188.4 (CHO); IR (KBr): ν 3324 (broad, NH), 1800 (C=O, lactam), 
1705 (C=O, ester), 1672 and 1520 (C=O, amide), 1370 (C-N), 1153 (C-O, ester), 1025 (S=O) cm-1; MS 
(FAB+, NOBA): m/z (%) = 441 (2) [M+Na]+, 419 (2) [M+H]+, 363 (80) [M+H–C4H8]+, 91 (100) [PhCH2+]; 
HRMS (FAB, m/z): calculated for C20H22O6N2SNa+: 441.1096 amu. Found: 441.1059 ± 0.0044 amu. 
 
tert-Butyl (7R,7aR)-3-(iodomethyl)-1,6-dioxo-7-[(2-phenylacetyl)amino]-1,6,7,7a-tetrahydro-2H- 
1λ4-azeto[2,1-b][1,3]thiazine-4-carboxylate (8)  
To a stirred solution of bromide 7 (1.0 g; 2.22 mmol) in dry acetone (25 ml), sodium iodide (0.665g; 
4.44 mmol) was added in one portion. The suspension was stirred in the dark at r.t. for 5h and then 
for 2.5h at 45°C. The color of the reaction mixture turned light brown. Acetone was removed in vacuo, 
ethyl acetate (75 ml) and 10% sodium thiosulfate (Na2S2O3) were added, and the clear aqueous 
solution was extracted with ethyl acetate (2x75 ml). The combined organic layers were washed with 
saturated NaHCO3 (1x75 ml) and brine (1x75 ml), dried (MgSO4) and concentrated in vacuo. The pale 
yellow solid 8 (1.07 g; 97%) was used without further purification. 
Mp 153-155°C (dec.); [α]D = -36.8° (c = 1.04; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.55 (s, 
9H, C(CH3)3), 3.44 and 3.69 (qAB, JAB = 18.2 Hz, 2H, SCH2), 3.60 (s, 2H, PhCH2), 4.23 and 4.58 (qAB, JAB 
= 9.6 Hz, 2H, CH2I), 4.46 (dd, J = 4.8 Hz 4J < 1.5 Hz, 1H, NHCHCHS), 5.97 (dd, J = 4.8 Hz J = 9.8 Hz, 
1H, NHCHCHS), 6.95 (d, J = 9.8 Hz, 1H, NH), 7.25-7.37 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ 
(ppm) = 4.7 (CH2I), 27.8 (C(CH3)3), 43.1 (PhCH2), 47.5 (SCH2), 58.9 (CHNH), 67.1 (CHS), 84.4 
(C(CH3)3), 121.3 (=CCH2I), 124.7 (=CCO2tBu) 127.4, 128.9, 129.3 and 133.8 (PhC), 159.5 (=CCO2tBu), 
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163.6 (C=O, lactam), 171.4 (PhCH2C(O)); IR (KBr): ν 3261 (broad, NH), 1785 (C=O, lactam), 1713 (C=O, 
ester), 1677 and 1522 (C=O, amide), 1369 (C-N), 1150 (C-O, ester), 1029 (S=O) cm-1; MS (FAB+, NOBA): 
m/z (%) = 553 (4) [M+Na]+, 531 (11) [M+H]+, 475 (30) [M+H-C4H8]+, 403 (24) [M-I]+, 347 (40) [M+H-I-
C4H8]+, 154 (100) [NOBA]*, 91 (80) [PhCH2+], 57 (60) [C4H9+] (* defragmentation of NOBA matrix); 
HRMS (FAB, m/z): calculated for C20H24O5N2SI+: 531.0451 amu. Found: 531.0421 ± 0.0053 amu. 
 
tert-Butyl (7R,7aR)-3-(hydroxymethyl)-1,6-dioxo-7-[(2-phenylacetyl)amino]-1,6,7,7a-tetrahydro- 
2H-1λ4-azeto[2,1-b][1,3]thiazine-4-carboxylate (9) 
The procedure as described for the preparation of  the sulfide analogue was followed using 
phenylacetyl protected 7-ACA-sulfoxide 21 (1.5 g; 3.7 mmol), immobilized cephalosporin acetyl 
hydrolase (4 g “wet” enzyme) and isourea (4 equiv.) derived from tert-butyl alcohol and DCC. Work-
up after 4-6h, followed by purification via chromatography (SiO2, ethyl acetate) afforded tert-butyl 
ester 9 as a white solid (0.96 g; 62%). An analytical sample was obtained by crystallization from ethyl 
acetate and heptane affording colorless plates. 
Alternative approach 
Alcohol 16 (1.0 g; 2.48 mmol) was oxidized with m-CPBA (0.57 g; 2.5 mmol) in dichloromethane (50 
ml) at 0°C for 2h. After addition of aqueous NaHCO3 the mixture was extracted with 
dichloromethane (2x50 ml). The combined organic layers were washed with brine, dried (MgSO4) and 
concentrated in vacuo giving sulfoxide 9 (0.83 g; 80%) as a white solid. 
Mp 198-199°C (dec.); [α]D = +87° (c = 0.51; acetone); 1H-NMR (300 MHz, DMSO-d6) δ (ppm) = 1.49 (s, 
9H, C(CH3)3), 3.53 and 3.85 (qAB, JAB = 18.6 Hz, 2H, SCH2), 3.49 and 3.75  (qAB, JAB = 14.1 Hz, 2H, 
PhCH2), 4.07 and 4.42 (dqAB, JAB = 13.9 Hz J = 5.6 Hz, 2H, CH2OH), 4.83 (d, J = 4.5 Hz, 1H, 
NHCHCHS), 5.13 (t, J = 5.6 Hz, 1H, CH2OH) 5.87 (dd, J = 4.5 Hz J = 8.4 Hz, 1H, NHCHCHS), 7.23-7.31 
(m, 5H, PhH), 8.34 (d, J = 8.4 Hz, 1H, NH); 13C-NMR (75 MHz, DMSO-d6) δ (ppm) = 27.7 (C(CH3)3), 
41.7 (SCH2), 45.5 (PhCH2), 58.2 (CH2OH), 60.4 (CHNH), 66.4 (CHS), 82.6 (C(CH3)3), 123.3 (=CCO2tBu), 
125.7 (=CCH2OH), 126.7, 128.5, 129.3 and 136.4 (PhC), 160.2 (CO2tBu), 164.2 (C=O, lactam), 171.2 
(PhCH2C(O)); IR (KBr): ν 3509 (broad, OH), 3229 (broad, NH), 1782 (C=O, lactam), 1695 (C=O, ester), 
1661 and 1541 (C=O, amide), 1327 (C-N), 1159 (C-O, ester), 1031 (S=O) cm-1; MS (FAB+, NOBA): m/z 
(%) = 443 (18) [M+Na]+, 421 (5) [M+H]+, 403 (10), 387 (10), 365 (12), 347 (38), 225 (48), 91 (92) [PhCH2+], 
57 (100) [C4H9+]; elem. anal.: calc. (found) for C20H24O6N2S: C: 57.13 (56.73), H: 5.75 (5.71), N: 6.66 
(6.62). 
 
tert-Butyl (7R,7aR)-3-[(acetyloxy)methyl]-6-oxo-7-(tritylamino)-7,7a-dihydro-4H,6H-azeto[2,1- 
b][1,3]thiazine-4-carboxylate (10) 
In a sealable flask (Grolsch beer bottle) 7-ACA (2) (10.0 g; 36.7 mmol) was suspended in 
dimethoxyethane (100 ml). After cooling below -10°C, concentrated sulfuric acid (9.3 ml) and 
isobutene (100 ml) were added and the flask was closed. The mixture was stirred for 3 days at r.t.. 
After cooling below -10°C, the flask was opened and the reaction mixture was quenched with a 
saturated solution of NaHCO3 at 0°C. The aqueous layer was extracted with ethyl acetate (2x100 ml), 
washed with brine, dried (MgSO4) and concentrated in vacuo. The crude tert-butyl ester was dissolved 
in dichloromethane under nitrogen, followed by addition of triethyl amine (3.8 ml; 55 mmol) and 
trityl chloride (5.6 g; 40.4 mmol). The mixture was stirred for 15h at r.t.. Then, water was added and 
the mixture was extracted with ethyl acetate (2x100 ml). The combined organic layers were washed 
with an aqueous NH4Cl solution, dried (MgSO4) and concentrated in vacuo. The crude product was 
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purified by flash chromatography (SiO2, ethyl acetate / hexane 1:6) to give 10 (2.6 g; 13%) as an off-
white solid with the double bond at the ∆2-position.  
Mp 81-83°C (dec.); [α]D = +338° (c = 1.04; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.40 (s, 9H, 
C(CH3)3), 2.05 (s, 3H, C(O)CH3), 3.14 (s, 1H, NH), 4.35 (d, J = 3.7 Hz, 1H, NHCHCHS), 4.45 and 4.66 
(qAB, JAB = 12.6 Hz, 2H, CH2OAc), 4.67 (dd, J = 3.7 Hz J = 11.7 Hz, 1H, NHCHCHS), 4.87 (s, 1H, 
CHCO2tBu), 6.20 (s, 1H, SCH=), 7.24-7.54 (m, 15H, TritylH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 20.8 
(OC(O)CH3), 27.8 (C(CH3)3), 50.3 (CHCO2tBu) 56.2 (CHS), 65.4 (CH2OAc), 67.7 (CHNH), 70.5 (CPh3), 
83.4 (C(CH3)3), 118.6 (SCH=), 127.8 (=CCH2OAc), 122.4, 126.8, 128.2, 128.4 and 145.1 (tritylC), 166.5 
(C=O, lactam), 168.6 (CHCO2tBu), 170.5 (OC(O)CH3); IR (KBr): ν 3250 (broad, NH), 3056 and 2975 and 
2934 (=CH, trityl), 1774 (C=O, lactam), 1744 (C=O, ester and acetyl), 1370 (C-N), 1148 (C-O, ester) cm-1; 
MS (FAB+, NOBA): m/z (%) = 570 (14) [M+], 327 (3) [M+H-Ph3C]+, 243 (100) [Ph3C+], 165 (10), 57 (4) 
[C4H9+]; HRMS (FAB, m/z): calculated for C33H35O5N2S+: 571.2267 amu. Found: 571.2267 ± 0.0057 
amu. 
 
tert-Butyl (7R,7aR)-3-(iodomethyl)-6-oxo-7-(tritylamino)-7,7a-dihydro-4H,6H-azeto[2,1- 
b][1,3]thiazine-4-carboxylate (11) 
The transformation of the acetate into the iodide was accomplished in a similar manner, as described 
by Mobashery et al..[15] To a solution of protected 7-ACA 10 (1.0 g; 1.75 mmol) in dichloromethane (10 
ml) under nitrogen, trimethylsilyl iodide (1.5 equiv.; ca. 0.4 ml) was slowly added. The organic layer 
was extracted successively with 10% NaS2O3 solution, water, saturated NaHCO3 solution and water, 
dried (MgSO4) and concentrated in vacuo to ca. 5 ml. The product was precipitated by addition of 
hexane (50 ml) and isolated by filtration as a yellow solid 11 (0.80 g; 72%). 
Mp 84-86°C (dec.); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.42 (s, 9H, C(CH3)3), 3.15 (bs, 1H, NH), 4.97 
and 4.22 (qAB, JAB = 10.0 Hz, 2H, CH2I), 4.31 (d, J = 3.7 Hz, 1H, NHCHCHS), 4.67 (bd, J = 2.9 Hz, 1H, 
NHCHCHS), 5.15 (s, 1H, CHCO2tBu), 6.30 (s, 1H, SCH=), 7.24-7.54 (m, 15H, TritylH); 13C-NMR (75 
MHz, CDCl3) δ (ppm) = 8.4 (CH2I), 27.9 (C(CH3)3), 50.7 (CHCO2tBu) 56.2 (CHS), 67.9 (CHNH), 70.6 
(CPh3), 83.7 (C(CH3)3), 121.0 (SCH=), 121.3 (=CCH2I), 126.8, 128.2, 128.4 and 145.1 (TritylC), 166.6 
(C=O, lactam), 168.3 (CHCO2tBu); IR (KBr): ν 3320 (broad, NH), 3056 and 2973 and 2927 (=CH, trityl), 
1776 (C=O, lactam), 1736 (C=O, ester), 1370 (C-N), 1148 (C-O, ester) cm-1; MS (FAB+, NOBA): m/z (%) 
= 638 (5) [M+], 395 (1) [M+H-Ph3C]+, 243 (100) [Ph3C+], 154 (14), 57 (5) [C4H9+]; HRMS (FAB, m/z): 
calculated for C33H35O5N2S+: 638.1100 amu. Found: 638.1144 ± 0.0064 amu. 
 
tert-Butyl (7R,7aR)-3-formyl-6-oxo-7-(tritylamino)-7,7a-dihydro-4H,6H-azeto[2,1-b][1,3]thiazine-4- 
carboxylate (12) 
Oxidation of compound 11 was accomplished by vigorously stirring a mixture of iodomethyl 11 
(0.100 g; 0.157 mmol), vanadyl sulfate (200 wt% VOSO4.5H2O; 0.200 g) under an oxygen atmosphere 
for 2h as was previously described by Tanaka et al..[9] Work-up was performed by filtration to remove 
all solids. The filtrate was diluted with ethyl acetate and washed with aqueous NaS2O3 and brine, 
dried over MgSO4, and concentrated in vacuo. TLC analysis (ethyl acetate / hexane = 1:3) of the crude 
product showed several spots, but 1H-NMR (CDCl3) showed formation of an aldehyde (singlet at 9.10 
ppm). Due to the complexity of the crude mixture of products, no attempt to purification were made. 
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(7R,7aR)-3-[(Acetyloxy)methyl]-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-2H,6H-azeto[2,1-
b][1,3]thiazine-4-carboxylic acid (13)  
To a solution of 7-ACA (2) (12.0 g; 44.1 mmol) in saturated aqueous NaHCO3 (300 ml) and acetone 
(100 ml) was added phenylacetyl chloride (ca. 2 equiv.; ca. 6 ml) in two portions. After 17h of stirring, 
the reaction mixture was acidified with concentrated HCl to pH 1.5 and extracted with 
dichloromethane (2x250 ml) and the combined organic layers were washed with brine, dried (MgSO4) 
and concentrated in vacuo. The residue was suspended in diethyl ether and stirred for 17h to remove 
phenylacetic acid (by-product). The product was filtered off, washed with diethyl ether and dried in 
vacuo. Phenylacetyl protected 7-ACA 13 was obtained as an off-white solid (14.2 g; 83%) and was used 
without further purification.  
Mp 168-171°C (dec.); [α]D = +86° (c = 1.0; dioxane); 1H-NMR (100 MHz, CDCl3 and DMSO-d6) δ (ppm) 
= 2.07 (s, 3H, CH3), 3.32 and 3.54 (qAB, JAB = 15.0 Hz, 2H, SCH2), 3.58 (s, 2H, PhCH2), 4.84 and 5.08 
(qAB, JAB = 13.3 Hz, 2H, CH2OAc), 4.95 (d, J = 4.9 Hz, 1H, NHCHCHS), 5.77 (dd, J = 4.8 Hz J = 8.5 Hz, 
1H, NHCHCHS), 7.29 (m, 5H, PhH), 8.18 (d, J = 8.5 Hz, 1H, NH), 9.64 (s, 1H, CO2H); 13C-NMR (75 
MHz, DMSO-d6) δ (ppm) = 20.8 (OC(O)CH3), 25.7 (SCH2), 41.8 (PhCH2), 57.6 (CHNH), 59.3 (CHS), 
62.9 (CH2OAc), 123.6 (=CCH2OAc) 126.5 (=CCO2H), 126.7, 128.4, 129.2 and 136.0 (PhC), 163.0 (C=O, 
lactam), 165.0 (CO2H), 170.4 (OC(O)CH3), 171.2 (PhCH2C(O)); IR (KBr): ν 3260 (broad, NH), 1782 
(C=O, lactam), 1748 (C=O, acetyl), 1738 (C=O, acid), 1658 and 1535 (C=O, amide), 1345 (C-N), 1228 (C-
O, acetyl) cm-1; MS (FAB+, NOBA): m/z (%) = 413 (50) [M+Na]+, 391 (17) [M+H]+, 331 (100) [M+H-
CO2CH3]+ 156 (85), 94 (67).  
 
tert-Butyl (4S,7R,7aR)-3-[(acetyloxy)methyl]-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-4H,6H-
azeto[2,1-b][1,3]thiazine-4-carboxylate (15)  
DCC (5.81 g; 28.2 mmol) was added to a cooled (-30°C) and stirred suspension of phenylacetyl 
protected 7-ACA 13 (10 g; 25.6 mmol), tert-butyl alcohol (5 ml) and DMAP (200 mg) in 
dichloromethane (200 ml) under nitrogen. The reaction mixture was stirred for 1h at 0°C and for 
another 15h at r.t.. After removal of DCU by filtration, 2N HCl was added to the filtrate. Crude tert-
butyl ester was obtained by extraction with dichloromethane (3x150 ml), washing with saturated 
NaHCO3 (1x75 ml) and brine (1x75 ml), drying (MgSO4) and concentration in vacuo. Recrystallization 
from ethyl acetate / heptane after treatment with active carbon gave pure tert-butyl ester 15 as white 
needles (10.1 g; 88%).  
Mp 227-229°C; [α]D = +409° (c = 0.53; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.47 (s, 9H, 
C(CH3)3), 2.06 (s, 3H, C(O)CH3), 3.64 (s, 2H, PhCH2), 4.53 and 4.71 (qAB, JAB = 12.7 Hz, 2H, CH2OAc), 
4.87 (s, 1H, CHCO2tBu), 5.26 (d, J = 4.0 Hz, 1H, NHCHCHS), 5.65 (dd, J = 4.0 Hz J = 8.7 Hz, 1H, 
NHCHCHS), 6.23 (d, J = 8.7 Hz, 1H, NH), 6.34 (s, 1H, SCH=), 7.26-7.40 (m, 5H, PhH); 13C-NMR (75 
MHz, CDCl3) δ (ppm) = 20.8 (OC(O)CH3), 27.9 (C(CH3)3), 43.3 (PhCH2), 50.6 (CHCO2tBu), 53.4 
(CHNH), 60.2 (CHS), 65.4 (CH2OH), 84.0 (C(CH3)3), 119.4 (SCH=), 121.2 (=CCH2OAc), 127.6, 129.1, 
129.4 and 133.6 (PhC), 164.2 (C=O, lactam), 165.9 (CHCO2tBu), 170.4 (OC(O)CH3), 171.0 (PhCH2C(O)); 
IR (KBr): ν 3246 (broad, NH), 3058 (CH, phenyl), 1782 (C=O, lactam), 1736 (C=O, ester and acetyl), 
1649 and 1560 (C=O, amide), 1387 (C-N), 1218 (C-O, acetyl) 1153 (C-O, ester) cm-1; MS (CI+): m/z (%) = 
446 (5) [M+], 405 (3) [M+H–COCH3]+, 345 (14) [M+H–COCH3–C4H8]+, 331 (60), 176 (72), 216 (95), 91 
(100) [C7H7+]; HRMS (EI, m/z): calculated for C22H26O6N2S: 446.15115 amu. Found: 446.15036 ± 
0.00134 amu. 
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tert-Butyl (4S,7R,7aR)-3-(hydroxymethyl)-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-4H,6H-
azeto[2,1-b][1,3]thiazine-4-carboxylate (16) 
Sodium hydroxide (0.90 g; 22.4 mmol) in methanol (30 ml) was added under nitrogen to a cooled (-
30°C) and stirred solution of triple protected 7-ACA 15 (5.0 g; 0.011 mol) in methanol (360 ml). The 
reaction mixture was stirred between -30 and -20°C for 4-5h until TLC analysis (ethyl acetate / hexane 
1:1) showed completion of the reaction. The reaction mixture was then poured into diluted HCl 
solution and extracted with CH2Cl2 (3x100 ml). The combined organic layers were washed with brine 
(1x50 ml), water (1x50 ml), dried (MgSO4) and concentrated in vacuo affording crude alcohol 16 as a 
yellow-orange foam (4.44 g; 98%). An analytical sample (white solid) was obtained after column 
chromatography (SiO2, ethyl acetate / heptane 2:1). 
Mp 85-87°C (dec.); [α]D = +471° (c = 0.525; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.48 (s, 9H, 
C(CH3)3), 2.46 (bs, 1H, CH2OH), 3.63 (s, 2H, PhCH2), 4.12 and 4.21 (dqAB, JAB = 13.4 Hz J = 5.5 Hz, 2H, 
CH2OH), 4.92 (d, 4J = ~1.0 Hz, 1H, CHCO2tBu), 5.22 (d, J = 4.0 Hz, 1H, NHCHCHS), 5.61 (dd, J = 4.0 
Hz J = 8.7 Hz, 1H, NHCHCHS), 6.23 (d, 4J = ~1.0 Hz, 1H, SCH), 6.27 (bs, 1H, NH), 7.26-7.38 (m, 5H, 
PhH), 13C-NMR (75 MHz, CDCl3) δ (ppm) = 27.9 (C(CH3)3), 43.2 (PhCH2), 50.7 (CHCO2tBu) 53.6 
(CHNH), 60.1 (CHS), 64.9 (CH2OH), 84.0 (C(CH3)3), 117.2 (SCH=), 124.3 (=CCH2OH) 127.6, 129.0, 
129.4 and 133.8 (PhC), 164.5 (C=O lactam), 166.5 (CHCO2tBu), 171.2 (PhCH2C(O)); IR (KBr): ν 3431 
(broad, OH), 3298 (broad, NH), 1770 (C=O, lactam), 1732 (C=O, ester), 1660 and 1535 (C=O, amide), 
1369 (C-N), 1151 (O-C, ester) cm-1; MS (FAB+, NOBA): m/z (%) = 427 (21) [M+Na]+, 404 (5) [M+], 331 
(35) [M+H–C4H8–H2O]+, 176 (57), 57 (100) [C4H4+]; elem. anal.: calc. (found) for C20H24O5N2S: C: 59.39 
(59.39), H: 5.98 (5.97), N: 6.93 (6.83), S: 7.93 (8.07). 
 
tert-Butyl (7R,7aR)-3-[(acetyloxy)methyl]-1,6-dioxo-7-[(2-phenylacetyl)amino]-1,6,7,7a-tetrahydro- 
2H-1λ4-azeto[2,1-b][1,3]thiazine-4-carboxylate (17) 
This reaction was carried out in a similar manner as described by Murphy et al..[31] A solution of ∆2-
ester 15 (2.6 g; 5.8 mmol) in chloroform (100 ml) was added to a solution of meta-chloroperbenzoic 
acid (1.1 equiv.; 1.57 g) in chloroform (15 ml) at 0°C. After stirring for 2h, TLC analysis showed 
completion of the reaction. The organic layer was washed with saturated NaHCO3 (1x75 ml) and 
brine (1x75 ml), dried (MgSO4) and concentrated in vacuo. Then methanol was added and the 
resulting solution was concentrated in vacuo again. Sulfoxide 17 was obtained as a jelly compound 
(2.65 g; 98%). An analytical sample (white crystals) was obtained by recrystallization from diethyl 
ether. 
Mp 144-146°C (dec.); [α]D = +56.2° (c = 0.99; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.53 (s, 
9H, C(CH3)3), 2.07 (s, 3H, C(O)CH3), 3.18 and 3.72 (qAB, JAB = 18.6 Hz, 2H, SCH2), 3.61 (s, 2H, PhCH2), 
4.43 (d, J = 4.7 Hz, 1H, NHCHCHS), 4.67 and 5.29 (qAB, JAB = 13.6 Hz, 2H, CH2OAc), 6.02 (dd, J = 4.7 
Hz J = 9.7 Hz, 1H, NHCHCHS), 6.90 (d, J = 9.7 Hz, 1H, NH), 7.26-7.33 (m, 5H, PhH); 13C-NMR (75 
MHz, CDCl3) δ (ppm) = 20.7 (OC(O)CH3), 27.7 (C(CH3)3), 43.1 (PhCH2), 45.7 (SCH2), 59.0 (CHNH), 
63.2 (CH2OAc), 66.7 (CHS), 84.3 (C(CH3)3), 118.0 (=CCH2OAc), 127.0 (=CCO2tBu) 127.4, 128.9, 129.3 
and 133.8 (PhC), 159.2 (=CCO2tBu), 164.0 (C=O, lactam), 170.4 (OC(O)CH3), 171.4 (PhCH2C(O)); IR 
(KBr): ν 3276 (broad, NH), 2978 (CH, phenyl), 1787 (C=O, lactam), 1744 (C=O, acetyl), 1720 (C=O, 
ester), 1669 and 1527 (C=O, amide), 1380 (C-N), 1226 (C-O, acetyl), 1154 (C-O, ester), 1047 (S=O) cm-1; 
MS (FAB+, NOBA): m/z (%) = 485 (18) [M+Na]+, 463 (14) [M+H]+, 407 (25) [M-C4H8]+, 403 (47) [M-
AcOH]+, 347 (100) [M+H-AcOH-C4H8]+, 91 (34) [PhCH2+]; HRMS (FAB, m/z): calculated for 
C22H27O7N2S+: 463.1539 amu. Found: 463.1546 ± 0.0046 amu. 
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tert-Butyl (7R,7aR)-3-[(acetyloxy)methyl]-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-2H,6H- 
azeto[2,1-b][1,3]thiazine-4-carboxylate (18) 
A slurry of dicylcohexylcarbodiimide (30.4 g; 0.147 mol), tert-butyl alcohol (12.8 g; 0.173 mol), and 
copper(I) chloride (0.3 g; catalyst) was stirred for 3 days. After filtration, 9 ml were diluted with 
dichloromethane (12 ml) and this mixture was added to 7-phenylacetyl-ACA 13 (3.9 g; 10 mmol) in 
dichloromethane (30 ml) at r.t.. After 15h, 2N HCl (40 ml) was added to the reaction mixture and the 
dicyclohexyl urea was removed by filtration. The organic layer was washed with saturated NaHCO3 
and water successively, dried (MgSO4), treated with active carbon and concentrated to a small 
volume. Then toluene was added and the mixture was stored at 4°C overnight. The purified (off-
white) tert-butyl ester 18 (3.54 g; 79%) was isolated by filtration. 
Mp 159-161°C; [α]D = +65.1° (c = 1.0; acetone); 1H-NMR (100 MHz, CDCl3) δ (ppm) = 1.51 (s, 9H, 
C(CH3)3), 2.07 (s, 3H, C(O)CH3), 3.31 and 3.50 (qAB, JAB = 18.4 Hz, 2H, SCH2), 3.64 (s, 2H, PhCH2), 4.77 
and 5.05 (qAB, JAB = 13.2 Hz, 2H, CH2OAc), 4.92 (d, J = 4.9 Hz, 1H, NHCHCHS), 5.82 (dd, J = 4.9 Hz J 
= 9.1 Hz, 1H, NHCHCHS), 6.28 (d, J = 9.1 Hz, 1H, NH), 7.26-7.31 (m, 5H, PhH); 13C-NMR (100 MHz, 
CDCl3) δ (ppm) = 20.6 (OC(O)CH3), 27.7 (C(CH3)3), 43.2 (PhCH2), 49.1 (SCH2), 57.3 (CHNH), 59.2 
(CHS), 63.0 (CH2OAc), 83.8 (C(CH3)3), 123.5 (=CCH2OAc), 127.3 (=CCO2tBu) 127.6, 129.1, 129.4 and 
133.8 (PhC), 160.2 (=CCO2tBu), 164.3 (C=O, lactam), 170.5 (OC(O)CH3), 171.2 (PhCH2C(O)); IR (KBr): ν 
3287 (broad, NH), 2936 (CH, phenyl), 1790 (C=O, lactam), 1742 (C=O, acetyl), 1715 (C=O, ester), 1657 
and 1538 (C=O, amide), 1385 (C-N), 1237 (C-O, acetyl), 1150 (C-O, ester) cm-1; MS (CI+): m/z (%) = 446 
(1) [M+], 387 (8) [M-HOAc]+, 331 (100) [M-HOAc-C4H8]+, 176 (51), 91 (53) [PhCH2+], 57 (43) [C4H9+]; 
HRMS (CI, m/z): calculated for C22H26O6N2S: 446.15115 amu. Found: 446.15042 ± 0.00133 amu. 
 
tert-Butyl (7R,7aR)-3-(hydroxymethyl)-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-2H,6H- 
azeto[2,1-b][1,3]thiazine-4-carboxylate (19) 
Phenylacetyl protected 7-ACA 13 (4.0 g; 10.2 mmol) was dissolved  in water (25 ml) and the pH was 
set to 7.0 with 0.6 M NaOH. After addition of  immobilized cephalosporin acetyl hydrolase (8 g “wet” 
enzyme) the pH was maintained at pH 7.0 by addition of 0.1 M NaOH (pH stat conditions). After 
completion of the reaction (4-6h) the enzyme was recovered by filtration. The filtrate was acidified to 
pH 1.8 after cooling to 0°C. The then formed precipitate was collected by filtration and dried in vacuo 
or extracted (3x75 ml) with ethyl acetate. The combined organic layers were washed with water (2x75 
ml) and brine, dried (MgSO4) and concentrated in vacuo. The crude product 20 was dissolved in dry 
THF. At room temperature, the carboxylic acid was esterified with isourea derived from tert-butyl 
alcohol and DCC (4 equiv.).[21] After stirring for 17h, DCU was removed by filtration. After addition 
of 2N HCl, the filtrate was extracted with dichloromethane (3x75 ml). The combined organic layers 
were extracted with saturated NaHCO3 (1x100 ml) and brine (1x100 ml), dried (MgSO4) providing 
tert-butyl ester 19 after column chromatography (SiO2, heptane / ethyl acetate 1:2) as a white solid 
(2.1 g; 61%). 
Mp 174-176°C (dec.); [α]D = +83° (c = 0.87; acetone);  1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.66 (s, 9H, 
C(CH3)3), 3.00 (bs, 1H, OH), 3.49 and 3.53 (qAB, JAB = 18.6 Hz, 2H, SCH2), 3.61 and 3.65  (qAB, JAB = 
15.9 Hz, 2H, PhCH2), 3.86 (dd, J = 5.0 Hz J = 12.6 Hz, 1H, CH2OH), 4.46 (d, J = 12.6 Hz, 1H, CH2OH), 
4.89 (d, J = 4.9 Hz, 1H, NHCHCHS), 5.83 (dd, J = 4.9 Hz J = 9.1 Hz, 1H, NHCHCHS), 6.53 (d, J = 9.1 
Hz, 1H, NH), 7.25-7.38 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 25.6 (SCH2), 27.3 
(C(CH3)3), 43.1 (PhCH2), 57.1 (CH2OH), 59.0 (CHNH), 61.9 (CHS), 84.0 (C(CH3)3), 126.5, 127.6, 129.1, 
129.4, 129.9, 133.7 (=CCO2tBu, =CCH2OH and PhC), 161.4 (CO2tBu), 164.6 (C=O, lactam), 171.3 
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(PhCH2C(O)); IR (KBr): ν 3409 (broad, OH), 3298 (broad, NH), 1756 (C=O, lactam), 1709 (C=O, ester), 
1661 and 1536 (C=O, amide), 1367 (C-N), 1163 (C-O, ester) cm-1; MS (FAB+, NOBA): m/z (%) = 427 (44) 
[M+Na]+, 405 (17) [M+H]+, 387 (42) [M+H–H2O]+, 331 (49) [M+H–C4H8–H2O]+, 178 (100); elem. anal.: 
calc. (found) for C20H24O5N2S: C: 59.39 (59.36), H: 5.98 (6.03), N: 6.93 (6.87), S: 7.93 (8.14). 
 
 (7R,7aR)-3-[(Acetyloxy)methyl]-1,6-dioxo-7-[(2-phenylacetyl)amino]-1,6,7,7a-tetrahydro-2H-1λ4-
azeto[2,1-b][1,3]thiazine-4-carboxylic acid (21) 
To a cooled (0°C) suspension of phenylacetyl protected 7-ACA 13 (0.78 g; 2.0 mmol) in 
dichloromethane (50 ml) 1.5 equiv. of pre-dried m-CPBA (0.518 g) was added in one portion while 
stirring. After additional stirring for 1.5h the precipitate (white solid) was collected by filtration, 
washed (2x75 ml) with CH2Cl2 to remove m-CBA, and dried in vacuo. The crude sulfoxide 21 (0.80 g; 
98%) was used without further purification. 
Mp 197-198°C (dec.); [α]D = +161° (c = 0.87; H2O); 1H-NMR (300 MHz, DMSO-d6) δ (ppm) = 2.02 (s, 
3H, CH3), 3.52 and 3.73 (qAB, JAB = 14.4 Hz, 2H, PhCH2), 3.56 and 3.88 (qAB, JAB = 18.5 Hz, 2H, SCH2), 
4.59 and 5.19 (qAX, JAX = 13.1 Hz, 2H, CH2OAc), 4.86 (d, J = 4.2 Hz, 1H, NHCHCHS), 5.81 (dd, J = 4.2 
Hz J = 8.2 Hz, 1H, NHCHCHS), 7.21-7.31 (m, 5H, PhH), 8.40 (d, J = 8.2 Hz, 1H, NH); 13C-NMR (75 
MHz, DMSO-d6) δ (ppm) = 20.8 (OC(O)CH3), 41.6 (PhCH2), 45.5 (SCH2), 58.4 (CH2OAc), 63.2 (CHS), 
66.4 (CHS), 118.7 (=CCH2OAc) 126.1 (=CCO2H), 126.7, 128.5, 129.3 and 136.0 (PhC), 162.3 (C=O 
lactam), 164.4 (CO2H), 170.3 (OC(O)CH3), 171.2 (PhCH2C(O)); IR (KBr): ν 3298 (broad, NH), 1775 
(C=O, lactam), 1742 (C=O, acetyl), 1723 (C=O, acid), 1658 and 1527 (C=O, amide), 1339 (C-N), 1222 (C-
O, acetyl), 1035 (S=O) cm-1; MS (FAB+, NOBA): m/z (%) = 429 (14) [M+Na]+, 407 (3) [M+H]+, 347 (12) 
[M+H-COCH3]+, 176 (18), ; 154 (100) [NOBA]*, 57 (56) [C4H9+] (* defragmentation of NOBA matrix); 
HRMS (FAB, m/z): calculated for C18H19O7N2S+: 407.0913 amu. Found: 407.0877 ± 0.0041 amu. 
 
(3R) and (3S) N1-[(5aR,6R)-3-bromo-1,7-dioxo-1,4,6,7-tetrahydro-3H,5aH-azeto[2,1-b]furo[3,4- 
d][1,3]thiazin-6-yl]-2-phenylacetamide (26a,b) 
Bromination was accomplished by silylation followed by addition of molecular bromine as was 
previously described by Sugawara et al..[10] Bromolactone 26a and its diastereomer 26b were obtained 
as colorless crystals in an overall yield of 55% (literature[10] 78%). 
All data were in complete agreement with those reported previously.[10] 
 
N1-[(5aR,6R)-3-hydroxy-1,7-dioxo-1,4,6,7-tetrahydro-3H,5aH-azeto[2,1-b]furo[3,4-d][1,3]thiazin-6-
yl]-2-phenylacetamide (27) 
A mixture of bromolactones 26a and 26b (0.5 g; 1.22 mmol) was dissolved in THF containing 10% 
water and stirred for 15h at r.t., and then for 6h at 55°C. After removal of the THF under reduced 
pressure, the product was extracted with dichloromethane. The combined organic layers were 
washed with brine, dried (MgSO4) and concentrated in vacuo. The crude product 27 (0.40 g; 95%) was 
dissolved in THF and precipitated by addition of a mixture (1:1) of ethyl acetate and hexane, which 
gave an analytical sample. 
All data were in agreement with those reported previously.[10] 
 
Methyl (7R,7aR)-3-formyl-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-2H,6H-azeto[2,1- 
b][1,3]thiazine-4-carboxylate (29)  
To a solution of hydroxylactone 27 (600 mg; 1.73 mmol) in dry tetrahydrofuran (5 ml) was added an 
excess of diazomethane in diethyl ether at 0°C until the reaction mixture was colored brightly yellow. 
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After 10 min. the reaction was complete and the solution was concentrated to dryness affording 
aldehyde 29 as a white foam (0.605 g; 97%). Purification by column chromatography (SiO2, ethyl 
acetate / hexane 1:1) gave an analytical sample. Probably due to the acidity of the silicagel, also some 
hydrolysis of the methyl ester had occurred. 
1H-NMR (100 MHz, CDCl3) δ (ppm) = 3.19 and 3.91 (qAB, JAB = 18.4 Hz, 2H, SCH2), 3.58 (s, 2H, 
PhCH2), 3.87 (s, 3H, CO2Me), 4.95 (d, J = 5.3 Hz, 1H, NHCHCHS), 5.89 (dd, J = 5.3 Hz J = 9.1 Hz, 1H, 
NHCHCHS), 6.24 (d, J = 9.1 Hz, 1H, NH), 7.20-7.260 (m, 5H, PhH), 9.72 (s, 1H, CHO). 
 
 
3.5 Crystal structure data 
 
tert-Butyl (7R,7aR)-3-formyl-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-2H,6H-azeto[2,1- 
b][1,3]thiazine-4-carboxylate (5)  
Crystals of aldehyde 5 suitable for X-ray diffraction studies were obtained from heptane-ethyl acetate. 
A single crystal was mounted in air on a glass fibre. Intensity data were collected at room 
temperature. An Enraf-Nonius CAD4 single-crystal diffractometer was used, Mo-Kα radiation, θ-2θ 
scan mode. Unit cell dimensions were determined from the angular setting of 25 reflections. Intensity 
data were corrected for Lorentz and polarization effects. Semi-empirical absorption correction (ψ-
scans)[33] was applied. The structure was solved by the program CRUNCH[34] and was refined with 
standard methods (refinement against F2 of all reflections with SHELXL97[35] with anisotropic 
parameters for the non-hydrogen atoms. All hydrogen atoms were initially placed at calculated 
positions and were freely refined, subsequently. A structure determination summary, a list of atom 
coordinates, a list of bond lengths and angles, a list of hydrogen coordinates, and a list of anisotropic 
displacement parameters are given in Table 2. 
A PLUTON[36] drawing is shown in Figure 2. 
 
Table 2: Crystal data and structure refinement for compound 5 
Crystal color transparent colorless 
Crystal shape rather regular fragment 
Size [mm] 0.52 x 0.36 x 0.17 mm 
Empirical formula C20H22N2O5S 
Molecular weight 402.46  g.mol-1 
Temperature 293(2) K 
Radiation / wavelength MoKα (graphite mon.) / 0.71073 Å 
Crystal system Monoclinic 
Space group C2 
Unit cell dimensions a = 27.2202(11) Å  α = 90° 
(25 reflections, 18.431 < θ < 21.309) b =  5.1944(4) Å β = 130.396(3)° 
 c = 18.7846(7) Å γ = 90° 
Volume 2022.8(2) Å3 
Z 4 
Calculated density 1.322 Mg.m-3 
Absorption coefficient 0.193 mm-1 
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Continuation of Table 2: Crystal data and structure refinement for compound 5 
Diffractometer / scan Enraf-Nonius CAD4 / θ-2θ 
F(000) 848 
θ-range for data collection 2.85 - 26.31° 
Index ranges -25 ≤ h ≤ 33, 0 ≤ k ≤ 6, -23 ≤ l ≤ 0 
Reflections collected / unique 2362 / 2293 [R(int) = 0.0123] 
Reflections observed 2112 ([Io > 2σ (Io)]) 
Absorption correction Semi-empirical from ψ-scans 
Range of rel. transm. factors 1.019 and 0.983 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2293 / 1 / 342 
Goodness-of-fit on F2 1.023 
SHELXL-97 weight parameters 0.036400    0.560700 
Final R indices [I > 2σ(I)] R1 = 0.0266, wR2 = 0.0660 
R indices (all data) R1 = 0.0304, wR2 = 0.0682 
Extinction coefficient 0.0017(5) 
Largest difference peak and hole 0.162 and -0.099 e.Å-3 
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A SYNTHETIC STUDY TOWARDS 3-NORCEPHALO-
SPORINS: BARTON’S RADICAL DECARBOXYLATION 
REACTION IN CEPHALOSPORIN CHEMISTRY 
 
 
 
 
 
 
 
 
 
 
4.1 Introduction 
 
3-Norcephalosporins bearing hydrogen or a heteroatom at the C3 position are an 
important class of β-lactam antibiotics. They generally show a high biological 
activity and as a medicine they can be administered orally.[1],[2] Important examples 
are cefaclor (1), ceftibuten (2) (R=CH(CH2CO2H)) or ceftizoxime (3) (R=N(OCH3)) 
(Figure 1). 
   
2 ceftibuten (R=CH(CH2CO2H))
3 ceftizoxime (R=N(OCH3))
1 cefaclor
N
SN
H
O Cl
CO2H
O
NH2
N
SNH2
N
SN
H
HO
CO2H
O
R
1
2
3
4
7
 
Figure 1. 
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So far, the reported syntheses of such 3-norcephalosporins mainly rely upon 
replacement of the C3-hydroxyl group in 3-hydroxy-ceph-3-em-4-carboxylates, 
which are derived from either natural penicillins or cephalosporins.[1],[3],[4] These 
excellent and high-yielding approaches, however, involve sophisticated and 
hazardous operations and/or are accompanied by undesired ∆3/∆2-migration of the 
double bond. Syntheses of the 3-unsubstituted ceph-3-ems have been reported 
before and the preferred routes are either via 3-exomethylene cephem derivatives[5] 
or via 3-hydroxy-3-cephem derivatives.[1],[3],[6]  
 
In order to evaluate alternative and more efficient routes to these 3-functionalised 
cephalosporins, (halo)-decarboxylation reactions of suitably substituted 
carboxycephalosporin molecule (vide infra) was studied. The attractive feature of this 
approach is that the removal of the carbon atom and the introduction of the 
heteroatom takes place simultaneously in one synthetic operation (Scheme 1). 
Eventually, the results of this study may result in a new route to 3-
norcephalosporins from 3-carboxycephalosporins.  
 
N
S
O
NH2
X
CO2H
N
S
O
RHN
CO2R'
CO2H
X = H, Cl, Br, I, SR", SeR"  
Scheme 1. 
 
When this study started, the required 3-carboxycephems were not readily available. 
Recently however, a new and improved synthesis of these molecules was developed 
(see Chapter 5).[7] 7-Aminodesacetoxy-cephalosporanic acid (7-ADCA) (4), protected 
as a phenylacetyl amide, was chosen as a model compound for this halo-
decarboxylation study (Scheme 2). This molecule contains the essential α,β-
unsaturated carboxylic acid functionality in a β-lactam nucleus, and the compound 
can easily be obtained by fermentation.[8]  
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Scheme 2. 
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4.2 Overview of the relevant literature 
 
The decarboxylation of organic carboxylic acids, which is accompanied by a 
concurrent replacement by a halogen, is an extremely useful and selective 
methodology for the synthesis of halogenated organic substances. The first and most 
well-known example of a halo-decarboxylation is the Hunsdiecker reaction. In this 
reaction the silver salt of a carboxylic acid is heated in the presence of halogen to 
give the corresponding halo compound. Later a number of other more efficient and 
selective methods was developed.[9] In general, the (halo)-decarboxylation reaction 
can either proceed via an ionic or a radical mechanism. Both approaches will be 
discussed below. 
 
 
Non-radical approach 
While the classical Hunsdiecker reaction involves a radical pathway, recently, a 
synthetic procedure for the oxidative bromo-decarboxylation of α,β-unsaturated 
carboxylic acids under non-radical conditions has been described.[10] This method 
uses iodosylbenzene or iodosylbenzene diacetate and N-bromosuccinimide (NBS) as 
the halogen donor. A major drawback of this method is that only compounds 
bearing an aromatic substituent at the β-position (cinnamic acid derivatives) gave 
good results (yields 31-78%). The tentative mechanism of this reaction is depicted in 
Scheme 3. 
IO
Ar
CO2H
+ I
O
O
O
O
Ar
Ar
NBS
I
O
O
O
O
Ar
Br
+
Ar
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-H2O
Ar
Br
+
I
+
O
O
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Scheme 3. 
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The corresponding chloro- or iodo-decarboxylation products could be obtained 
using N-chlorosuccinimide or N-iodosuccinimide as the halogen source, although 
the yields were generally lower than for the bromo variant. Substrates bearing an 
alkyl group at the β-position were not very reactive and only a trace amount of the 
bromo-decarboxylation product was formed. 
 
More recently, Chowdhury et al. performed non-radical Hunsdiecker reactions on 
α,β-unsaturated carboxylic acids in a catalytic fashion, using less hazardous 
conditions than needed for the classical Hunsdiecker reaction.[11],[12] A conceptually 
simple strategy employing in situ generated metal carboxylates yielded β-
halostyrenes from the corresponding α,β-unsaturated aromatic carboxylic acids 
using N-halosuccinimides as the halogen source and Group-1 metal acetates as the 
catalysts. Recently, this reaction has also been carried out using microwave 
conditions.[13] Two possible mechanisms, via an ionic pathway, have been reported 
for this reaction (Scheme 4).  
O
O
NBS O
OBr
+
-OAc
O
OOAc
Br
Br
-CO2
Br
+
O
O
- O
O
Br
MW MW
under microwave conditions (MW)
MW
-OAc
 
Scheme 4. 
 
The lithium acetate assisted mechanism is observed at room temperature, whereas 
the mechanism via the thermal decomposition of the intermediate β-lactone is 
suggested to occur under microwave conditions.[12],[13] The thermal decomposition of 
β-lactones is a well-established method for the synthesis of substituted alkenes.[14]  
 
A nitrone trapping experiment indicated a predominance of the abovementioned 
ionic pathway over a possible radical route. In another communication, the first 
example of a metal-free Hunsdiecker reaction, catalyzed by tetrabutylammonium 
trifluoroacetate, was reported.[15] A limitation of this method is that only for α,β-
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unsaturated carboxylic acids, bearing aromatic groups at the β-position, good yields 
of the corresponding halides were obtained. 
 
Radical approach 
The generation of carboxyl radicals requires the preparation of suitable precursors 
containing a weak carboxyl-X bond susceptible to homolytic cleavage. In the 
classical Hunsdiecker reaction, the precursor is an acyl hypo halite (X is halogen). 
More recently, the acylhalites are prepared in situ by reaction of a metal salt of the 
carboxylic acid with a halogen. Originally, silver salts were used, but problems 
associated with the preparation of dry silver carboxylates, as well as the high costs, 
have led to the development of methods using mercury and thallium salts.[16]   
 
Also lead(IV) carboxylates are used as precursors for the homolytic cleavage 
reaction. The generation of lead(IV) carboxylates involves exchange of an acetate of 
lead(IV) acetate (LTA) for the acid to be decarboxylated. The weak bond to be 
cleaved is a carboxyl-lead(IV) bond. The higher activation energy for 
decarboxylation of acetoxyl radicals ensures preferential decarboxylation of most 
alkanoic acids. On the other hand, attempts to decarboxylate of aryl acids fail due to 
competing acetoxyl decarboxylation.[9] The mechanism of this modified Hunsdiecker 
reaction is believed to be as follows (Scheme 5): 
 
R OH
O
+ Pb(OAc)4
R O
O
Pb(OAc)3
X2
R O
O
X- AcOH - XPb(OAc)3  
 
R O
O
X RCOO X
R CO2
RX RCOO
RCOO
RCOOXR
. .
..
. .+
+
+
+
(initiation)
(propagation)
etc.  
Scheme 5. 
 
Recently, methods have been devised for carboxyl radical generation by homolytic 
cleavage of weak carboxyl-N single bonds. Such methods have great potential in 
organic synthesis since the generation requires neither strong oxidants nor strong 
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electrophilic species. Such precursors are therefore compatible with a large range of 
functional groups. The method most commonly employed involves the use of O-acyl 
thiohydroxamates. These compounds are generally prepared by reaction of acyl 
chlorides or mixed anhydrides with the commercially available sodium salt of 2-
mercapto-pyridine-N-oxide (Scheme 6).[16]  
 
R X
O
+ N S
O
Na
+
N
R O
O
S
X = Cl, OC(O)R'  
Scheme 6. 
 
This radical chain decarboxylation process, resulting from the thermal or 
photochemical decomposition of thiohydroxamic esters, is better known as Barton's 
radical decarboxylation reaction. A variety of aromatic and vinylic acids has been 
decarboxylated by an adaptation of this method involving the use of AIBN as the 
radical chain initiator. Hence, this procedure has prospects for the (halo)-
decarboxylation of the cephalosporin molecules.[17],[18] 
 
In this chapter studies concerning the (halo)-decarboxylation of model compound 7-
phenylacetyl-ADCA 4, applying the above-mentioned methods, will be described. 
 
 
4.3 Results and discussion 
 
Non-radical approach 
First the oxidative halo-decarboxylation using iodosylbenzene or iodosylbenzene 
diacetate and N-halosuccinimide, a procedure which gave good results for a limited 
number of α,β-unsaturated carboxylic acids,[10] was tried with 7-phenylacetyl-ADCA 
4 as the substrate in order to synthesize 4-norcephalosporins 5 (Scheme 7). 
Unfortunately, no decarboxylation reaction did take place according to TLC analysis. 
Presumably, halogenation of the starting material had occurred instead of 
decarboxylation. Even an excess of N-halosuccinimide or longer reaction times did 
not lead to any decarboxylation product. 
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5b  
a) 0.5 equiv.  iodosylbenzene diacetate, CH3CN / H2O (2:1), NBS, 60°C, 30'; b) NBS, Mn(OAc)2 (0.1 equiv.), 
CH3CN / H2O (1:1), r.t., 16h; c) LiOAc (0.1 equiv.), CH3CN / H2O (1:1), NBS, 8h. 
Scheme 7. 
 
Using the procedures of Chowdhury et al.,[11],[12],[15] in which the non-radical 
Hunsdiecker reaction on α,β-unsaturated carboxylic acids is performed in a catalytic 
fashion, was also not successful. TLC analysis did not show any of the desired 
products. Therefore, it can be concluded that a non-radical approach is not likely to 
work for substrates of type 4. The conditions as used in the ionic decarboxylation 
reactions cannot be applied to the rather complicated and sensitive cephalosporin 
system without major changes. Therefore, more attention was paid to the radical 
approach of the decarboxylation reaction of 4. 
 
 
Radical approach 
The classical Hunsdiecker conditions are not suitable for the halo-decarboxylation of 
4. It is obvious that methods using molecular halogen as the halogen radical source 
cannot be applied for the halo-decarboxylation of 4 because of the presence of the 
olefin moiety. Furthermore, ring-opening reactions have been reported when 
molecular chlorine was brought into reaction with a penicillin molecule.[19] 
Moreover, the use of lead(IV) acetate in the presence of metal halides does not seem 
a good choice because this aggressive reagent causes unwanted side reactions and 
the work-up is usually troublesome.[20] A typical example is the unwanted 
Pummerer rearrangement at the sulfide of the cephalosporin, which takes place 
when the rather sensitive cephalosporin system is treated with lead(IV) acetate.[19] 
Finally, the most important limitation is the reported poor synthetic efficiency for 
α,β-unsaturated carboxylic acids (cinnamic acid derivatives).[17],[20] Therefore, no 
experimental attention was paid to the radical Hunsdiecker reaction and its variants. 
 
The radical chain decarboxylation process involving the thermal or photochemical 
decomposition of thiohydroxamic esters, as developed by Barton et al.,[17],[21] seems a 
suitable method for the halo-decarboxylation of 4, as milder reaction conditions are 
used and no free halogen is present. It is assumed that the thermal or photochemical 
decomposition of the thiohydroxamic esters initially produces carboxyl radical 7, 
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which then rapidly decarboxylates to the corresponding carbon radical 9 (Scheme 8). 
In the presence of an efficient radical trapping agent X-Y, substitution takes place to 
give 11 and a new radical 10. Reaction of this radical 10 with 6 leads to propagation 
of this chain process. In the absence of an efficient trapping agent propagation occurs 
by reaction of the carbon radical 9 with the thiohydroxamic ester 6 leading to pyridyl 
sulfide 12. The attractive features of Barton's radical decarboxylation process are its 
synthetic scope and the relatively mild reaction conditions. By varying the radical 
trapping agent X-Y, in principle a great variety of different substitution products 11 
can be obtained.[22]  
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Scheme 8. 
 
When this mechanism is projected on the decarboxylation of 7-phenylacetyl-ADCA 
4, the intermediate formation of vinylic radical 13 is expected (Scheme 9). Usually 
formation of vinylic radicals is rather difficult and requires harsh conditions. 
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Scheme 9. 
 
This vinylic radical may exhibit a high reactivity since it is not stabilized by any 
conjugation. Thus, the decarboxylation of vinylic carboxylic acids requires, as does 
the decarboxylation of aromatic acids, a high activation energy. Therefore, the yields 
of the vinylic type of decarboxylation products are generally low.[20] This is 
illustrated by the reluctance of aromatic acids to undergo radical type 
decarboxylation. Once the vinylic radical 13 is formed it presumably reacts with any 
trapping agent available in the reaction mixture. This would be beneficial for the 
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scope of such radical reactions in the cephalosporin system. Thus, the conceivable 
occurrence of such vinylic radicals 13 may extend this Barton methodology to 
cephalosporins. This would considerable enhance the scope of Barton's radical 
decarboxylation reaction. 
 
Even though Barton’s radical decarboxylation reaction is a well-studied reaction and  
is rather general applicable for primary, secondary, tertiary aliphatic acids, and to 
some extent also for aromatic acids, not much attention has been paid to the α,β-
unsaturated acids.[23] Only a few examples of its application to α,β-unsaturated acids 
(mainly cinnamic acid or benzoic acid derivatives) are described.[10] The yields of the 
corresponding decarboxylation products, mostly bromides, are usually low. The few 
examples, in which reasonable yields have been reported, are collected below.[24] 
Clearly, these substrates do not contain additional functionalities that may cause 
unwanted side reactions. This in sharp contrast to cephalosporins, which have the 
sensitive β-lactam ring in addition to the vulnerable sulfur atom. 
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H
H
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R = Ph, iPr
(     )
 
 
Initially, route A using thiohydroxamic ester 14 was examined (Scheme 10). The 
required ester was prepared by converting acid 4 into the corresponding acyl 
chloride using oxalyl chloride, followed by treatment with the sodium salt of N-
hydroxypyridine-2-thione (Scheme 10). Usually, such so-called Barton esters are 
rather unstable compounds.[25] Due to its presumed instability, thiohydroxamic ester 
14 was immediately subjected to the radical decarboxylation conditions. In order to 
get insight in the reaction conditions and the efficiency of this radical 
decarboxylation process, the replacement of the carboxylic acid moiety by bromide 
was studied first. This type of trapping reaction usually gives good to excellent 
yields. For this purpose 14 was heated in bromotrichloromethane at reflux, while 
irradiating with a tungsten lamp. In this reaction the solvent bromotrichloromethane 
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also acts as the trapping agent. Although TLC analysis showed no starting material 
anymore, the yield of bromo-decarboxylation product 5b was disappointing (8-10%). 
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X = Cl, Br, I, SPy, SPh, SePh, H
 
 
a) oxalyl chloride, CH2Cl2, 0 ºC, 30’, 81%; b) 1 equiv. Barton reagent (Na-salt), CH2Cl2, r.t., overnight, 95%; c) 
radical trap (solvent), reflux, 30% AIBN, 30’. 
Scheme 10. 
 
Table 1: Results of Barton's radical decarboxylation reactions from ester 14  
entry: product: trapping agent: product (-X): % yield method A: 
1 5a 
5g 
14 
CCl4 Cl 
 
9 
9 
50 
2 5b CBrCl3 Br 60 
3 5c CHI3 I 80 
4 5d (PhSe)2 SePh 34a 
5 5e 
5g 
(PhS)2 SPh 
H 
38a 
9 
6 5f 
5g 
- Spy 
H 
20b 
16 
7 5g tert-BuSH H 30 
a  Decomposition during chromatography; TLC analysis showed a yield > 70% 
b  Product thermally unstable (decomposition under reaction conditions) 
 
Barton et al. already reported that decarboxylation reactions of aromatic 
thiohydroxamic esters gave relatively low yields of the corresponding bromo-
decarboxylation products.[23] The thiohydroxamic ester concentration builds up as a 
result of a relatively slow decarboxylation step of the carboxylic radical (according to 
Scheme 8). Once the reactive vinylic radical is formed, a highly efficient propagation 
process takes place in which the vinylic radical attacks the Barton ester leading to the 
formation of sulfide 12 in a large amount (Scheme 8). In the present case, the 
formation of pyridyl sulfide 5f would be expected. However, no sulfide 5f was 
isolated.  
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The following reasoning can be put forward to improve the Barton reaction. By 
generating more trichloromethyl radicals, the concentration Barton ester 14 during 
the reaction would decrease and hence favor the desired pathway, thereby 
suppressing unwanted side reactions leading to pyridyl sulfide 5f. Indeed, prior 
addition of the external radical initiator AIBN (30-60%) to the reaction mixture in 
order to accelerate the decomposition of the thiohydroxamic ester 14 and to avoid 
the formation of sulfide 5f, resulted in a more efficient attack of the vinylic radical to 
ester 14. A remarkable improvement from 8 to 50% yield of bromide 5b was 
achieved in this manner.  
 
In contrast with the published examples, it appeared possible to isolate 
thiohydroxamic ester 14 which proved to be stable at room temperature for several 
weeks. The use of the more pure ester in the Barton decarboxylation process led to 
an extra improved product formation. Bromide 5b was now obtained in yields up to 
60% (Table 1).  
 
The halo-decarboxylation reaction of 14 was studied under standard conditions with 
a variety of trapping agents. All results are collected in Table 1. For the synthesis of 
4-chloro-7-ADCA 5a a solution of thiohydroxamic ester 14 in dichloromethane was 
added dropwise to a solution of AIBN in a mixture of chlorobenzene and 
tetrachloromethane under reflux, while irradiating with a tungsten lamp. A mixture 
of two products together with some starting material was obtained from which the 
desired chloride 5a was isolated in only 9%. The second product was identified as 
the parent β-lactam skeleton 5g (9% yield), while 50% of starting material 14 was 
recovered (Table 1). The nature of the trapping agent is the major factor that causes a 
lower yield for the chloro-decarboxylation as compared with the bromo-
decarboxylation. It is energetically more difficult to break a C-Cl bond (e.g. in CCl4) 
than a C-Br bond (e.g. in CBrCl3). Therefore,  trapping of the vinyl radical is less 
efficient for organic chlorides, and the yield of the corresponding chloride is 
consistently lower than that of the corresponding bromide.  
 
Attempts to improve the formation of chloride 5a by using other chlorine donors as 
trapping agents (e.g. NCS or tert-butyl hypochorite,[25] trityl chloride, Cl3CSCl, 
hexachloroacetone) did not meet with success. Sonication-induced halo-
decarboxylation, as was described by Dauben et al.,[26] in some cases leads to a better 
yield of the corresponding chloro-decarboxylation products. The ultrasonic 
irradiation (20 kHz, <60 W / cm2) of thiohydroxamic ester 14 or 15 (Scheme 13) in 
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CCl4 at room temperature did not show any reaction at all, whereas irradiation in 
BrCCl3 after 10 minutes gave complete conversion to bromide 5b (TLC analysis). 
Apparently, ultrasound is capable to produce trichloromethyl radicals from 
bromotrichloromethane, but not from tetrachloromethane. This result convincingly 
demonstrates that the reluctance of the C-Cl bond cleavage in the trapping agent 
under the conditions applied, is the major factor that is responsible for the 
inefficiency of this chloro-decarboxylation process. As may be expected on the basis 
of the relative weakness of the C-I bond, an excellent result was obtained for the 
iodo-decarboxylation of 14, when iodoform was used as the trapping agent. By 
generating radical 13 in chlorobenzene in the presence of a large excess of iodoform 
iodide 5c was obtained in a yield of 80% (Table 1).  
 
Having successfully accomplished the halo-decarboxylation of acid 4 using Barton's 
procedure, the question arose whether this methodology would be applicable for the 
introduction of other heteroatom containing substituents at the C4 position. The 
formation of pyridyl sulfide 12 (see Scheme 8) usually takes place in the absence of a 
radical trap.[25] In the present case, pyridyl sulfide 5f could be readily synthesized by 
heating ester 14 in refluxing chlorobenzene in the presence of AIBN as the radical 
initiator. This sulfide 5f appeared to be thermally unstable under the reaction 
conditions used, and therefore the yield of the isolated product was only 20% (Table 
1). The second product was β-lactam 5g (16% yield) in which the carboxylic group is 
replaced by a hydrogen atom. The inherent instability of pyridyl sulfide 5f may be 
the reason that this product could not be isolated in other trapping experiments. 
 
The radical chalcogenation of a variety of carboxylic acids has already been studied 
by Barton et al.[27] and was shown to proceed quite well in many cases, depending on 
the efficiency of the trapping agent used. When diphenyl disulfide or diphenyl 
diselenide was used as the trapping agent under standard reaction conditions, 
radical decarboxylation of 4 led to phenylsulfide 5e or its selenium analogue 5d in 
38% and 34% yield, respectively (Table 1). In the case of diphenyldisulfide as the 
trapping agent, in addition of sulfide 5e also 9% of parent compound 5g was 
isolated. TLC analysis, however, showed conversions of higher than 70%, indicating 
considerable decomposition of the products. The sulfur and selenium containing 
products were indeed rather unstable. During purification via column 
chromatography over silica gel considerable loss of products had to be accepted. 
These results show that the disulfide bond and diselenide bond in the trapping 
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agents are weak enough to compete with the thiohydroxamic ester in trapping the 
vinylic radical 13. 
 
The product 5g, which essentially is the result of a decarboxylation, could be 
obtained more efficiently using tert-butyl mercaptane as the trapping agent under 
standard conditions (30% yield; Table 1). 
  
In order to establish the scope of the Barton reaction, 7-ACA 16 (containing an 
acetate group at the C10 position) was also subjected to the Barton decarboxylation 
procedure (Scheme 11). The presence of the relative labile acetate group caused no 
problems in the case of the bromo-decarboxylation, as bromide 18 was obtained in 
65% using method A. This finding is very pleasing as the acetate group can be used 
for further synthetic elaboration at the C10 position, and thereby allowing the 
synthesis of a variety of 4-halo-3-substituted cephalosporins. 
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a) oxalyl chloride, CH2Cl2, 0 ºC, 30’, 70%; b) 1 equiv. Barton reagent (Na-salt), CH2Cl2, r.t., overnight, 97%;  
c) radical trap (solvent), reflux, 30% AIBN, 30’, 65%. 
Scheme 11. 
 
The only literature, examples, which led to efficient decarboxylation of α,β-
unsaturated acid derivatives, all involve slightly different thiohydroxamic esters 
(derived from N-hydroxy-4-methyl-2-thiazolinethione).[24],[28],[29] In earlier 
studies,[29],[30] these readily available compounds were found to be much less 
sensitive to visible light and significantly more robust towards hydrolysis. This 
would allow a slow generation of radicals without unwanted ionic side reactions, 
usually caused by anhydride formation, as shown in Scheme 12.[17] 
N
S
OR
O
6
N
S
OR
O
N
N
+
S
OR
O
S
R O
O
R O R
OO
N
N
+
S
O
S
-
+
-
 
Scheme 12. 
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After optimization experiments, the best results were obtained using the slightly 
modified Barton ester 15 (Scheme 14). This ester appeared to be more stable than 14 
and could be handled better in the subsequent decarboxylation reactions.[28] An 
additional advantage is the decreased formation of very polar products (TLC 
analysis), caused by decomposition of the thiohydroxamic ester via an ionic pathway 
(Scheme 12).[17] The results of the radical decarboxylation reactions using ester 15 
(route B) are collected in Table 2.  
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a) oxalyl chloride, CH2Cl2, 0 ºC, 30’, 81%; b) 1.0 equiv. Barton reagent (alcohol), CH2Cl2, r.t., overnight, 96%; 
c) radical trap (solvent), reflux, 30% AIBN, 30’. 
Scheme 13. 
 
Table 2.: Results of Barton's radical decarboxylation reactions from esters 14 and 15 
entry: trapping 
agent: 
product: product 
(-X): 
%  yield 
method A: 
% yield 
method B: 
1 CCl4 5a 
5g 
14 or 15 
Cl 
H 
 
9 
9 
50 
12 
9 
60 
2 CBrCl3 5b Br 60 80 
3 CHI3 5c I 80 80 
4 (PhSe)2 5d SePh 34a 21a 
5 (PhS)2 5e 
5g 
SPh 
H 
38a 
9 
28a 
6 - 5f 
5g 
Spy 
H 
20b 
16 
-c 
7 tert-BuSH 5g H 30 46 
a  decomposition during flash chromatography; TLC analysis showed a yield > 70% 
b  product thermally unstable (decomposition under reaction conditions) 
c not performed 
 
The data in this Table reveal that in most cases the yields of the decarboxylation 
products using ester 15 are significantly higher. Especially the introduction of 
bromine and iodine appears to be more efficient, whereas the introduction of 
hydrogen and chlorine is still troublesome. The lower yields observed for the 
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formation phenylsulfide 5e and phenylselenide 5d are probably not the result of 
lower product efficiency in the radical decarboxylation process, but are most likely 
due to the instability of these compounds on silica gel (vide supra). 
 
 
4.4 Concluding remarks  
 
The results described in this chapter show that radical decarboxylation reactions 
using Barton's thiohydroxamic radical chemistry is successful in cephalosporin 
molecules. Other methods, following non-radical approaches all failed. Starting from 
the model substrate 7-phenylacetyl-ADCA 4, and using the slightly modified 
thiohydroxamic ester 15, a variety of 4-functionalised cephalosporins has been 
synthesized. It should be noted that this successful radical approach to the halo-
decarboxylation is highly remarkable for the sensitive β-lactam system. The only 
drawback is the rather low efficiency for the introduction of chloride. However, this 
is a general phenomenon in the Barton halo-decarboxylation, and due to the 
relatively high stability of the organic chlorine donors. The results of this model 
study offer good prospects for a functionalization of cephalosporins at the C3-
position leading to the important 3-norcephalosporins (including 3-
halocephalosporins), using this Barton radical decarboxylation methodology.  
 
 
4.5 Experimental part 
 
General remarks 
100 MHz 1H-NMR spectra were recorded on a Bruker AC 100 spectrometer and 300 MHz 1H-NMR 
spectra and all 13C-NMR spectra were recorded on a Bruker AC 300 using Me4Si as internal standard. 
All coupling constants are given as 3J in Hz, unless indicated otherwise. Melting points were 
measured with a Reichert Thermopan microscope and are uncorrected. IR spectra were recorded on a 
Bio-Rad FTS-25 instrument. For mass spectra a double focusing VG7070E mass spectrometer was 
used. For some samples, High Resolution FAB was carried out using a JEOL JMS SX/SX102A four-
sector mass spectrometer (JEOL Ltd. 1-2 Musashino  3-chome, Akishima Tokyo), coupled to a MS-MP 
9021D/UPD data system (University of Amsterdam). Elemental analyses were conducted on a Carlo 
Erba Instruments CHNSO EA 1108 element analyzer. For the determination of optical rotations a 
Perkin-Elmer 241 polarimeter was used. Solvents were dried using the following methods: 
dichloromethane was distilled from P2O5; ethyl acetate was distilled from K2CO3; diethyl ether was 
distilled from NaH; hexane and heptane were distilled from CaH2. All other solvents were of 
analytical grade. Thin layer chromatography (TLC) was carried out on a Merck precoated silica gel 60 
F254 plates (0.25 mm). Spots were visualized with UV or using a molybdate spray. Flash 
chromatography was carried out at a pressure of ca. 1.5 bar, using Merck Kieselgel 60H. Column 
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chromatography at atmospheric pressure was performed with ACROS silicagel (0.035-0.070 mm; pore 
diameter ca. 6 nm). 
Systematic names were generated using the ACD/Name program provided by Advanced Chemistry 
Development Inc. (Toronto, Canada). 
 
 
(7R,7aR)-3-Methyl-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-2H,6H-azeto[2,1-b][1,3]thiazine-4-
carbonyl chloride (4a) 
To a solution of 7-phenylacetyl-ADCA 4 (10.0 g; 0.0312 mol) in dichloromethane (250 ml) was added 
oxalyl chloride (3.6 ml; 1.3 equivalents) and a few drops of DMF. After stirring for ca. 1h, the reaction 
mixture became clear. Then two volumes of hexane (300 ml) were added. The resulting precipitate 
was collected by filtration, washed with hexane and dried in vacuo. The crude acid chloride 4a (8.60 g; 
81% yield) was used for reactions without further purification. 
 
General procedure for the radical decarboxylation reactions (1.0 mmol scale) 
Thiohydroxamic ester 14, 15 or 17 in dichloromethane (3-5 ml) protected from light was gradually 
added in 15-30 min. to a solution of trapping agent in an appropriate solvent (or trapping agent only) 
containing radical initiator AIBN (0.055 g; 0.3 mmol). During the addition, the reaction mixture was 
heated at reflux (or 110 °C) under nitrogen and irradiated with a 250 W tungsten lamp. Then the 
reaction mixture was stirred for another 10 minutes, cooled to room temperature and concentrated 
under reduced pressure. The crude product was purified via flash chromatography over silica gel, 
followed by recrystallisation.  
 
N1-[(7R,7aR)-4-Chloro-3-methyl-6-oxo-7,7a-dihydro-2H,6H-azeto[2,1-b][1,3]thiazin-7-yl]-2-
phenylacetamide (5a)  
Following the general procedure (Barton ester 15, addition time: 25 min., chlorobenzene as solvent 
and tetrachloro methane as trapping agent (v/v = 1/1)), flash chromatography (SiO2, n-hexane / 
ethyl acetate 1:1) gave 5a as a slightly yellow solid (0.076 g; 12%) and 5g (0.054 g; 9%) and starting 
thiohydroxamic ester 15 (60%). 
Mp 194-196°C (dec.); [α]D = +150° (c = 0.11; acetone);  1H-NMR (100 MHz, CDCl3) δ (ppm) = 1.85 (s, 
3H, CH3), 3.09 and 3.49 (qAB, JAB = 17.3 Hz, 2H, SCH2), 3.64 (s, 2H, PhCH2), 5.01 (d, J = 4.8 Hz, 1H, 
NHCHCHS), 5.76 (dd, J = 4.8 Hz J = 9.0 Hz, 1H, NHCHCHS), 6.35 (d, J = 9.0 Hz, 1H, NH), 7.31 (m, 5H, 
PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 18.7 (CH3), 30.0 (SCH2), 43.4 (PhCH2), 59.3 (CHNH), 59.6 
(CHS), 115.0 (=CCl), 119.5 (=C(CH3)), 127.8, 129.2, 129.5 and 133.5 (PhC), 164.1 (C=O, lactam), 171.1 
(PhCH2C(O)); IR (KBr): ν 3266 (broad, NH), 1777 (C=O, lactam), 1661 and 1535 (C=O, amide), 1340 
(CN) cm-1; MS (FAB+, NOBA): m/z (%) = 345 (4) [M+Na]+, 323 (22) [M+H]+, 289 (8) [M+H-Cl]+, 57 
(100); HRMS (CI+, m/z): calculated for C15H16O2N2SCl: 323.06210 amu. Found: 323.06194 ± 0.00097 
amu. 
 
N1-[(7R,7aR)-4-Bromo-3-methyl-6-oxo-7,7a-dihydro-2H,6H-azeto[2,1-b][1,3]thiazin-7-yl]-2-
phenylacetamide (5b) 
Following the general procedure (Barton ester 15, addition time: 15 min., bromotrichloromethane (15 
ml) as trapping agent, flash chromatography (SiO2, n-hexane / ethyl acetate 1:1) resulted, after 
crystallization (hexane / ethyl acetate), in 5b (0.293 g; 80%) as white needles. 
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Mp 156-157°C; [α]D = +42° (c = 0.1; CHCl3); 1H-NMR (100 MHz, CDCl3) δ (ppm) = 1.86 (s, 3H, CH3), 
3.12 and 3.50 (qAB, JAB = 17.4 Hz, 2H, SCH2), 3.64 (s, 2H, PhCH2), 5.03 (d, J = 4.7 Hz, 1H, NHCHCHS), 
5.75 (dd, J = 4.7 Hz J = 9.0 Hz, 1H, NHCHCHS), 6.17 (d, J = 9.0 Hz, 1H, NH), 7.32 (m, 5H, PhH); 13C-
NMR (75 MHz, CDCl3) δ (ppm) = 21.3 (CH3), 30.3 (SCH2), 43.3 (PhCH2), 59.3 (CHNH), 59.9 (CHS), 
107.6 (=CBr), 118.5 (=C(CH3)), 127.7, 129.2, 129.5 and 133.6 (PhC), 164.3 (C=O, lactam), 171.1 
(PhCH2C(O)); IR (KBr): ν 3265 (broad, NH), 1768 (C=O, lactam), 1649 and 1535 (C=O, amide), 1340 (C-
N) cm-1; MS (EI+): m/z (%) = 366 (<1) and 368 (<1) [M+], 338 (2) and 340 (2) [M-CO]+, 259 (11) [M-CO-
Br]+, 91 (100) [PhCH2]+; elem. anal.: calc. (found) for C15H15O2N2SBr: C: 49.06 (49.06), H: 4.12 (4.14), N: 
7.63 (7.54), S: 8.43 (8.69). 
 
N1-[(7R,7aR)-4-Iodo-3-methyl-6-oxo-7,7a-dihydro-2H,6H-azeto[2,1-b][1,3]thiazin-7-yl]-2-
phenylacetamide (5c) 
Following the general procedure (Barton ester 15, addition time: 25 minutes, chlorobenzene (5 ml) as 
solvent, iodoform (1.18 g; 3 equiv.) as trapping agent dissolved in chlorobenzene (10 ml), flash 
chromatography (SiO2, n-hexane/ethyl acetate 1:1) resulted, after crystallization (hexane / ethyl 
acetate), in iodide 5c (0.324 g; 80%) as white needles. 
Mp 158-159°C (dec.); [α]D = +83° (c = 0.41; acetone); 1H-NMR (100 MHz, CDCl3) δ (ppm) = 1.91 (s, 3H, 
CH3), 3.20 and 3.57 (qAB, JAB = 17.1 Hz, 2H, SCH2), 3.65 (s, 2H, PhCH2), 5.05 (d, J = 4.7 Hz, 1H, 
NHCHCHS), 5.72 (dd, J = 4.7 Hz J = 9.0 Hz, 1H, NHCHCHS), 6.08 (d, J = 9.0 Hz, 1H, NH), 7.32 (m, 5H, 
PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 26.2 (CH3), 29.9 (SCH2), 43.4 (PhCH2), 59.5 (CHNH), 60.0 
(CHS), 107.3 (=CI), 124.4 (=C(CH3)), 127.7, 129.2, 129.5 and 133.6 (PhC), 164.5 (C=O, lactam), 170.9 
(PhCH2C(O)); IR (KBr): ν 3280 (broad, NH), 1757 (C=O, lactam), 1655 and 1536 (C=O, amide), 1355 (C-
N) cm-1; ; MS (EI+): m/z (%) = 414 (<1) [M+], 386 (<1) [M-CO]+, 287 (6) [M-I]+, 259 (26) [M-CO-I]+, 240 
(50), 176 (48), 141 (24), 91 (100) [PhCH2+]; elem. anal.: calc. (found) for C15H15O2N2SI: C: 43.49 (43.69), 
H: 3.65 (3.63), N: 6.76 (6.77), S: 7.74 (8.02). 
 
N1-[(7R,7aR)-3-Methyl-6-oxo-4-(phenylselanyl)-7,7a-dihydro-2H,6H-azeto[2,1-b][1,3]thiazin-7-yl]-2-
phenylacetamide (5d) 
Following the general procedure (Barton ester 14, addition time: 25 min., chlorobenzene (5 ml) as 
solvent and diphenyldiselenide (0.625 g; 2 equiv.) as trapping agent), flash chromatography (n-hexane 
/ ethyl acetate 2:1) gave 5d (0.145 g; 34%) as a white solid. The product appeared to be unstable 
during purification by flash chromatography (SiO2, n-hexane / ethyl acetate 1:1).  
Mp 118-120°C (dec.); [α]D = +48° (c = 0.55; acetone); 1H-NMR (100 MHz, CDCl3) δ (ppm) = 1.85 (s, 3H, 
CH3), 3.49 and 3.09 (qAB, JAB = 17.3 Hz, 2H, SCH2), 3.64 (s, 2H, PhCH2), 5.01 (d, J = 4.8 Hz, 1H, 
NHCHCHS), 5.76 (dd, J = 4.8 Hz J = 9.0 Hz, 1H, NHCHCHS), 6.35 (d, J = 9.0 Hz, 1H, NH), 7.31 (m, 5H, 
PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 22.1 (CH3), 29.6 (SCH2), 43.2 (PhCH2), 58.7 (CHNH), 59.5 
(CHS), 108.2 (=CCH3), 125.3 (=CSPh), 127.5, 127.5, 128.9, 129.2, 129.3, 129.4, 132.1, 132.2, 132.3 and 
133.8 (PhC), 163.9 (C=O, lactam), 171.2 (PhCH2C(O)); IR (KBr): ν 3273 (broad, NH),  3053 (CH, 
phenyl), 1761 (C=O, lactam), 1658 and 1534 (C=O, amide), 1335 (C-N) cm-1; MS (FAB+, NOBA): m/z 
(%) = 467 (16) [M+Na]+, 445 (31) [M+H]+, 416 (8) [M+H-CO]+, 339 (8), 270 (56), 260 (28) [M+H-CO-
SePh]+, 91 (100) [PhCH2+]; elem. anal.: calc. (found) for C21H20O2N2SSe: C: 56.88 (56.54), H: 4.55 (4.48), 
N: 6.32 (6.29). 
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N1-[(7R,7aR)-3-Methyl-6-oxo-4-(phenylsulfanyl)-7,7a-dihydro-2H,6H-azeto[2,1-b][1,3]thiazin-7-yl]-
2-phenylacetamide (5e) 
Following the general procedure (addition time: 20 min., chlorobenzene (15 ml) as solvent containing 
diphenyldisulfide (2.18 g; 10 equiv.) thiohydroxamic ester 14 added in chlorobenzene (3 ml)), flash 
chromatography (SiO2, n-hexane / ethyl acetate 1:1) gave 5e (0.150 g; 38%) as a yellow-white solid 
and 5g (0.027 g; 9%) as yellow-white solid. 
Mp 182-184°C (dec.); [α]D = +25° (c = 0.55; acetone); 1H-NMR (100 MHz, CDCl3) δ (ppm) = 2.05 (s, 3H, 
CH3), 3.17 and 3.53 (qAB, JAB = 17.8 Hz, 2H, SCH2), 3.60 (s, 2H, PhCH2), 4.88 (d, J = 4.7 Hz, 1H, 
NHCHCHS), 5.54 (dd, J = 4.8 Hz J = 8.9 Hz, 1H, NHCHCHS), 6.35 (d, J = 8.9 Hz, 1H, NH), 7.28 (m, 5H, 
PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 20.2 (CH3), 29.9 (SCH2), 43.2 (PhCH2), 58.7 (CHNH), 59.6 
(CHS), 123.1 (=CCH3), 124.8 (=CSPh), 127.1, 127.5, 129.0, 129.4, 129.4, 129.6, 130.0, 133.3 and 133.8 
(PhC), 163.7 (C=O, lactam), 171.2 (PhCH2C(O)); IR (KBr): ν 3291 (broad, NH), 3044 (CH, phenyl), 1768 
(C=O, lactam), 1660 and 1531 (C=O, amide), 1334 (C-N) cm-1; MS (FAB+, NOBA): m/z (%) = 419 (33) 
[M+Na]+, 397 (47) [M+H]+, 368 (13) [M+H-CO]+, 261 (19) [M+H-CO-SPh]+, 222 (73), 178 (35), 109 (26) 
[SPh+], 91 (100) [PhCH2]+; elem. anal.: calc. (found) for C21H20O2N2S2: C: 63.61 (63.47), H: 5.08 (5.00), N: 
7.06 (6.98). 
 
N1-[(7R,7aR)-3-Methyl-6-oxo-4-(2-pyridylsulfanyl)-7,7a-dihydro-2H,6H-azeto[2,1-b][1,3]thiazin-7-
yl]-2-phenylacetamide (5f) 
Thiohydroxamic ester 5 (0.430 g; 1 mmol) and AIBN (100 mg) were dissolved in chlorobenzene (5 ml) 
and the reaction mixture was heated at reflux for 90 min. and irradiated, under nitrogen, with a 250 
W tungsten lamp. Then the reaction mixture was allowed to cool to room temperature and 
concentrated in vacuo. The crude product was purified by flash chromatography (SiO2, n-hexane / 
ethyl acetate 1:3) which afforded 5f (0.076 g, 20%) as an yellow-white solid. 
Mp 85-87°C (dec.); [α]D = +40° (c = 0.27; acetone); 1H-NMR (100 MHz, CDCl3) δ (ppm) = 2.01 (s, 3H, 
CH3), 3.21 and 3.61 (qAB, JAB = 17.7 Hz, 2H, SCH2), 3.72 (s, 2H, PhCH2), 5.07 (d, J = 4.7 Hz, 1H, 
NHCHCHS), 5.61 (dd, J = 4.7 Hz J = 8.8 Hz, 1H, NHCHCHS), 6.71 (d, J = 8.8 Hz, 1H, NH), 6.92-8.62 
(m, 9H, PhH and -PyH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 20.3 (CH3), 30.1 (SCH2), 43.2 (PhCH2), 
58.9 (CHNH), 59.6 (CHS), 113.5 (=CCH3), 120.7, 122.3 (PyC), 127.6, 129.4, 129.4 and 133.8 (PhC), 136.8 
(PyC), 137.5 (=C-SPy), 149.9 (=NCH=), 156.8 (SC=N), 163.4 (C=O, lactam), 171.3 (PhCH2C(O)); IR 
(KBr): ν 3258 (broad, NH), 1775 (C=O, lactam), 1659 and 1563 (C=O, amide), 1615 (SC=N), 1343 (C-N) 
cm-1; MS (FAB+, NOBA): m/z (%) = 398 (27) [M+Na]+, 365 (1) [M+H]+, 287 (3) [M-Py]+, 281 (9), 221 (18), 
136 (26) [M+H-SPy-PhCH2-CO]+, 57 (100); HRMS (CI+, m/z): calculated for C20H19O2N3S2: 398.09970 
amu. Found: 398.09922 ± 0.00119 amu. 
 
N1-[(7R,7aR)-3-Methyl-6-oxo-7,7a-dihydro-2H,6H-azeto[2,1-b][1,3]thiazin-7-yl]-2-phenylacetamide 
(5g)  
Following the general procedure (Barton ester 15, addition time: 25 min., chlorobenzene (10 ml) as 
solvent and tert-butylmercaptane (0.451 g; 5 equiv.) as trapping agent, AIBN (30%) added together 
with thiohydroxamic ester 15), flash chromatography (SiO2, n-hexane / ethyl acetate 1:1) resulted, 
after crystallization (hexane / ethyl acetate), in 5g (0.129 g; 46%) as white needles. 
Mp 231-233°C (dec.); [α]D = -35° (c = 0.52; acetone); 1H-NMR (100 MHz, CDCl3) δ (ppm) = 1.75 (s, 3H, 
CH3), 2.95 and 3.45 (qAB, JAB = 17.3 Hz, 2H, SCH2), 3.64 (s, 2H, PhCH2), 4.90 (d, J = 4.6 Hz, 1H, 
NHCHCHS), 5.70 (dd, J = 4.6 Hz J = 9.2 Hz, 1H, NHCHCHS), 6.28 (d, J = 9.2 Hz, 1H, NH) 6.41 (s, 1H, 
CH=), 7.31 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 21.2 (CH3), 28.2 (SCH2), 43.4 (PhCH2), 
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56.8 (CHNH), 59.0 (CHS), 109.6 (=CH), 116.4 (=C(CH3)), 127.7, 129.1, 129.5 and 133.7 (PhC), 163.4 
(C=O, lactam), 171.1 (PhCH2C(O)); IR (KBr): ν 3280 (broad, NH), 1757 (C=O, lactam), 1655 and 1536 
(C=O, amide), 1355 (C-N) cm-1; MS (EI+): m/z (%) = 288 (4) [M+], 260 (8) [M-CO]+, 176 (35), 114 (90), 91 
(100), [PhCH2+]; elem. anal.: calc. (found) for C15H16O2N2S: C: 62.48 (62.47), H: 5.59 (5.51), N: 9.71 
(9.68). 
 
2-Thioxo-1,2-dihydro-1-pyridinyl (7R,7aR)-3-methyl-6-oxo-7-[(2-phenylacetyl)amino]-7,7a- 
dihydro-2H,6H-azeto[2,1-b][1,3]thiazine-4-carboxylate (14) 
To a solution of acid chloride 4a (4.00 g; 11.8 mmol) in dichloromethane (80 ml) was added N-
hydroxypyridin-2-thione sodium salt (1.67 g; 0.95 equiv.). After stirring at room temperature for 15h 
the reaction mixture was extracted with a saturated solution of NaHCO3 (2x50 ml) and the organic 
layer was washed with brine. After drying (MgSO4) and concentration in vacuo Barton ester 14 (5.68 g; 
95%) was obtained as a strongly yellow colored solid material which was sufficiently pure for the 
decarboxylation reactions. 
Mp 78-83°C (dec.); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 2.18 (s, 3H, CH3), 3.21 and 3.58 (qAB, JAB = 
18.7 Hz, 2H, SCH2), 3.62 and 3,68 (qAB, JAB = 16.0 Hz, 2H, PhCH2), 5.07 (d, J = 4.7 Hz, 1H, 
NHCHCHS), 5.85 (dd, J = 4.7 Hz J = 9.1 Hz, 1H, NHCHCHS), 6.56 (d, J = 9.1 Hz, 1H, NH), 6.65 (dt, J = 
1.7 Hz J = 6.9 Hz, 1H, PyH), 7.20-738 (m, 6H, PhH, PyH), 7.69 (dd, J = 8.8 Hz J = 1.6 Hz, 1H, PyH), 7.83 
(dd, J = 6.9 Hz 4J = ~1.0 Hz, 1H, PyH); IR (KBr): ν 3281 (broad, NH), 3027 and 2923 (=CH-), 1774 (C=O, 
lactam and ester), 1650 and 1527 (C=O, amide), 1447 (CO2-N), 1367 (C-N), 1133 (C=S) cm-1; MS (FAB+, 
NOBA): m/z (%) = 457 (1) [M+Na]+, 434 (11) [M+H]+, 154 (100) [NOBA]*, 91 (22) [PhCH2+] (* 
defragmentation of NOBA matrix); 
 
4-Methyl-2-thioxo-2,3-dihydro-1,3-thiazol-3-yl (7R,7aR)-3-methyl-6-oxo-7-[(2-phenylacetyl)amino]- 
7,7a-dihydro-2H,6H-azeto[2,1-b][1,3]thiazine-4-carboxylate (15) 
3-Hydroxy-4-methyl-2,3-dihydro-1,3-thiazole-2-thione (0.662 g; 4.5 mmol) was added to a ice-cooled 
suspension of crude acid chloride 4a (1.75 g; 5.0 mmol) in dichloromethane (50 ml). The reaction 
mixture was stirred for 18h at room temperature. After addition of saturated aqueous NaHCO3, the 
aqueous layer was extracted with dichloromethane (3x75 ml). The combined organic layers were 
washed with brine (1x100 ml), dried (MgSO4), and concentrated in vacuo. The crude product was 
purified via column  chromatography (SiO2, ethyl acetate / heptane 1:1) to give 15 as a yellow-white 
solid (1.99 g; 96%). 
Mp 97-98°C (dec.); [α]D = -31° (c = 0.49; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 2.01 (s, 3H, 
CH3), 3.37 and 3.55 (qAB, JAB = 18.1 Hz, 2H, SCH2), 3.49 and 3.57 (qAB, JAB = 13.9 Hz, 2H, PhCH2), 5.01 
(d, J = 4.6 Hz, 1H, NHCHCHS), 5.57 (dd, J = 4.6 Hz, J = 8.4 Hz, 1H, NHCHCHS), 7.25 (m, 5H, PhH), 
9.07 (d, J = 8.4 Hz, 1H, NH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 19.6, 29.2, 41.8, 57.3, 59.0, 59.1, 
123.0, 126.7, 128.4, 129.2, 130.1, 136.1, 163.7, 164.5, 171.2; IR (KBr): ν 3270 (broad, NH), 3027 (=CH-), 
1777 (C=O, lactam and ester), 1658 and 1530 (C=O, amide), 1366 and 1336 (C-N), 1125 (C=S) cm-1; MS 
(FAB+, NOBA): m/z (%) = 484 (2) [M+Na]+, 462 (13) [M+H]+, 329 (9) [M+H-C4H6NS2]+, 287 (10) [M+H-
C4H6NS2-CO2]+, 154 (100) [NOBA]* (* defragmentation of NOBA matrix). 
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(7R,7aR)-4-Chlorocarbonyl-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-2H,6H-azeto[2,1-
b][1,3]thiazin-3-ylmethyl acetate (16a) 
This compound was prepared as described for the synthesis of acyl chloride 4a. Starting from 7-
phenylacetyl-ACA[7] 16 (2.0 g; 5.1 mmol) crude 16a was obtained as a white/yellow solid (1.46 g; 
70%), which was used without further purification.  
 
2-Thioxo-1,2-dihydro-1-pyridinyl (7R,7aR)-3-[(acetyloxy)methyl]-6-oxo-7-[(2-phenylacetyl)amino]-
7,7a-dihydro-2H,6H-azeto[2,1-b][1,3]thiazine-4-carboxylate (17) 
To a solution of acid chloride 16a (4.00 g; 11.8 mmol) in dichloromethane (80 ml) was added N-
hydroxypyridin-2-thione sodium salt (1.67 g; 0.95 equiv.). After stirring at room temperature for 15h 
the reaction mixture was extracted with saturated aqueous NaHCO3 and the organic layer was 
washed with brine. After drying (MgSO4) and concentration in vacuo, 17 (5.80 g; 97%) was obtained as 
a pale yellow solid material, which was sufficiently pure for the decarboxylation reactions. 
Mp 85-89°C (dec.); 1H-NMR (100 MHz, CDCl3) δ (ppm) = 2.09 (s, 3H, C(O)CH3), 3.42 and 3.64 (qAB, 
JAB = 18.8 Hz, 2H, SCH2), 3.66 (s, 2H, PhCH2), 5.02 (s, 2H, CH2OAc), 5.08 (d, J = 4.8 Hz, 1H, 
NHCHCHS), 5.92 (dd, J = 4.8 Hz J = 9.1 Hz, 1H, NHCHCHS), 6.47 (d, J = 9.1 Hz, 1H, NH), 6.62 (dt, J = 
8.7 Hz J = 1.8 Hz, 1H, PyH), 7.15-7.32 (m, 6H, PhH and PyH); 7.69 (dd, J = 8.7 Hz J = 1.8 Hz, 1H, PyH), 
7.72 (dd, J = 5.9 Hz J < 1.8 Hz, 1H, PyH); IR (KBr): ν 3289 (broad, NH), 3027 (=CH-), 1782 (C=O, lactam 
and ester), 1741 (C=O, acetyl), 1683 and 1527 (C=O, amide), 1447 (CO2-N), 1353 (C-N), 1227 (C-O, 
acetyl), 1133 (C=S) cm-1; MS (FAB+, NOBA): m/z (%) = 522 (3) [M+Na]+, 500 (25) [M+H]+, 331 (68), 237 
(46), 154 (100) [NOBA],* 136 (73), 91 (55). (* defragmentation of NOBA matrix). HRMS (FAB, m/z): 
calculated for C21H20O4N3S2+: 442.0895 amu. Found: 442.0891 ± 0.0044 amu. 
 
N1-(7R,7aR)-4-Bromo-3-[(isopropenyloxy)methyl]-6-oxo-7,7a-dihydro-2H,6H-azeto[2,1-
b][1,3]thiazin-7-yl-2-phenylacetamide (18) 
Following the general procedure (thiohydroxamic ester 17, addition time: 15 min., 
bromotrichloromethane (15 ml) as trapping agent, flash chromatography (SiO2, n-hexane / ethyl 
acetate 1:1) resulted, after crystallization (hexane / ethyl acetate), in 18 (0.276 g; 65%) as white 
needles. 
Mp 121-122°C (dec.); [α]D = +38° (c = 0.52; acetone); 1H-NMR (100 MHz, CDCl3) δ (ppm) = 2.08 (s, 3H, 
C(O)CH3), 3.34 and 3.54 (qAB, JAB = 17.4 Hz, 2H, SCH2), 3.86 (s, 2H, PhCH2), 4.73 (s, 2H, CH2OAc), 
5.07 (d, J = 4.9 Hz, 1H, NHCHCHS), 5.81 (dd, J = 4.9 Hz J = 9.0 Hz, 1H, NHCHCHS), 6.23 (d, J = 9.0 
Hz, 1H, NH), 7.27-7.33 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 20.7 (CH3), 27.9 (SCH2), 
43.2 (PhCH2), 59.5 (CHNH), 60.7 (CHS),  65.4 (CH2OAc), 112.0 (=CBr), 115.7 (=CCH2OAc), 127.7, 129.2, 
129.4 and 133.5 (PhC), 164.5 (C=O, lactam), 170.7 (OC(O)CH3), 171.2 (PhCH2C(O)); IR (KBr): ν 3264 
(broad, NH), 1777 (C=O, lactam), 1741 (C=O, acetyl), 1658 and 1535 (C=O, amide), 1226 and 1059 (C-
O, acetyl) cm-1; MS (FAB+, NOBA): m/z (%) = 447 (5) + 449 (5) [M+Na]+, 425 (6) and 427 (7) [M+H]+, 
365 (48) and 367 (50) [M+H-C2H4O2]+, 337 (15) and 339 (15) [M+H-C2H4O2-CO]+, 219 (27) and 221 (27) 
[M+H-C2H4O2-CO-PhCH2CO]+, 91 (100) [PhCH2+]; elem. anal.: calc. (found) for C17H17O4N2SBr: C: 
48.01 (47.98), H: 4.03 (4.14), N: 6.59 (6.48). 
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5 
 
 
A NEW SYNTHESIS OF 3-CARBOXYCEPHEMS AND 
THEIR APPLICATION IN THE SYNTHESIS OF  
3-NORCEHALOSPORINS 
 
 
 
 
 
 
 
 
 
 
5.1 Introduction 
 
Modifications of natural cephalosporins by chemical modification at C3 have yielded 
biologically important derivatives.[1] Amongst others, 3-norcephalosporins bearing 
non-carbon atom substituents directly attached to the C3 position are an interesting 
subclass of β-lactam antibiotics, particularly as potent orally active broad-spectrum 
drugs.[2]  
 
2 ceftibuten (R=CH(CH2CO2H))
3 ceftizoxime (R=N(OCH3))
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Figure 1. 
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Important examples are cefaclor (1), ceftibuten (2) (R=CH(CH2CO2H)) or ceftizoxime 
(3) (R=N(OCH3)) (Figure 1). The most frequently encountered strategy to prepare 
these compounds starts with the fermentation products penicillin G or V and 
involves ozonolysis as the key step for the inevitable oxidative removal of one 
carbon atom.[3] Hitherto, no method for the preparation of 3-norcephalosporins has 
been described involving 3-carboxy-cephalosporins as the key-intermediates 
(Scheme 1).  
 
N
S
O
NH2
X
CO2H
N
S
O
RHN
CO2R'
CO2H
X = H, Cl, Br, I  
Scheme 1. 
 
In chapter 4, the results of a synthetic study towards 3-norcephalosporins from 3-
carboxycephems have been presented. Non-radical as well as radical approaches to 
accomplish a (halo)-decarboxylation reaction on the model compound 7-
phenylacetyl-ADCA were investigated. Using Barton’s radical decarboxylation 
reaction, a variety of 4-functionalized cephalosporins could be synthesized. 
Moderate to good yields were obtained for the introduction of hydrogen, chloride, 
bromide, iodide, and for the incorporation of selenium- and sulfur-containing 
groups.[4] In order to apply these findings to the 3-carboxycephalosporins, an 
improved synthesis of these important intermediates was needed, since these 
compounds are not readily available. 
 
Although several syntheses of 3-carboxycephems have been reported, no convenient 
general procedure for both isomers regarding the double bond in the six-membered 
ring has been described so far. Spry et al.[5] and Peter et al.[6] were the first who 
synthesized the 3-carboxycephem derivatives from the corresponding 3-formylceph-
2-ems in a sequence of reactions. In these approaches the conversion of the formyl 
group into the carboxyl group involved at least four separate steps. Also starting 
from cephalosporin thiolactones, a multi step procedure (bromination, hydrolysis, 
oxidation and opening of the dioxo thiophene ring) afforded the 3-carboxyceph-3-
ems.[7] In addition, a few total syntheses have been reported.[8] Until now, no method 
for the direct oxidation of the 3-formylcephems to the 3-carboxycephems has been 
described. An economical and convenient synthesis of 3-carboxycephems with the 
double bond in the ∆3- as well in the ∆2-position will be reported in this chapter.[9]  
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Having secured the access to 3-carboxycephalosporins, the potential of the (halo)-
decarboxylation reaction on these substrates was investigated. It will be shown that 
Barton's radical decarboxylation methodology allows the conversion of 3-
carboxycephalosporins into 3-norcephalosporins with X = H, Cl, Br, and I. 
 
 
5.2 Results and discussion 
 
5.2.1 Synthesis of 3-carboxycephalosporins  
 
In designing a new synthesis of 3-norcephalosporins, all possible isomers of 3-
carboxycephalosporins with respect to the position of the double bond as well as the 
oxidation state of the sulfur atom had to be synthesized. It is well known that the 
chemical behavior, and therefore the stability, of the β-lactam nucleus strongly 
depends on the position of the double bond and the oxidation state of the sulfur 
atom. These subtle structural differences are possibly also of importance for the 
development of a new synthesis of 3-norcephalosporins.  
 
The 3-formylcephalosporins[10] were chosen as the starting material. First 3-
formylceph-3-em 4 was used in an oxidation reaction. Gratifyingly, oxidation of this 
formyl group in 4 to the carboxyl group was accomplished in a one step procedure 
by treatment with sodium chlorite (NaClO2) in THF / phosphate buffer and 
cyclohexene as chlorine scavenger, thereby producing 3-carboxyceph-2-em 5 in an 
excellent yield of 93% (Scheme 2). 
 
In principle, the synthesis of the corresponding 3-carboxyceph-3-em 7 (sulfoxide) can 
be realized in a similar manner. Again, formyl compound 6 was readily oxidized to 
the carboxylic acid by sodium chlorite in high yield. Disappointingly, when 3-
formylceph-3-em 8 was used as the starting material, direct oxidation to the 
corresponding carboxyl group, using conditions similar to those used for the 
synthesis of 3-carboxyceph-2-em 5, failed completely. Only severe decomposition 
had taken place as was deduced from TLC analysis. Probably opening of the β-
lactam ring occurred by attack of a nucleophile (e.g. water) as was also observed by 
others.[11] The presence of an electron-withdrawing group on the C3-position (in 
conjugation with the lactam moiety) also results in an enhanced chemical reactivity 
of the β-lactam C6 carbonyl group.[6] When compared with the corresponding 
sulfoxide 6, it should be mentioned that the sulfoxide function has a stabilizing effect 
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on the molecule.[12] Since this direct route to target compound 9 seems not possible, a 
detour via sulfoxide 7 was considered.  
 
S
N O
O
N
H
O
CO2tBu
S
N O
O
N
H
O
CO2tBu
S
N O
O
N
H
O
O
CO2tBu
S
N
O
N
H
O
CO2tBu
CO2H
S
N
O
N
H
O
CO2tBu
CO2H
S
N
O
N
H
O
O
CO2tBu
CO2H
a
b
c
d
e
4 5
6 7
8 9
X
 
a) NaClO2, cyclohexene, THF/phosphate buffer, 0°C, o/n 93%; b) NaClO2, cyclohexene, THF/phosphate buffer, 
0°C, o/n, 80%; c) NaClO2, cyclohexene, THF/phosphate buffer, 0°C, 0%; d) m-CPBA, MeCN-CH2Cl2, 0°C, 4h, 
78%; e) AcCl, SnCl2, DMF, 0°C, 2h, 55%. 
Scheme 2. 
 
This sulfoxide could be synthesized via two methods: i. by oxidation of the 
corresponding ∆2-isomer 5 with meta-chloroperbenzoic acid by adopting the 
procedure of Peter et al..[6] This oxidation gave compound 7 in 78% yield, ii. by 
oxidation of the formyl group in 6 (vide supra). The thus obtained sulfoxide 7 was 
then reduced to sulfide 9 by treatment with acetyl chloride in DMF in the presence of 
a catalytic amount of tin(II) chloride.[13] Thus, the abovementioned detour to target 
compound 9 via the sulfoxide route is indeed possible (Scheme 2). The chemistry 
shown in Scheme 2 clearly shows that subtle structural changes in the cephalosporin 
nucleus may change the course of reactions entirely. 
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5.2.2 Synthesis of 3-norcephalosporins using Barton's radical 
decarboxylation reactions  
 
The crucial step in the synthesis of 3-norcephalsporins is the coupling of the 3-
carboxycephalosporins with N-hydroxy-4-methyl-2-thiazolinethione. The question 
arises whether the same conditions can be used as for the synthesis of 4-
norcephalosporins, which were described in the preceding chapter.[4],[10]  
 
In a first attempt, the conversion of the carboxylic acid 7 to the corresponding acid 
chloride 10 was rather problematic, because above 0°C the formation of many by-
products was observed (Scheme 3). It turned out that acid chloride 10 is only stable 
below 0°C. The quality of the acid chloride 10 was simply tested by its reaction with 
methanol which produces the corresponding methyl ester. At ambient temperature, 
this simple test only showed a mixture of products, which points to severe 
decomposition of compound 10, and gave no methyl ester at all. It should be noted 
that during the formation of the acid chloride a reduction of the sulfoxide takes 
place, as was deduced from the spectra of the methyl ester.  
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a) Oxalylchloride, DMF (cat.), CH2Cl2, 0°C; b) 1 equiv. Barton reagent (hydroxy compound or Na-salt), 
CH2Cl2, r.t., overnight; c) DCC, Barton reagent (hydroxy compound), DMAP (cat.), CH2Cl2; d) BrCCl3, reflux, 
30% AIBN, 30’. 
Scheme 3. 
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As an alternative, an in situ formation of Barton ester 11a or 11b to avoid 
decomposition of the acid chloride, was attempted (Scheme 3). Thus, after formation 
of acyl chloride 10, the Barton reagent (e.g. N-hydroxy-4-methyl-2-thiazolinethione) 
was immediately added at 0°C. However, no ester 11a or 11b could be isolated. In a 
final attempt, acid chloride 10 was added to N-hydroxy-4-methyl-2-thiazolinethione 
in bromotrichloro methane at reflux under radical conditions, but again no Barton 
ester 11b or desired decarboxylation product 15b was observed. In view of these 
disappointing results with acid chloride 10, other methods were considered. 
 
As a first alternative, the coupling of N-hydroxy-4-methyl-2-thiazolinethione was 
tried with DCC (Scheme 3), but again the same serious problems were encountered. 
Apparently, the intermediate activated carboxylic acid derivative is, just as the acid 
chloride 10, unstable under the chosen conditions and undergoes decomposition 
instead of coupling with the Barton reagent (OH compound). From the literature it 
became clear that oxalyl chloride and DCC can activate sulfoxides to give 
Pummerer-type of reactions.[14] From the viewpoint of electronic effects, a number of 
unsaturated electron withdrawing groups have been introduced at the 3-position, 
which are in conjugation with the ∆3-double bond in the cephem ring. These groups 
participate in the delocalization of nitrogen's lone pair electrons thereby enhancing 
the reactivity (and therefore the instability) of the β-lactam amide bond.[15]  
 
In view of the disappointing experience in the ∆3-cephem derivative 7, a substrate 
with the double bond in the ∆2-position was investigated. Fortunately, 3-
carboxyceph-2-em 5 appeared to be much more stable, since DCC coupling with N-
hydroxy-4-methyl-2-thiazolinethione afforded Barton ester 12 in an excellent yield of 
90% (Scheme 4). Purification of this ester by column chromatography confirmed the 
improved stability, which is probably attributable to the ∆2-position of the double 
bond. Subsequently, the Barton bromo-decarboxylation reaction was studied. Thus, 
Barton ester 12 in dichloromethane was added under nitrogen to a solution of radical 
initiator AIBN in bromotrichloro methane at reflux, while irradiating with a tungsten 
lamp. This afforded bromide 13b after purification in quite an acceptable yield of 
69% (Table 1). 
 
Applying the appropriate trapping agent, chloride and iodide could be introduced 
as well (Table 1). As expected, the yield of the chloride product 13a is considerable 
lower than that of bromo compound 13b. The trapping agent CCl4 is much less able 
to release a chlorine radical than bromotrichloro methane a bromine radical. It 
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should be noted however, that in spite of the low yield, this introduction of a 
chloride at the C3 position constitutes a new approach to the synthesis of the β-
lactam core of cefaclor. 
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5 12
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a) DCC, Barton reagent (OH compound), DMAP (cat.), -30°C → r.t., overnight, 90%; b) radical trap (solvent), 
reflux, 30% AIBN, 15-30', column chromatography.  
Scheme 4. 
 
Table 1: Results of Barton's radical decarboxylation reactions with 3-carboxycephalosporin 5. 
 
 
Iodide 13c was obtained when iodoform was used as the trapping agent. The 
reaction conditions appeared to be very tricky, because prolonged reaction times 
lead to decomposition of the product. The solution slowly turned violet, due to the 
formation of several decomposition products. By monitoring the reaction very 
carefully, iodide 13c was isolated in a maximum yield of 28%. With diiodomethane 
as the trapping agent,[16] no desired iodide 13c was produced, but instead a small 
amount of sulfide 13d. The structure of 13d was deduced from its 1H-NMR and mass 
spectrum. The formation of this sulfide 13d is the result of trapping of the initial 
vinylic radical at C3 by the Barton ester 12. Such sulfides are usually encountered 
 
entry: trapping agent: product (X = ): nr: yield (%): 
1 CCl4 Cl 13a 10 
2 CBrCl3 Br 13b 69 
3 CHI3 I 13c 28 
4 CH2I2 SPy 13d trace 
5 tert-BuSH H 13e 15 
6 n-Bu3SnH H 13e 0 
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when no effective trapping agent is available (see discussion in Chapter 4, section 
4.3).  
 
The replacement of the C3 carboxyl group by hydrogen with the aim to synthesize 
the building block for target compound 2 or 3 was not as straightforward as 
expected. Initially, tert-butyl mercaptane as the trapping agent[17] seemed 
unsuccessful. Therefore, another trapping agent was tried, viz. tributyltin hydride, 
which has been used for decarboxylations before.[18] Unfortunately, according to a 
TLC analysis, only very polar products were formed. Detailed reconsidering the 
reaction conditions (especially shortening the reaction time), for tert-butyl 
mercaptane as the trapping agent, afforded the parent cephalosporin skeleton 13e in 
a modest yield of 15%.  
 
Comparison of the results obtained in this chapter with those for the Barton (halo)-
decarboxylation of the C4-carboxyl group in 7-phenylacetyl-ADCA reveals that the 
radical decarboxylation proceeded more smoothly in the case of the C4-carboxyl 
compound (see formulas below).  
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(see Chapter 4)
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Apparently, this difference in behavior between the Barton decarboxylation reaction  
at C3 an C4 must be due to the different nature of the respective intermediate vinylic 
radicals. When such a radical is generated from ∆3-3-carboxycephem 9 (see formula 
below), the presence of the electron-withdrawing ester group at C4 and a double 
bond in ∆3-position, cause a destabilizing effect on the β-lactam ring, which results in 
untimely decomposition reactions.[15]  
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O
CO2tBu
.
vinylic radical generated
from ∆3 3-carboxycephem 9  
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When the double bond is present in the ∆2-position, this destabilizing effect via 
conjugation with the β-lactam amide bond is not possible and therefore the vinylic 
radical generated from the ∆2-3-carboxycephem system show a better trapping 
behavior in the Barton reaction. In the model compound, the vinylic radical at C4 
does not suffer from destabilizing effects by a substituent at C3, hence better 
decarboxylation results are to be expected. From the discussion above, it may be 
concluded that for the synthesis of 3-norcephalosporins the ∆2-3-
carboxycephalosporins are the substrates of choice when the Barton radical 
decarboxylation is used as the key reaction. However, for antibacterial activity, it is 
necessary to convert the double bond to the ∆3-position. In β-lactam chemistry this 
conversion is a standard procedure and involves oxidation of the sulfide to the 
corresponding sulfoxide (e.g. with m-CPBA).[13] During this oxidation the double 
bond migrates to the ∆3-position. Subsequent reduction back to the corresponding 
sulfide the double bond is retained in the ∆3-position (Scheme 5). 
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a) m-CPBA, CH2Cl2, 0°C, 1.5h; b) TFAA, sodium iodide, acetone, 0°C, 1-2h. 
Scheme 5. 
 
Table 2: Results of the oxidation - reduction sequence to obtain  the corresponding ∆3-isomers. 
a  decomposition 
b  not investigated 
 
The results of the conversion of the ∆2-compounds via the corresponding sulfoxides 
into the ∆3-sulfide analogs are collected in Table 2. The data in the table show that 
conversion to the sulfoxides is facile and high yielding for all compounds except for 
iodide 13d. A possible explanation could be the formation of hyper valent iodine 
compounds upon treatment with m-CPBA. The use of a milder reagent for the 
 entry: substrate (X = ): sulfoxide (%): sulfide (%): 
1      13a  Cl 14a  (92) 15a (69) 
2      13b  Br 14b  (92) 15b (50) 
3      13c   I 14c  (0)a 15c -b 
4      13e  H 14e  (61) 15e (72) 
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oxidation (e.g. dimethyldioxirane) could possibly circumvent this problem with 
iodide 13d.  
 
 
5.3 Concluding remarks 
 
A convenient synthesis of some 3-carboxycephems, namely for 3-carboxyceph-2-em 
5 and 3-carboxyceph-3-em sulfoxide 7, and the corresponding sulfide 9, starting 
from the 3-formylcephalosporins was developed. These 3-carboxy derivatives 
precursors for the synthesis of 3-norcephalosporins. Using the Barton radical 
decarboxylation reaction, hydrogen, chloride, and iodide could be introduced in low 
to modest yields, while bromide was incorporated in an excellent yield. A 
remarkable difference was encountered in the reactivity and stability of the ∆2- and 
∆3-isomers. The most rewarding results were obtained for substrate 5 with the 
double bond in the ∆2-position. The (halo)-decarboxylation reactions represent the 
use of radical chemistry in the synthesis of 3-norcephalosporins for the first time.  
 
From an industrial point of view, at this stage, the Barton methodology is less 
attractive for the synthesis of C3-unsubstituted and 3-chloro-substituted cephems, 
because of the low yields of the (halo)-decarboxylation reactions. It should be noted, 
however, that the Barton decarboxylation reaction on itself would not be the 
bottleneck in an industrial process, as this reaction has already been conducted on a 
large scale in industry in the area of steroid chemistry.[19]  
 
 
5.4 Experimental part  
 
General remarks 
100 MHz 1H-NMR spectra were recorded on a Bruker AC 100 spectrometer and 300 MHz 1H-NMR 
spectra and all 13C-NMR spectra were recorded on a Bruker AC 300 using Me4Si as internal standard. 
All coupling constants are given as 3J in Hz, unless indicated otherwise. Melting points were 
measured with a Reichert Thermopan microscope and are uncorrected. IR spectra were recorded on a 
Bio-Rad FTS-25 instrument. For mass spectra a double focusing VG7070E mass spectrometer was 
used. Elemental analyses were conducted on a Carlo Erba Instruments CHNSO EA 1108 element 
analyzer. For the determination of optical rotations a Perkin-Elmer 241 polarimeter was used. 
Solvents were dried using the following methods: dichloromethane was distilled from P2O5; ethyl 
acetate was distilled from K2CO3; diethyl ether was distilled from NaH; hexane and heptane were 
distilled from CaH2; tetrahydrofuran was distilled from sodium just before use. All other solvents 
were of analytical grade. Thin layer chromatography (TLC) was carried out on a Merck precoated 
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silica gel 60 F254 plates (0.25 mm). Spots were visualized with UV or using a molybdate spray. Flash 
chromatography was carried out at a pressure of ca. 1.5 bar, using Merck Kieselgel 60H. Column 
chromatography at atmospheric pressure was performed with ACROS silicagel (0.035-0.070 mm; pore 
diameter ca. 6 nm). 
Systematic names were generated using the ACD/Name program provided by Advanced Chemistry 
Development Inc. (Toronto, Canada). 
 
 
(4S,7R,7aR)-4-(tert-Butoxycarbonyl)-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-4H,6H-azeto[2,1-
b][1,3]thiazine-3-carboxylic acid (5) 
Aldehyde 4 (0.8 g; 1.99 mmol) was dissolved in THF (28 ml) and cyclohexene (8 ml) was added. After 
cooling to 0°C a mixture of KH2PO4 (1.5 g) and NaClO2 (1.2 g) dissolved in water (28 ml) was added. 
The reaction mixture was allowed to warm up to room temperature slowly and then stirred 
overnight. The reaction mixture was then acidified with 2N HCl and THF was removed in vacuo. The 
aqueous layer was extracted with ethyl acetate (3x75 ml). The combined organic layers were washed 
with brine (1x100 ml), dried (MgSO4) and concentrated under reduced pressure. The crude residue 
was washed with ether to obtain acid 5 (770 mg; 93%). An analytically pure sample was obtained by 
column chromatography (SiO2, ethyl acetate / hexane 1:1).  
Mp 178-180°C (dec.); [α]D = +535° (c = 1.0; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.44 (s, 9H, 
C(CH3)3), 3.64 (s, 2H, PhCH2), 5.15 (d, J = 3.9 Hz, 1H, NHCHCHS), 5.21 (s, 1H, CHCO2tBu), 5.55 (dd, J 
= 3.9 Hz J = 7.8 Hz, 1H, NHCHCHS), 6.61 (d, J = 7.8 Hz, 1H, NH), 7.25-7.35 (m, 5H, PhH), 7.74 (s, 
SCH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 27.8 (C(CH3)3), 43.1 (PhCH2), 49.8 (CHCO2tBu) 53.9 
(CHNH), 60.4 (CHS), 83.7 (C(CH3)3), 116.1 (=CCO2H), 127.7, 129.1, 129.4 and 133.5 (PhC), 138.0 (SCH) 
163.9 (C=O, lactam), 165.7 (CHCO2tBu), 167.5 (CO2H), 171.5 (PhCH2C(O)); IR (KBr): ν 3326 (broad, 
NH), 1805 (C=O, lactam), 1736 (C=O, ester), 1678 and 1537 (C=O, amide), 1640 (C=O, acid), 1389 (C-
N) 1162 (C-O, ester) cm-1; MS (FAB+, NOBA): m/z (%) = 441 (16) [M+Na]+, 419 (7) [M+H]+, 385 (8) 
[M+Na-C4H8]+, 363 (33) [M+H-C4H8]+, 317 (5) [M+H-C4H8-CO2]+, 178 (100); elem. anal.: calc. (found) 
for C20H22O6N2S: C: 57.40 (57.56), H: 5.30 (5.35), N: 6.69 (6.65). 
 
(7R,7aR)-4-(tert-Butoxycarbonyl)-1,6-dioxo-7-[(2-phenylacetyl)amino]-1,6,7,7a-tetrahydro-2H-1λ4-
azeto[2,1-b][1,3]thiazine-3-carboxylic acid (7)  
This compound was prepared from aldehyde 6 (0.777 g; 1.86 mmol) in the same way as described for 
the synthesis of 3-carboxyceph-2-em 5. Yield after purification (0.645 g; 80%). 
Alternative approach 
3-Carboxyceph-2-em 5 (0.320 g; 0.77 mmol) was treated with 1.5 equiv. of pre-dried m-CPBA in a 
mixture of dichloromethane / acetonitrile (1:1) at 0°C for 4h. After completion, a saturated solution of 
NaHCO3 was added and the aqueous layer was extracted with dichloromethane (2x50 ml). The 
combined organic layers were dried (MgSO4) and concentrated in vacuo. The crude product thus 
obtained was purified by stirring in diethyl ether to remove m-chlorobenzoic acid affording 7 as a 
white amorphous solid (0.260 g; 78%). 
Mp 163-165°C (dec.); [α]D = 9.80° (c = 0.49; acetone); 1H-NMR (300 MHz, acetone-d6) δ (ppm) = 1.52 (s, 
9H, C(CH3)3), 3.44 (dd, J = 18.1 Hz 4J = 1.8 Hz, 1H, SCH2), 3.63 (qAB, JAB = 14.6 Hz, 2H, PhCH2), 4.26 
(d, J = 18.1 Hz, 1H, SCH2), 4.89 (dd, J = 5.1 Hz 4J = 1.6 Hz, 1H, NHCHCHS), 6.12 (d, J = 5.1 Hz, 1H, 
NHCHCHS), 7.25-7.40 (m, 5H, PhH); 13C-NMR (75 MHz, acetone-d6) δ (ppm) = 27.8 (C(CH3)3), 43.1 
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(SCH2), 44.8 (PhCH2), 60.3 (CHNH), 68.1 (CHS), 83.9 (C(CH3)3), 119.7 (=CCO2H), 127.6, 129.3, 130.1 
and 136.4 (PhC), 136.6 (=CCO2tBu), 161.1 (CO2tBu), 165.5 (C=O, lactam), 167.9 (CO2H), 172.6 
(PhCH2C(O)); IR (KBr): ν 3332 (broad, NH), 2980 and 2927 (COO-H), 1793 (C=O, lactam), 1729 (C=O, 
ester), 1689 (C=O, acid), 1657 and 1523 (C=O, amide) 1380 (C-N), 1215 (C-O, ester), 1039 (S=O) cm-1; 
MS (FAB+, NOBA): m/z (%) = 457 (4) [M+Na]+, 434 (4) [M+], 393 (12) [M+Na-C4H8]+, 379 (11) [M+H-
C4H8]+, 322 (12), 154 (100) [NOBA]*, 57 (74) [C4H9+]; HRMS (FAB, m/z): calculated for 
C20H22O7N2SNa+: 457.1045 amu. Found: 457.0984 ± 0.0046 amu. 
 
(7R,7aR)-4-(tert-Butoxycarbonyl)-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-2H,6H-azeto[2,1-
b][1,3]thiazine-3-carboxylic acid (9)  
A solution of sulfoxide 7 (0.350 g; 0.73 mmol) in dry DMF (3 ml) was treated with tin(II) chloride 
(0.481 g; 2.75 mmol) and an excess of acetyl chloride (1.5 ml) at 0°C for 2h. After removal of excess 
acetyl chloride (in vacuo) ethyl acetate and water were added. Extraction with ethyl acetate (2x50 ml), 
drying (MgSO4) and concentration in vacuo afforded the crude sulfide in nearly quantitative yield. 
Purification by column chromatography (SiO2, ethyl acetate / acetone 1:1) gave sulfide 9 (0.185 g; 
55%) as a white solid. An analytically pure sample was obtained by recrystallization from diethyl 
ether. 
Mp 165-167 °C (dec.); [α]D = -58.8° (c = 0.32; acetone); 1H-NMR (300 MHz, acetone-d6) δ (ppm) = 1.51 
(s, 9H, C(CH3)3), 3.57 and 3.86 (qAB, JAB = 17.8 Hz, 2H, SCH2), 3.67 and 3.68 (qAB, JAB = 14.3 Hz, 2H, 
PhCH2), 5.17 (d, J = 5.1 Hz, 1H, NHCHCHS), 5.90 (dd, J = 5.1 Hz J = 8.9 Hz, 1H, NHCHCHS), 7.24-7.38 
(m, 5H, PhH), 8.17 (d, J = 8.9 Hz, 1H, NH); 13C-NMR (75 MHz, acetone-d6) δ (ppm) = 25.0 (SCH2), 27.8 
(C(CH3)3), 43.0 (PhCH2), 60.0 and 60.8 (CHNH and CHS), 83.6 (C(CH3)3), 110.7 (=CCO2H), 127.5, 129.1, 
130.0 and 136.4 (PhC), 136.6 (=CCO2tBu), 161.7 (CO2tBu), 165.3 (C=O, lactam), 166.3 (CO2H), 171.6 
(PhCH2C(O)); IR (KBr): ν 3298 (broad, NH), 2978 (COO-H), 1795 (C=O, lactam), 1730 (C=O, ester), 
1716 (C=O, acid), 1684 and 1523 (C=O, amide) 1369 (C-N), 1155 (C-O, ester) cm-1; MS (FAB+, NOBA): 
m/z (%) = 441 (14) [M+Na]+, 419 (16) [M+H]+, 363 (53) [M+H-C4H8]+, 176 (100); elem. anal.: calc. 
(found) for C20H22O6N2S: C: 57.40 (57.29), H: 5.30 (5.30), N: 6.69 (6.54). 
 
4-(tert-Butyl) 3-(4-methyl-2-thioxo-2,3-dihydro-1,3-thiazol-3-yl) (4S,7R,7aR)-6-oxo-7-[(2- 
phenylacetyl)amino]-7,7a-dihydro-4H,6H-azeto[2,1-b][1,3]thiazine-3,4-dicarboxylate (12) 
To a cooled (-30°C) and stirred solution of 3-carboxyceph-2-em 5 (0.150 g; 1.07 mmol) in 
dichloromethane (15 ml), DCC (0.331 g; 1.61 mmol), Barton reagent (0.236 g; 1.61 mmol) and DMAP 
as a catalyst were added, under a nitrogen atmosphere. After stirring for 1h at -30°C, the reaction 
mixture was allowed to warm to room temperature and stirred for another 15h. After concentration in 
vacuo, ethyl acetate was added and the DCU, formed during the reaction, was removed by filtration 
over hyflo. The filtrate was extracted with 5% HCl solution. The combined organic layers were 
washed with saturated aqueous NaHCO3 and brine, dried (MgSO4) and concentrated under reduced 
pressure. The crude product was purified using column chromatography (SiO2, ethyl acetate / 
heptane 1:1) affording 12 (0.530 g; 90%) as a white solid. 
Mp 120-122°C (dec.); [α]D = +422.4° (c = 0.50; acetone); 1H-NMR (400 MHz, 60°C, acetone-d6) δ (ppm) 
= 1.46 (s, 9H, C(CH3)3), 3.64 (s, 2H, PhCH2), 5.21 (bs, 1H, NHCHCHS), 5.34 (s, 1H, CHCO2tBu), 5.56 
(dd, J = 3.9 Hz J = 7.5 Hz, 1H, NHCHCHS), 6.19 (s, 1H, MeC=CHS), 6.23 (bs, 1H, NH), 7.25-7.38 (m, 
5H, PhH), 8.20 (bs, 1H, SCH=); IR (KBr): ν 3283 (broad, NH), 1775 (C=O, lactam), 1734 (C=O, ester), 
1651 and 1522 (C=O, amide), 1340 (C-N), 1154 (C-O, ester) cm-1; MS (FAB+, NOBA): m/z (%) = 570 (10) 
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[M+Na]+, 548 (73) [M+H]+, 492 (10) [M+H-C4H8]+, 419 (6) [M+H-C4H4NS2]+, 346 (25), 290 (23), 225 
(100), 176 (29), 148 (84); HRMS (FAB, m/z): calculated for C24H25O6N3S3+ [M+H]+: 548.0984 amu. 
Found: 548.1007 ± 0.0055 amu. 
 
tert-Butyl (4R,7R,7aR)-3-chloro-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-4H,6H- 
azeto[2,1-b][1,3]thiazine-4-carboxylate (13a)  
Thiohydroxamic ester 12 (0.130 g; 0.237 mmol) in chlorobenzene (5 ml) was added, under nitrogen, to 
a boiling mixture of chlorobenzene and carbon tetrachloride (3:2) containing AIBN (50 mg). During 
addition the reaction mixture was irradiated with a tungsten lamp (250 W). After completion (30 
min.), all solvents were removed in vacuo. The crude product was purified via column 
chromatography (SiO2, CH2Cl2 / acetone 19:1) yielding 13a (9.6 mg; 10%) as a white solid. An 
analytical sample was obtained by recrystallization from heptane / ethyl acetate. 
Mp 107-108°C (dec.); [α]D = +492° (c = 0.50; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.49 (s, 
9H, C(CH3)3), 3.63 and 3.65 (qAB, JAB = 16.1 Hz, 2H, PhCH2), 4.75 (d, 4J = 1.6 Hz, 1H, CHCO2tBu), 5.29 
(d, J = 4.0 Hz, 1H, NHCHCHS), 5.63 (dd, J = 4.0 Hz J = 8.7 Hz, 1H, NHCHCHS), 6.28 (d, 4J = 1.6 Hz, 
1H, SCH=), 6.30 (d, J = 8.7 Hz, 1H, NH), 7.25-7.40 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 
27.8 (C(CH3)3), 43.3 (PhCH2), 53.1 (CHCO2tBu)*, 54.5 (CHNH)*, 60.0 (CHS), 84.3 (C(CH3)3), 114.5 
(=CCl), 116.9 (SCH=), 127.7, 129.2, 129.5 and 133.5 (PhC), 164.2 (C=O, lactam), 165.1 (CHCO2tBu), 
171.0 (PhCH2C(O)) (*: signals may have interchanged); IR (KBr): ν 3311 (broad, NH), 1775 (C=O, 
lactam), 1728 (C=O, ester), 1658 and 1526 (C=O, amide), 1333 (C-N), 1157 (O-C, ester) cm-1; MS (FAB+, 
NOBA): m/z (%) = 431 (14) [M+Na]+, 409 (16) [M+H]+, 353 (7) [M+H-C4H8], 234 (17), 176 (100), 91 (22) 
[PhCH2+], 57 (18) [C4H9+]; HRMS (CI+, m/z): calculated for C19H21O4N2SCl [M+H]+: 409.09888 amu. 
Found: 409.09852 ± 0.00123 amu. 
 
tert-Butyl (4R,7R,7aR)-3-bromo-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-4H,6H-azeto[2,1- 
b][1,3]thiazine-4-carboxylate (13b)  
Barton ester 12 (0.340 g; 0.622 mmol) dissolved in a mixture of bromotrichloromethane and 
dichloromethane (10 ml) was added, under nitrogen, to a solution of AIBN (100 mg) in 
bromotrichloromethane at reflux conditions while irradiated with a 250 W tungsten lamp. When TLC 
analysis (hexane / ethyl acetate 1:1) showed completion of the reaction, the reaction mixture was 
concentrated to dryness. The crude product was purified over silicagel (heptane / ethyl acetate 1:1) to 
give bromine 13b as a white solid (0.196 g, 69%) that was recrystallized from heptane / ethyl acetate. 
Mp 149-151°C (dec.); [α]D = +502° (c = 0.155; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.50 (s, 
9H, C(CH3)3), 3.63 and 3.66 (qAB, JAB = 16.2 Hz, 2H, PhCH2), 4.81 (d, 4J = 1.7 Hz, 1H, CHCO2tBu), 5.32 
(d, J = 4.0 Hz, 1H, NHCHCHS), 5.63 (dd, J = 4.0 Hz J = 8.7 Hz, 1H, NHCHCHS), 6.21 (d, J = 8.7 Hz, 1H, 
NH), 6.49 (d, 4J = 1.7 Hz, 1H, SCH=), 7.25-7.41 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 
27.8 (C(CH3)3), 43.3 (PhCH2), 52.9 (CHCO2tBu)*, 55.4 (CHNH)*, 60.3 (CHS), 84.3 (C(CH3)3), 101.5 
(=CBr), 119.6 (SCH=), 127.7, 129.2, 129.5 and 133.5 (PhC), 164.0 (C=O, lactam), 165.2 (CHCO2tBu), 
171.0 (PhCH2C(O)) (*: signals may have interchanged); IR (KBr): ν 3296 (broad, NH), 1780 (C=O, 
lactam), 1738 (C=O, ester), 1669 and 1540 (C=O, amide), 1370 (C-N), 1151 (O-C, ester) cm-1; MS (CI+): 
m/z (%) = 453 (3) and 455 (3) [M+H]+, 425 (5) and 427 (5) [M+H-CO]+, 397 (5) and 399 (5) [M+H-C4H8]+, 
351 (3) and 353 (4) [M+H-C4H8-CO2]+, 278 (24) and 280 (24) [M+H-C4H8-C7H7-CO]+, 222 (47) and 224 
(48), 176 (100), 91 (58) [PhCH2+], 57 (66) [C4H9+]; HRMS (CI+, m/z): calculated for C19H21O4N2SBr 
[M+H]+: 453.04838 amu. Found: 453.04730 ± 0.00136 amu. 
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tert-Butyl (4R,7R,7aR)-3-iodo-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-4H,6H- 
azeto[2,1-b][1,3]thiazine-4-carboxylate (13c) 
Barton ester 12 (0.100 g; 0.182 mmol) and AIBN (0.20 g) in dichloromethane were added, under 
nitrogen, to a solution of iodoform (0.80 g, 2.0 mmol) in toluene (10 ml) at reflux while irradiating 
with a tungsten lamp (250 W). The reaction was carefully monitored by TLC and after completion the 
solvents were removed in vacuo. Purification by column chromatography (SiO2, CH2Cl2 / acetone 
19:1) gave 13c (0.026 g; 28%) as yellowish white plates. The compound was light sensitive (color 
turned brown upon standing).  
Mp 55-57°C (dec.); 1H-NMR (100 MHz, CDCl3) δ (ppm) = 1.52 (s, 9H, C(CH3)3), 3.63 (s, 2H, PhCH2), 
4.82 (d, 4J = 1.7 Hz, 1H, CHCO2tBu), 5.36 (d, J = 4.0 Hz, 1H, NHCHCHS), 5.60 (dd, J = 4.0 Hz J = 8.6 Hz, 
1H, NHCHCHS), 6.33 (d, J = 8.6 Hz, 1H, NH), 6.72 (d, 4J = 1.7 Hz, 1H, SCH=), 7.27-7.33 (m, 5H, PhH); 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 27.9 (C(CH3)3), 43.3 (PhCH2), 52.5 (CHCO2tBu)*, 57.2 (CHNH)*, 
60.7 (CHS), 70.7 (=CI), 84.4 (C(CH3)3), 125.7 (SCH=), 127.8, 129.2, 129.5 and 133.6 (PhC), 163.8 (C=O, 
lactam), 165.3 (CHCO2tBu), 171.1 (PhCH2C(O)) (*: signals may have interchanged); IR (KBr): ν 3043 
(broad, NH), 1780 (C=O, lactam), 1736 (C=O, ester), 1662 and 1541 (C=O, amide), 1369 (C-N), 1148 (O-
C, ester) cm-1; MS (CI+): m/z (%) = 501 (2) [M+H]+, 445 (4) [M+H-C4H8]+, 326 (9), 270 (21), 234 (7), 176 
(100), 57 (10) [C4H9+]; HRMS (CI+, m/z): calculated for C19H21O4N2SI [M+H]+: 501.03450 amu. Found: 
501.03328 ± 0.00150 amu. 
 
tert-Butyl (7R,7aR)-3-[(4-methyl-1,3-thiazol-2-yl)sulfanyl]-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-
dihydro-2H,6H-azeto[2,1-b][1,3]thiazine-4-carboxylate (13d)  
The reaction was carried out as described for compound 13c, using diiodomethane as the trapping 
agent. Only a trace amount of sulfide 13d was isolated. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.45 (s, 9H, C(CH3)3), 2.40 (s, 3H, CH3), 3.67 (s, 2H, PhCH2), 5.23 
(d, J = 3.9 Hz, 1H, NHCHCHS), 5.38 (d, J = 1.1 Hz, 1H, C=CHCO2tBu), 5.60 (dd, J = 3.9 Hz J = 7.7 Hz, 
1H, NHCHCHS), 6.12 (d, J = 7.7 Hz, 1H, NH), 7.28-7.38 (m, 6H, PhH and SCH=CCH3), 6.24 (d, J = 10.4 
Hz J = 1.1 Hz, 1H, SCH=C); MS (FAB+, NOBA): m/z (%) = 504 (20) [M+H]+, 448 (<1) [M+H-C4H8]+, 345 
(41), 288 (80), 176 (72), 154 (100) [NOBA]*, 91 (54) [PhCH2+], 57 (43) [C4H9+] (* defragmentation of 
NOBA matrix).  
 
tert-Butyl (4R,7R,7aR)-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-4H,6H-azeto[2,1-
b][1,3]thiazine-4-carboxylate (13e)  
A solution of thiohydroxamic ester 12 (0.300 g; 0.548 mmol) and AIBN (100 mg) in dichloromethane (5 
ml) was added dropwise, under an inert atmosphere, to a solution of tert-butyl mercaptane (1 ml) in 
toluene at reflux, while irradiating with a tungsten lamp (250 W). After complete conversion, the 
reaction mixture was concentrated in vacuo to remove all solvents and the crude product was purified 
over silica gel (heptane / ethyl acetate 1:1), giving 13e (0.030 g; 15%) as a white solid material. 1H-
NMR showed an inseparable mixture of ∆2- / ∆3-isomers (1:1). 
∆3-isomer 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.51 (s, 9H, C(CH3)3), 3.38 and 3.50 (qAB, JAB = 19.1 Hz J = 6.2 
Hz J = 2.5 Hz, 2H, SCH2), 3.62 (s, 2H, PhCH2), 4.88 (d, J = 5.0 Hz, 1H, NHCHCHS), 5.88 (dd, J = 5.0 Hz 
J = 9.2 Hz, 1H, NHCHCHS), 6.38 (dd, J = 6.1 Hz J = 2.4 Hz, 1H, =CH), 6.93 (d, J = 9.2 Hz, 1H, NH), 
7.23-7.36 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 24.0 (SCH2), 27.8 (C(CH3)3), 42.9 
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(PhCH2), 56.8 (HNH), 59.3 (CHS), 82.8 (C(CH3)3), 118.5 (=CH), 129.1 (=CCO2tBu), 127.2, 128.7, 129.1 
and 134.1 (PhC), 160.4 (CO2tBu),  164.7 (C=O, lactam), 171.3 (PhCH2C(O)). 
∆2-isomer 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.46 (s, 9H, C(CH3)3), 3.62 (s, 2H, PhCH2), 4.75 (dd, J = 2.4 Hz J 
= 4.3 Hz, 1H, C=CHCO2tBu), 5.15 (d, J = 4.0 Hz, 1H, NHCHCHS), 5.67 (dd, J = 4.0 Hz J = 8.7 Hz, 1H, 
NHCHCHS), 5.76 (dd, J = 10.4 Hz J = 4.3 Hz, 1H, SCH=CH), 6.24 (dd, J = 10.4 Hz J = 2.4 Hz, 1H, 
SCH=CH), 6.65 (d, J = 8.7 Hz, 1H, NH), 7.23-7.36 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 
27.8 (C(CH3)3), 43.1 (PhCH2), 50.0 (CHNH)*, 53.5 (CHCO2tBu)*, 60.5 (CHS), 83.3 (C(CH3)3), 113.5 
(SCH=CH), 119.7 (SCH=), 127.3, 128.8, 129.2 and 133.8 (PhC), 160.4 (C=O, lactam), 166.3 (CHCO2tBu), 
171.1 (PhCH2C(O)) (*: signals may have interchanged); IR (KBr): ν 3308 (broad, NH), 1770 (broad, 
C=O, lactam), 1716 (C=O, ester), 1681, 1661 and 1539 (C=O, amide), 1367 and 1406 (C-N), 1155 (C-O, 
ester) cm-1; MS (CI+): m/z (%) = 374 (2) [M+], 319 (15) [M+H-C4H8]+, 176 (100), 144 (61), 91 (84) 
[PhCH2+], 57 (79) [C4H9+]; HRMS (CI+, m/z): calculated for C19H22O4N2S [M+H]+: 375.13785 amu. 
Found: 375.13701 ± 0.00112 amu. 
 
tert-Butyl (7R,7aR)-3-chloro-1,6-dioxo-7-[(2-phenylacetyl)amino]-1,6,7,7a-tetrahydro-2H-1λ4- 
azeto[2,1-b][1,3]thiazine-4-carboxylate (14a)  
To a solution of sulfide 13a (0.300 g; 0.73 mmol) in dichloromethane (10 ml), m-CPBA (0.133 g; 0.77 
mmol) was added at 0°C. After stirring for 1h at 0°C, the reaction mixture was concentrated in vacuo. 
Silica gel chromatography (heptane / ethyl acetate 2:3) afforded sulfoxide 14a (0.287 g; 92%) as a 
white solid. 
Mp 173-175°C (dec.); [α]D = +53.1° (c = 0.52; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.54 (s, 
9H, C(CH3)3), 3.51 and 3.81 (qAB, JAB = 18.5 Hz J = 1.6 Hz, 2H, SCH2), 3.61 and 3.62 (qAB, JAB = 15.8 
Hz, 2H, PhCH2), 4.53 (dd, J = 4.9 Hz J < 1.5 Hz, 1H, NHCHCHS), 5.98 (dd, J = 4.9 Hz J = 9.7 Hz, 1H, 
NHCHCHS), 7.08 (d, J = 9.7 Hz, 1H, NH), 7.24-7.34 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) 
= 27.8 (C(CH3)3), 42.9 (PhCH2), 50.4 (SCH2), 58.9 (CHNH), 67.0 (CHS), 84.6 (C(CH3)3), 117.7 (=CCl), 
126.0 (=CCO2tBu), 127.4, 128.9, 129.3 and 133.9 (PhC), 158.2 (CO2tBu),  163.3 (C=O, lactam), 171.7 
(PhCH2C(O)); IR (KBr): ν 3282 (broad, NH), 1786 (C=O, lactam), 1726 (C=O, ester), 1651 and 1533 
(C=O, amide), 1369 (C-N), 1156 (C-O, ester), 1040 (S=O) cm-1; MS (CI+): m/z (%) = 369 (3) [M+H-
C4H8]+, 324 (5) [M+H-C4H8-CO2]+, 276 (11), 235 (19), 219 (17), 203 (54), 91 (100) [PhCH2+], 57 (72) 
[C4H9+]; HRMS (CI+, m/z): calculated for C19H21O5N2SCl [M+H]+: 425.09380 amu. Found: 425.09365 ± 
0.00128 amu. 
 
tert-Butyl (7R,7aR)-3-bromo-1,6-dioxo-7-[(2-phenylacetyl)amino]-1,6,7,7a-tetrahydro-2H-1λ4- 
azeto[2,1-b][1,3]thiazine-4-carboxylate (14b)  
Sulfide 13b (0.196 g; 0.43 mmol) was oxidized following the procedure described for chloride 13a. 
Column chromatography (heptane / ethyl acetate 2:3) afforded 14b (0.187 g; 92%) as a white 
crystalline solid. 
Mp 210°C (dec.); [α]D = +32.4° (c = 0.50; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.55 (s, 9H, 
C(CH3)3), 3.57 and 3.98 (qAB, JAB = 18.6 Hz J = 1.5 Hz, 2H, SCH2), 3.60 and 3.63 (qAB, JAB = 15.5 Hz, 
2H, PhCH2), 4.52 (dd, J = 4.7 Hz J < 1.5 Hz, 1H, NHCHCHS), 6.00 (dd, J = 4.7 Hz J = 9.8 Hz, 1H, 
NHCHCHS), 6.90 (d, J = 9.8 Hz, 1H, NH), 7.25-7.40 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) 
= 27.8 (C(CH3)3), 43.1 (PhCH2), 52.1 (SCH2), 59.3 (CHNH), 66.9 (CHS), 84.8 (C(CH3)3), 105.0 (=CBr), 
127.7 (=CCO2tBu), 127.5, 128.9, 129.4 and 133.8 (PhC), 158.8 (CO2tBu),  163.0 (C=O, lactam), 171.4 
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(PhCH2C(O)); IR (KBr): ν 3280 (broad, NH), 1784 (C=O, lactam), 1726 (C=O, ester), 1651 and 1533 
(C=O, amide), 1368 (C-N), 1155 (C-O, ester), 1040 (S=O) cm-1; MS (CI+): m/z (%) = 413 (1) and 415 (1) 
[M+H-C4H8]+, 369 (1) and 371 (1) [M+H-C4H8-CO2]+, 219 (21), 203 (86), 135 (34), 119 (25), 91 (77) 
[PhCH2+], 57 (100) [C4H9+]; HRMS (CI+, m/z): calculated for C15H14O5N2SBr [M+H-C4H8]+: 412.98069 
amu. Found: 425.97974 ± 0.00128 amu. 
 
tert-Butyl (7R,7aR)-1,6-dioxo-7-[(2-phenylacetyl)amino]-1,6,7,7a-tetrahydro-2H-1λ4-azeto[2,1-
b][1,3]thiazine-4-carboxylate (14e) 
Sulfoxide 14e was prepared in the same manner as described for sulfoxide 14a. Starting from sulfide 
13e (0.030 g; 0.08 mmol). Compound 14e (0.017 g; 61%) was obtained as white amorphous solid after 
column chromatography (SiO2, ethyl acetate / heptane 7:3). An analytical sample was obtained by 
recrystallization from ethyl acetate. 
Mp >215°C (dec.); [α]D = +146.6° (c = 0.21; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.53 (s, 9H, 
C(CH3)3), 3.19 (dt, J = 19.0 Hz 4J ~ 2.0 Hz, 1H, SCH2), 3.63 and 3.66 (qAB, JAB = 16.2 Hz, 2H, PhCH2), 
3.78 (dd, J = 19.0 Hz J = 6.3 Hz, 1H, SCH2), 4.45 (dd, J = 4.9 Hz 4J ~ 1.6 Hz, 1H, NHCHCHS), 6.06 (dd, J 
= 4.9 Hz J = 9.8 Hz, 1H, NHCHCHS), 6.24 (dd, J = 6.3 Hz J = 2.4 Hz, 1H, =CH), 6.86 (d, J = 9.8 Hz, 1H, 
NH), 7.25-7.39 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 27.8 (C(CH3)3), 43.3 (PhCH2)*, 43.9 
(SCH2)*, 59.9 (CHNH), 67.2 (CHS), 83.5 (C(CH3)3), 111.5 (=CH), 127.5, 128.9, 129.3 and 133.7 (PhC), 
129.9 (=CCO2tBu), 159.2 (CO2tBu), 163.4 (C=O, lactam), 171.3 (PhCH2C(O)) (*: signals may have 
interchanged); IR (KBr): ν 3219 (broad, NH), 1786 (C=O, lactam), 1721 (C=O, ester), 1658 and 1539 
(C=O, amide), 1368 (C-N), 1156 (C-O, ester), 1024 (S=O) cm-1; MS (CI+): m/z (%) = 419 (1) [M+C2H5]+, 
405 (1) [M+CH3]+,  390 (1) [M+H]+, 335 (13) [M+H-C4H8]+, 287 (11), 176 (11), 136 (22), 118 (12), 91 (57) 
[PhCH2+], 57 (100) [C4H9+]; HRMS (CI+, m/z): calculated for C19H22O5N2S [M+H]+: 391.13725 amu. 
Found: 391.13698 ± 0.00115 amu. 
 
tert-Butyl (7R,7aR)-3-chloro-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-2H,6H-azeto[2,1-
b][1,3]thiazine-4-carboxylate (15a)  
To a pre-cooled (0°C) solution of sulfoxide 14a (0.100 g; 0.235 mmol) in acetone sodium iodide (0.084 
g; 0.56 mmol) and trifluoroacetic anhydride (0.1 g; ca. 2 equiv.) were successively added. After 
completion (1.5h), a saturated bicarbonate solution and ethyl acetate were added and the aqueous 
layer was extracted with ethyl acetate (2x10 ml). The combined organic layers were washed with 
brine, dried (MgSO4) and concentrated in vacuo. The crude product was purified by column 
chromatography (SiO2, ethyl acetate / hexane 2:1) giving 15a (0.066 g; 69%) as a jelly compound. An 
analytical sample was obtained by stirring 15a in diisopropyl ether and evaporation of the solvents in 
vacuo. 
Mp 105-107°C (dec.); [α]D = +272.6° (c = 0.135; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.53 (s, 
9H, C(CH3)3), 3.52 and 3.74 (qAB, JAB = 18.4 Hz, 2H, SCH2), 3.61 (s, 2H, PhCH2), 4.97 (d, J = 4.9 Hz, 1H, 
NHCHCHS), 5.85 (dd, J = 4.9 Hz J = 9.2 Hz, 1H, NHCHCHS), 6.85 (d, J = 9.2 Hz, 1H, NH), 7.26-7.33 
(m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 27.8 (C(CH3)3), 30.8 (SCH2), 43.0 (PhCH2), 57.1 
(CHNH), 58.7 (CHS), 84.1 (C(CH3)3), 123.4 (=CCl), 125.6 (=CCO2tBu), 127.4, 128.9, 129.2 and 134.0 
(PhC), 159.0 (CO2tBu),  164.5 (C=O, lactam), 171.5 (PhCH2C(O)); IR (KBr): ν 3275 (broad, NH), 1777 
(C=O, lactam), 1725 (C=O, ester), 1657 and 1537 (C=O, amide), 1369 (C-N), 1154 (C-O, ester) cm-1; MS 
(CI+): m/z (%) = 409 (3) [M+H]+, 381 (6) [M+H-CO]+, 353 (10) [M+H-C4H8]+, 307 (5) [M+H-C4H8-CO2]+, 
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273 (4) [M+H-C4H8-CO2-Cl]+, 234 (26), 176 (99), 91 (100) [PhCH2+], 57 (96) [C4H9+]; HRMS (CI+, m/z): 
calculated for C19H21O4N2SCl [M+H]+: 409.09888 amu. Found: 409.09848 ± 0.00123 amu. 
 
tert-Butyl (7R,7aR)-3-bromo-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-2H,6H-azeto[2,1- 
b][1,3]thiazine-4-carboxylate (15b)  
Bromo derivative 15b was prepared analogously to 15a from its sulfoxide 14b (0.068 g; 0.14 mmol), 
yielding, after purification, sulfide 15b (0.067 g; 50%) as a jelly compound. 
Mp 142-144°C; [α]D = +62.6° (c = 0.61; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.50 (s, 9H, 
C(CH3)3), 3.61 and 3.64 (qAB, JAB = 15.7 Hz, 2H, PhCH2), 3.62 and 3.83 (qAB, JAB = 18.4 Hz, 2H, SCH2), 
5.00 (d, J = 4.9 Hz, 1H, NHCHCHS), 5.83 (dd, J = 4.9 Hz J = 9.2 Hz, 1H, NHCHCHS), 6.53 (d, J = 9.2 
Hz, 1H, NH), 7.25-7.37 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 27.8 (C(CH3)3), 32.4 
(SCH2), 43.1 (PhCH2), 57.0 (CHNH), 59.2 (CHS), 84.3 (C(CH3)3), 110.6 (=CBr), 127.4 (=CCO2tBu), 127.6, 
129.0, 129.3 and 133.8 (PhC), 159.6 (CO2tBu),  163.8 (C=O, lactam), 171.3 (PhCH2C(O)); IR (KBr): ν 3331 
(broad, NH), 1759 (C=O, lactam), 1725 (C=O, ester), 1681 and 1534 (C=O, amide), 1368 (C-N), 1154 (C-
O, ester) cm-1; MS (CI+): m/z (%) = 481 (1) and 483 (1) [M+C2H5]+, 452 (1) and 454 (1) [M+], 397 (2) and 
399 (2) [M+H-C4H8]+, 319 (2) [M+H-C4H8-Br]+, 273 (13), 176 (60), 91 (46) [PhCH2+], 57 (100) [C4H9+]; 
HRMS (CI+, m/z): calculated for C19H21O4N2SBr [M+H]+: 453.04838 amu. Found: 453.04767 ± 0.00136 
amu. 
 
tert-Butyl (7R,7aR)-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-2H,6H-azeto[2,1-b][1,3]thiazine-4-
carboxylate (15e)  
Hydrogen compound 15e was prepared analogously to 15a from its sulfoxide 14e (0.200 g; 0.51 
mmol), yielding, after purification, sulfide 15e (0.138 g; 72%) as a white solid. An analytical sample 
(colorless plates) was obtained by crystallization from ethyl acetate / heptane. 
Mp 151-153°C; [α]D = +118.1° (c = 0.54; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.51 (s, 9H, 
C(CH3)3), 3.39 and 3.50 (qAB, JAB = 19.1 Hz J = 6.2 Hz J = 2.6 Hz, 2H, SCH2), 3.62 (qAB, JAB = 15.9 Hz, 
2H, PhCH2), 4.88 (d, J = 5.0 Hz, 1H, NHCHCHS), 5.89 (dd, J = 5.0 Hz J = 9.3 Hz, 1H, NHCHCHS), 6.37 
(dd, J = 6.2 Hz J = 2.6 Hz, 1H, =CH), 6.94 (d, J = 9.3 Hz, 1H, NH), 7.23-7.34 (m, 5H, PhH); 13C-NMR (75 
MHz, CDCl3) δ (ppm) = 24.0 (SCH2), 27.8 (C(CH3)3), 43.0 (PhCH2), 56.8 (CHNH), 59.3 (CHS), 82.8 
(C(CH3)3), 118.5 (=CH), 129.1 (=CCO2tBu), 127.2, 128.7, 129.2 and 134.1 (PhC), 160.5 (CO2tBu), 164.8 
(C=O, lactam), 171.4 (PhCH2C(O)); IR (KBr): ν 3323 (broad, NH), 1767 (C=O, lactam), 1719 (C=O, 
ester), 1662 and 1520 (C=O, amide), 1394 (C-N), 1150 (C-O, ester) cm-1; MS (CI+): m/z (%) = 403 (1) 
[M+C2H5]+, 374 (3) [M+], 347 (4) [M+C2H5-C4H8]+, 319 (19) [M+H-C4H8]+, 176 (100), 144 (57), 91 (83) 
[PhCH2+], 57 (85) [C4H9+]; HRMS (CI+, m/z): calculated for C19H22O4N2S [M+H]+: 375.13785 amu. 
Found: 375.13714 ± 0.00113 amu. 
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WITTIG-TYPE REACTIONS WITH  
3-FORMYLCEPHALOSPORINS 
 
 
 
 
 
 
 
 
 
 
6.1 Introduction 
 
Due to the important role that cephalosporin antibiotics still play in current medical 
practice, considerable effort has been invested in the search for cephalosporin 
derivatives with improved therapeutic properties. β-Lactam antibiotics, which show 
an improved biological activity, are cephalosporins substituted with an alkene at the 
C3-position. 
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Figure 1. 
 
Important members of this family of 3-alkenylcephalosporins, which are active 
against both Gram-positive and Gram-negative bacteria, are cefdinir (1), cefixime (2) 
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and cefprozil (3) (Figure 1). The discovery of these active, orally administrable 
cephalosporins has been a stimulus for increased synthetic activity aimed at finding 
new 3-alkenyl based cephalosporins.[1] 
 
The most frequently employed synthesis to 3-alkenylcephalosporins 6 starts with a 
properly protected C10-halogenated cephalosporin 4, which is converted into the 
corresponding phosphonium derivative 5. This salt 5 is then applied in a 
conventional Wittig reaction with an aldehyde, or in an epoxide mediated Wittig 
reaction (Scheme 1).[2],[3]  
 
X = Cl, Br
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a) PPh3, CH2Cl2; b) R"CHO, base or epoxide. 
Scheme 1. 
 
Hitherto, several syntheses of cefprozil (3) have been reported.[2],[4] Recently, Farina[5] 
and Torii[6] have developed new methodologies for the synthesis of 3-vinyl-cephems 
8.  Starting from the readily available penicillin V sulfoxide diphenylmethyl ester, 
allenylazetidinones 7[7] were synthesized, which were transformed in 8 by 
subsequent reaction with alkenyltributyltin compounds[7] or organocuprates[8] 
(Scheme 2).  
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a) [(Z)-propenyl]2CuLi, THF, -78°C, 1h, 55%.  
Scheme 2. 
 
In addition, high-yielding palladium-catalyzed coupling reactions of organotin 
compounds with 3-triflioxy cephems[9] and cross-coupling reactions of 3-sulfonato or 
3-bromo-cephems 9 with alkenyltin reagents to vinylcephems 10 have been 
described (Scheme 3).[10]  
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X = Br, OSO2CF3
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a) allylSnBu3, Pd(OAc)2, LiI, Et3N, NMP, r.t., 85-93%. 
Scheme 3. 
 
Until now, only a few 3-alkenylcephalosporins 12 have been synthesized from the 
corresponding 3-formylcephalosporins 11.[11],[12] In this approach the aldehyde 
compound of the Wittig reaction is present in the cephalosporin substrate, whereas 
in the abovementioned synthesis the ylide was part of the β-lactam unit. In almost all 
reported examples, aldehyde 11 is coupled with stabilized phosphorous ylides. In 
this chapter, a general approach to 3-alkenylcephalosporins 12 from readily available 
3-formylcephalosporins 11 is described (Scheme 4). In principle, this route to the 
cephalosporin core structures of cefdinir (1) and cefprozil (3) looks very attractive, as 
in principle stabilized as well as non-stabilized phosphorous ylides can be used for 
the olefination reaction. 
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Scheme 4. 
 
The main problem that may arise in the synthesis of 3-alkenyl β-lactams, employing 
the Wittig methodology, is the inevitable use of phosphorous ylides, which have 
both basic and nucleophilic properties. As a consequence, these Wittig reactions may 
lead to disintegration of the β-lactam core or result in mixtures of ∆2/∆3-isomers.[13] 
An other important structural aspect is control of the geometry of the newly formed 
double bond. A high selective Wittig olefination is crucial, as Z- and E-isomers exert 
different antibacterial activity. 
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6.2 Results and discussion 
 
6.2.1 Stabilized phosphorous ylides 
 
Stabilized ylides can usually be handled at room temperature, unlike non-stabilized 
phosphorous ylides, and can be prepared without using strong bases (such as butyl 
lithium). These ylides do hardly have a basic character. The stability of these ylides 
has its origin in the strong electronic conjugation of the P=C bond with an ester, 
carbonyl or a nitrile π-system. In order to evaluate the Wittig olefination of aldehyde 
11 (R = tBu) in a general sense, the first experiments were carried out with stabilized 
phosphorous ylides,[12] in order to avoid possible base induced side reactions 
(Scheme 5). Aldehyde 11 was synthesized as described in chapter 3. The results of 
the Wittig reactions are shown in Table 1. 
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11 13a-d(R = tBu)  
a) Ph3P=CR’, CH2Cl2, 0°C, 4-8h. 
Scheme 5. 
 
Table 1: Wittig olefination of 3-formylcephalosporin 11. 
a   yields not optimized 
b  no reaction; only starting material recovered 
c  >99% trans selectivity (no cis products observed) 
 
The data in this Table 1 clearly reveal that the nature of the applied ylide subtly 
determines the outcome of the reaction. While ethyl 2-
(triphenylphosphanylidene)acetate and 2-(triphenylphosphanylidene)acetonitrile 
(entries 1 and 2) leads to the desired ∆3-isomers 13a and 13b in acceptable yield and 
high E-selectivity,[14] the ylides 1-(triphenylphosphanylidene)acetone and ethyl 2-
(triphenylphosphanylidene)propanoate (entries 3 and 4) did not react at all at 0°C. 
 entry: ylide: R' = R" = productc (%): 
1 Ph3P=CHCO2Et CO2Et H 13a 51a 
2 Ph3P=CHCN CN H 13b 53a 
3 Ph3P=CHC(O)Me C(O)Me H 13c 0b 
4 Ph3P=C(Me)CO2Et CO2Et Me 13d 0b 
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Increasing the temperature to room temperature led in the first three cases to 
considerable decomposition of the starting aldehyde 11 and to a diminished 
selectivity in the olefination of 11 in entries 1 and 2. Also the use of two equivalents 
of phosphorane did not help, but led to less selectivity (partly isomerization to ∆2-
product) or a lower yield. The presence of an extra methyl group in ethyl 2-
(triphenylphosphanylidene)propanoate (entry 4) did not result in any reaction, 
probably due to a lower reactivity of this ylide caused by severe steric hindrance. 
Raising the temperature to 40°C, or even performing the reaction in toluene at reflux 
temperature, did not lead to any reaction with this ylide, and only a little amount of 
starting material 11 was recovered. These results show that stabilized ylides are not 
very reactive neither as nucleophile, nor as a base, because no isomerized (∆2-) 
products were isolated at 0°C. 
 
Disappointingly, Wittig reactions of the hydroxycephalolactone 14a, which is 
obtained after deprotection of the tert-butyl ester of aldehyde 11 and is supposed to 
be equivalent with the open aldehyde structure 14b, with stabilized phosphoranes 
were also not successful (Scheme 6). Even attempts to perform the reaction in 
refluxing toluene, or by using 2.2 equivalents of ylide, did not lead to any noticeable 
conversion, and starting material 14a was recovered. 
 
N
S
O
N
H
O
CO2H
CO2Et
N
S
O
N
H
O
O
O
OH
a
14a
15
N
S
O
N
H
O
CO2H
CHO
14b
X
 
a) Ph3P=CHCO2Et, CH2Cl2 (r.t.) or toluene (reflux), 4-8h. 
Scheme 6. 
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6.2.2 Direct conversion of 3-hydroxymethylcephalosporins into Wittig 
products  
 
Recently, Taylor et al.[15] described an oxidative Wittig process in which (non)-
activated alcohols were treated with manganese(IV) oxide in the presence of a 
stabilized Wittig reagent. The essential feature of this methodology is that the 
alcohol is oxidized in situ to the corresponding aldehyde, which then is immediately 
entrapped by the Wittig ylide. This process is particular usefully in those cases 
where the corresponding aldehyde is unstable, or difficult to isolate or purify. The 3-
hydroxymethylcephalosporins 16 and 17 are readily available (see chapter 3), and 
therefore they are attractive substrates for this oxidative Wittig reaction for the 
synthesis of 3-alkenylcephalosporins 13 (Scheme 7). The results of this direct Wittig 
olefination of 3-hydroxymethyl compounds 16 and 17 are collected in Table 2. 
 
N
S
O
N
H
R'
CO2R
ON
S
O
N
H
OH
CO2R
O
a
R = tBu
R = CHPh2
16
17
R = tBu
R = CHPh2
13
18
 
a) MnO2, CH2Cl2, 1.2 equiv. Ph3P=CHCO2Et or Ph3P=CHCN, r.t., 8h. 
Scheme 7. 
 
Table 2: Direct Wittig olefination of 3-hydroxymethylcephalosporins 16 and 17. 
 a  overall yield; reactions not optimized 
 
Although the overall yields of the oxidative olefination of the alcohols are moderate, 
this methodology could indeed successfully be applied to cephalosporin alcohols. 
The yields for the tert-butyl esters 13 are slightly better than those for the benzhydryl 
esters 18, which is in line with other reported Wittig reactions with 3-
formylcephems.[16] The somewhat lower yields must be due to a less effective 
olefination of the in situ formed aldehyde, as the oxidation of the 3-
 entry: alcohol: R =  ylide: R' = product (%)a: 
1 16 tBu Ph3P=CHCO2Et CO2Et 13a 39 
2 16 tBu Ph3P=CHCN CN 13b 39 
3 17 CHPh2 Ph3P=CHCO2Et CO2Et 18a 30 
4 17 CHPh2 Ph3P=CHCN CN 18b 32 
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hydroxymethylcepahlosporins with manganese(IV) oxide to the corresponding 
formyl compound is usually a high yielding reaction.[17] 
  
Attempts to use IBX or the Dess-Martin periodide instead of manganese(IV) oxide in 
this olefination process,[18] were not successful for the β-lactams. No trace of the 
desired olefins could be isolated after work-up, instead severe decomposition was 
observed. Apparently, these combinations of oxidants and Wittig reagents are not 
allowed for the sensitive cephalosporin system. 
 
 
6.2.3 Non-stabilized phosphorous ylides 
 
In order to have access to the core structures of cefdinir (1) and cefprozil (3), Wittig 
olefination of aldehyde 11 (R = tBu) with non-stabilized phosphoranes is the obvious 
choice. These ylides, which require strong bases (e.g. BuLi) for their preparation, 
usually favor the formation of Z-alkenes (as is present in cefprozil 3). Epoxides, 
which are commonly used in the dehydrohalogenation of phosphonium salts in 
Wittig reactions[3],[19] cannot be applied in the present case as they are not sufficiently 
reactive to produce the ylides from the corresponding phosphonium salts.  
 
The results of the attempted Wittig reactions with non-stabilized ylides (Scheme 8) 
are summarized in Table 3. The ylides were prepared by addition of butyllithium to 
a solution of 1.5 equivalents of phosphonium salt in THF at -30°C (or at 0°C) under a 
nitrogen atmosphere. The appearance of a strongly yellow color indicated the 
formation of the ylides. 
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R = H, CH3
N
S
O
N
H
CO2tBu
O
R
N
S
O
N
H
O
CO2tBu
O
O
a
N
S
O
N
H
O
CO2tBu
O N
S
O
N
H
CO2tBu
O
Rb
(   )n
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19 (n = 1)
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21 22
X
X
 
Scheme 8. 
 
Table 3: Wittig olefination of 3-formylcephalosporins 11, 19, and 21 using non-stabilized ylides 
 a also addition of the ylide to the aldehyde led to decomposition 
 
None of these olefinations was successful, either complete decomposition of the 
starting material was observed or recovery of starting aldehyde up to 40% in the case 
of substrate 21. Even at -78°C, aldehydes 11 and 19 had completely decomposed 
within 10 minutes. Immediately after the addition of ylide, the reaction mixture 
turned strongly dark brown to black. The corresponding ∆2-isomer 21 is slightly less 
unstable, because complete decomposition was only observed after 1 hour (at -78°C). 
The non-stabilized phosphorous ylides used here are relatively strong bases and 
reactive nucleophiles, which probably causes the unwanted opening of the β-lactam 
ring, which is then followed by a cascade of decomposition reactions. 
 
The unfortunate conclusion of the above described experiments is that the desired 
syntheses of the cores of cefdinir (1), cefixime (2), and cefprozil (3) via a Wittig 
entry: aldehyde: ylide: R = conditions: result: 
1 11 Ph3P=CH2 H -78°C → 0°C  severe decomposition 
2 11 Ph3P=CH2 H -78°C,  
quenching 
with HCl (aq) 
decomposition 
3 19 Ph3P=CHCH3 Me -78°Ca decomposition 
4 21 Ph3P=CHCH3 Me -78°C decomposition and  
21 (recovery) 
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olefination of 3-formylcephalosporins using non-stabilized phosphoranes cannot be 
accomplished. 
 
 
6.2.4 Alternative approaches to the synthesis of the core structures of 
cefixime and cefdinir 
 
As is described above, the Wittig approach to the 3-alkenylcephalosporins from 3-
formylcephalosporins is not successful. Therefore, other methods to accomplish the 
desired transformation were considered. First, the recently reported one-pot 
conversion of aldehydes into E-alkenylsilanes using iodoform, manganese, 
trimethylsilyl chloride and a catalytic amount of chromium(II) chloride[20] was tried 
with the 3-formylcephalosporins (Scheme 9). Disappointingly, the ∆3-isomer 11 led 
only to decomposition, whereas the ∆2-analogue 21 gave only a trace of the silyl 
alkene 23, which was identified by 1H-NMR analysis. This approach was abandoned 
because of the very low yield. 
 
N
S
O
N
H
OO
CO2tBu
N
S
O
N
H
O
CO2tBu
SiMe3
a
trace21 23  
a) CHI3, Mn, Me3SiCl, CrCl2 (cat.), THF, r.t., 24h. 
Scheme 9. 
 
Secondly, the so-called Tebbe reaction was examined for the introduction of a 
methylene group. The Tebbe reagent Cp2TiCH2.AlMe2Cl (24),[21] is a source of the 
reactive titanium methylene species "Cp2Ti=CH2", which is actually the species 
responsible for the methylation.[22] The formation of this methylene intermediate is 
accelerated by THF or pyridine. The driving force of this process is the high 
oxophilicity of titanium. The scope of the reaction is larger than for the 
corresponding phosporanes.[23] Even esters and imides are converted into vinyl 
ethers and enamines by the Tebbe reagent.[24] The major advantage of this approach, 
as compared with the use of phosphoranes, is the lower basicity of the titanium 
reagent. Therefore, the Tebbe reaction may be applicable in the case of cephalosporin 
aldehydes, although nucleophilic opening of the β-lactam ring still may be a serious 
problem. Indeed, aldehydes 11 and 19, with the double bond in the ∆3-position, led 
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to a very fast uncontrolled reaction as was indicated by the instantaneous blackening 
of the reaction mixture after addition of the Tebbe reagent 24 at -78°C.  
 
N
S
O
N
H
OO
CO2tBu
N
S
O
N
H
O
CO2tBu
a Cp2Ti
Cl
Al
Tebbe reagent
21 2425
trace  
a) Tebbe reagent 24, THF, -78°C, 1%.  
Scheme 10. 
 
Only 3-formylceph-2-em 21 gave, besides various decomposition products, the 
desired methylene compound 25, albeit in a very low yield of 1% (Scheme 10). Both 
mass and 1H-NMR spectra were in agreement with this structure. Apparently, 
cephalosporin compounds are too sensitive for the Tebbe reaction. In spite of the 
relatively low basicity, the high nucleophilicity of the Tebbe reagent probably causes 
opening of the β-lactam ring, which is detrimental for a successful methylenation 
reaction. 
 
 
6.3 Concluding remarks 
 
The olefination reaction of 3-formylcephalosporins was successfully carried out with 
phosphorous ylides stabilized by conjugation, viz. for ester and cyano substituted 
ylides, in moderate yields of ca. 50%. In β-lactam chemistry, expeditious yield 
optimization studies frequently lead to improvements in yield. The direct olefination 
of 3-hydroxymethylcephalosporins employing the oxidative Wittig process could be 
accomplished with the same type of ylides in yields ranging from 32-39%. 
Disappointingly, the olefination of 3-formylcephalosporins with non-stabilized 
ylides was not met with success, only decomposition of the cephalosporin nucleus 
was observed. Alternative routes to 3-alkenylcephalosporins also failed to form the 
desired products. 
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6.4 Experimental part 
 
General remarks 
100 MHz 1H-NMR spectra were recorded on a Bruker AC 100 spectrometer and 300 MHz 1H-NMR 
spectra and all 13C-NMR spectra were recorded on a Bruker AC 300 using Me4Si as internal standard. 
All coupling constants are given as 3J in Hz, unless indicated otherwise. Melting points were 
measured with a Reichert Thermopan microscope and are uncorrected. IR spectra were recorded on a 
Bio-Rad FTS-25 instrument. For mass spectra a double focusing VG7070E mass spectrometer was 
used. For some samples, High Resolution FAB was carried out using a JEOL JMS SX/SX102A four-
sector mass spectrometer (JEOL Ltd. 1-2 Musashino  3-chome, Akishima Tokyo), coupled to a MS-MP 
9021D/UPD data system (University of Amsterdam). Elemental analyses were conducted on a Carlo 
Erba Instruments CHNSO EA 1108 element analyzer. For the determination of optical rotations a 
Perkin-Elmer 241 polarimeter was used. Solvents were dried using the following methods: 
dichloromethane was distilled from P2O5; ethyl acetate was distilled from K2CO3; hexane and heptane 
were distilled from CaH2; tetrahydrofuran was distilled from sodium just before use. All other 
solvents were of analytical grade. Thin layer chromatography (TLC) was carried out on a Merck 
precoated silica gel 60 F254 plates (0.25 mm). Spots were visualized with UV or using a molybdate 
spray. Flash chromatography was carried out at a pressure of ca. 1.5 bar, using Merck Kieselgel 60H. 
Column chromatography at atmospheric pressure was performed with ACROS silicagel (0.035-0.070 
mm; pore diameter ca. 6 nm). 
Systematic names were generated using the ACD/Name program provided by Advanced Chemistry 
Development Inc. (Toronto, Canada). Alcohol 17 was a generous gift of DSM Anti-Infectives, Delft. 
Aldehydes 11, 19, and 21 were prepared according to a known procedure.[17]  
 
 
tert-Butyl (7R,7aR)-3-[(E)-3-ethoxy-3-oxo-1-propenyl]-6-oxo-7-[(2-phenylacetyl)amino]-7,7a- 
dihydro-2H,6H-azeto[2,1-b][1,3]thiazine-4-carboxylate (13a) 
Freshly prepared ethyl 2-(triphenylphosphanylidene)acetate (0.091 g; 0.26 mmol) was added in one 
portion to a cooled (0°C) and stirred solution of aldehyde 11 (0.10 g; 0.248 mmol) in dichloromethane 
(5 ml). After stirring at 0°C for another 4h, the reaction mixture was concentrated in vacuo and 
purified by column chromatography (SiO2, n-heptane/ethyl acetate 1:2), affording 13a (0.060 g; 51%) 
as a white-yellow foam and a trace of aldehyde 11. 
Direct oxidation Wittig approach 
Activated manganese(II) oxide (1.3 g; ca. 30 equivalents) was added in three portions at ambient 
temperature to a mixture of alcohol 16 (0.200 g; 0.494 mmol) and ethyl 2-
(triphenylphosphanylidene)acetate (0.207 g; 0.593 mmol) in dichloromethane (7 ml). After complete 
conversion (4-8h), the reaction mixture was filtered over hyflo and concentrated in vacuo. Purification 
by column chromatography (SiO2, n-heptane/ethyl acetate 1:2) afforded Wittig product 13a (0.090 g; 
39%) as a yellow foam. 
Mp 94-96°C; [α]D = -76.9° (c = 0.52; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.30 (t, J = 7.1 Hz, 
3H, CH2CH3), 1.56 (s, 9H, C(CH3)3), 3.46 and 3.55 (qAB, JAB = 17.7 Hz, 2H, SCH2), 3.62 (s, 2H, PhCH2), 
4.22 (dq, J = 7.1 Hz 4J = 2.3 Hz, 2H, CH2CH3), 4.95 (d, J = 5.0 Hz, 1H, NHCHCHS), 5.89 (dd, J = 5.0 Hz J 
= 9.3 Hz, 1H, NHCHCHS), 5.98 (d, J = 16.0 Hz, 1H, =CHCO2Et), 6.67 (d, J = 9.3 Hz, 1H, NH), 7.26-7.37 
(m, 5H, PhH), 7.87 (d, J = 16.0 Hz, 1H, CH=CHCO2Et); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 14.2 
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(CH2CH3), 24.1 (SCH2), 27.7 (C(CH3)3), 43.0 (PhCH2), 57.6 (CHNH), 59.3 (CHS)*, 60.7 (CH2CH3)*, 84.4 
(C(CH3)3), 120.3 (CH=CHCO2Et), 120.8 (=CCH=CHCO2Et), 127.5, 129.0, 129.3 and 133.8 (PhC), 130.3 
(=CCO2tBu), 139.0 (CH=CHCO2Et), 160.0 (CO2tBu), 164.6 (C=O, lactam), 166.0 (CO2Et), 171.3 
(PhCH2C(O)) (*: signals may have interchanged); IR (KBr): ν 3339 (broad, NH), 1788 (C=O, lactam), 
1711 and 1709 (C=O, esters), 1685 and 1534 (C=O, amide), 1367 (C-N), 1153 (C-O, ester) cm-1; MS 
(FAB+, NOBA): m/z (%) = 495 (4) [M+Na]+, 473 (3) [M+H]+, 417 (12) [M+H-C4H8]+, 298 (12), 242 (95), 
176 (100), 91 (58) [PhCH2]+. 
 
tert-Butyl (7R,7aR)-3-[(E)-2-cyano-1-ethenyl]-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-2H,6H-
azeto[2,1-b][1,3]thiazine-4-carboxylate (13b) 
This compound was prepared in the same way as described for 13a, starting from aldehyde 11 (0.17 g; 
0.422 mmol) and triphenylphosphoranylidene acetonitrile (0.14 g; 0.46 mmol), yielding 13b (0.096 g; 
53%) as white needles after column chromatography (SiO2, n-heptane/ethyl acetate 1:1), followed by 
crystallization from ethyl acetate / heptane. 
Direct oxidation Wittig approach 
Prepared in the same way as described for 13a, starting from alcohol 16 (0.270 g; 0.667 mmol) and 
ylide (0.201 g; 0.80 mmol), giving 13b as white needles (0.110 g; 39%). 
Mp 147-149°C; [α]D = -181.9° (c = 0.52; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.52 (s, 9H, 
C(CH3)3), 3.63 and 3.67 (qAB, JAB = 16.0 Hz, 2H, PhCH2), 3.79 and 4.13 (qAB, JAB = 17.9 Hz, 2H, SCH2), 
4.99 (d, J = 5.3 Hz, 1H, NHCHCHS), 5.36 (d, J = 12.4 Hz, 1H, =CHCN), 5.93 (dd, J = 5.3 Hz J = 9.3 Hz, 
1H, NHCHCHS), 6.28 (d, J = 9.3 Hz, 1H, NH), 7.26-7.40 (m, 6H, CH=CHCN and PhH); 13C-NMR (75 
MHz, CDCl3) δ (ppm) = 25.1 (SCH2), 27.7 (C(CH3)3), 43.3 (PhCH2), 57.7 (CHNH), 59.7 (CHS), 84.9 
(C(CH3)3), 96.8 (CHCN), 117.2 (CN), 123.4 (=CCH=CHCN), 127.8, 129.2, 129.4 and 133.5 (PhC), 131.3 
(=CCO2tBu), 143.5 (CH=CHCN), 159.9 (CO2tBu),  164.5 (C=O, lactam), 171.1 (PhCH2C(O)); IR (KBr): ν 
3325 (broad, NH), 2267 (C≡N), 1789 (C=O, lactam), 1703 (C=O, ester), 1688 and 1534 (C=O, amide), 
1367 (C-N), 1151 (C-O, ester) cm-1; MS (CI+): m/z (%) = 426 (2) [M+H]+, 370 (26) [M+H-C4H8]+, 195 (33), 
176 (48), 91 (46) [PhCH2+], 57 (100) [C4H9+]; HRMS (CI+, m/z): calculated for C22H23O4N3S: 425.14090 
amu. Found: 425.14011 ± 0.00128 amu. 
 
Benzhydryl (7R,7aR)-3-[(E)-3-ethoxy-3-oxo-1-propenyl]-6-oxo-7-[(2-phenylacetyl)amino]-7,7a- 
dihydro-2H,6H-azeto[2,1-b][1,3]thiazine-4-carboxylate (18a) 
To a suspension of alcohol 17 (0.278 g; 0.54 mmol) and ethyl 2-(triphenylphosphanylidene)acetate 
(0.226 g; 0.648 mmol) in dichloromethane (10 ml) was added activated manganese(IV) oxide (1.4 g; ca. 
30 equivalents) at room temperature. After completion (4-8h), the reaction mixture was concentrated 
in vacuo and the residue was purified by column chromatography (SiO2, n-heptane/ethyl acetate 2:3) 
giving Wittig product 18a (0.096 g; 30%) as a yellow-brown foam.  
Mp 159-163°C (dec.); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 3.59 and 3.66 (qAB, JAB = 16.0 Hz, 2H, 
PhCH2), 3.75 and 4.09 (qAB, JAB = 18.0 Hz, 2H, SCH2), 5.08 (d, J = 5.2 Hz, 1H, NHCHCHS), 5.90 (d, J = 
16.0 Hz, 1H, =CHCO2Et), 5.98 (dd, J = 5.2 Hz J = 9.1 Hz, 1H, NHCHCHS), 6.23 (d, J = 9.1 Hz, 1H, NH), 
6.95 (s, 1H, CHPh2), 7.24-7.40 (m, 15H, PhH), 7.87 (d, J = 16.0 Hz, 1H, CH=CHCO2Et); 13C-NMR (75 
MHz, CDCl3) δ (ppm) = 14.1(CH2CH3), 25.1(SCH2), 43.3(PhCH2), 57.7 (CHNH), 59.8 (CHS)*, 60.5 
CH2CH3)* 80.1 CHPh2), 120.4 CH=CHCO2Et), 120.5 =CCH=CHCO2Et), 127.0, 127.8, 128.1, 128.3, 128.5, 
128.6, 128.8, 129.3, 129.4, 133.5, 138.5 and 138.8 (PhC), 129.4 (=CCO2CHPh2), 139.0 (CH=CHCO2Et), 
159.9 (CO2CHPh2),  164.5 (C=O, lactam), 171.3 (PhCH2C(O)) (*: signals may have interchanged); IR 
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(KBr): ν 3276 (broad, NH), 1785 (C=O, lactam), 1713 and 1705  (C=O, esters), 1665 and 1524 (C=O, 
amide), 1351 (C-N), 1228 (C-O, ester) cm-1; MS (CI+): m/z (%) = 583 (0.3) [M+H]+, 492 (2) [M+H-
CHPh2]+, 217 (50), 167 (100) [CHPh2+], 91 (52) [PhCH2+]. 
 
Benzhydryl (7R,7aR)-3-[(E)-2-cyano-1-ethenyl]-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro- 
2H,6H-azeto[2,1-b][1,3]thiazine-4-carboxylate (18b) 
This compound was prepared in the same manner as described for compound 18a, starting from 
alcohol 17 (0.515 g; 1.0 mmol), and triphenylphosphoranylidene acetonitrile (0.331 g; 1.10 mmol). 
After work-up and purification pure 18b (0.172 g; 32%) was obtained. 
Mp 180-182°C (dec.); [α]D = -175.6° (c = 0.23; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 3.60 and 
3.65 (qAB, JAB = 16.0 Hz, 2H, PhCH2), 3.77 and 4.10 (qAB, JAB = 18.1 Hz, 2H, SCH2), 5.0 (d, J = 5.1 Hz, 
1H, NHCHCHS), 5.23 (d, J = 12.4 Hz, 1H, =CHCN), 5.94 (dd, J = 5.1 Hz J = 9.2 Hz, 1H, NHCHCHS), 
6.25 (d, J = 9.2 Hz, 1H, NH), 6.95 (s, 1H, CHPh2), 7.11 (d, J = 12.4 Hz, 1H, CH=CHCN), 7.24-7.40 (m, 
15H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 25.2 (SCH2), 43.2 (PhCH2), 57.7 (CHNH), 59.8 (CHS), 
80.2 (CHPh2), 97.5 (CHCN), 116.9 (CN), 122.2 (=CCH=CHCN), 126.9, 127.7, 128.0, 128.3, 128.4, 128.5, 
128.6, 129.2, 129.4, 133.5, 138.4 and 138.7 (PhC), 129.6 (=CCO2CHPh2), 143.3 (CH=CHCN), 160.4 
(CO2CHPh2),  164.8 (C=O, lactam), 171.1 (PhCH2C(O)); IR (KBr): ν 3276 (broad, NH), 2267 (C≡N), 1784 
(C=O, lactam), 1725 (C=O, ester), 1660 and 1521 (C=O, amide), 1350 (C-N), 1224 (C-O, ester) cm-1; MS 
(CI+): m/z (%) = 536 (0.1) [M+H]+, 369 (1) [M+H-CHPh2]+, 279 (32), 217 (50), 167 (100) [CHPh2+], 136 
(71), 91 (43) [PhCH2+].  
 
tert-Butyl (4R,7R,7aR)-6-oxo-7-[(2-phenylacetyl)amino]-3-vinyl-7,7a-dihydro-4H,6H-azeto[2,1-
b][1,3]thiazine-4-carboxylate (25) 
Tebbe's reagent (24)  in toluene (2.5 ml) was added to a cooled (-78°C) solution of aldehyde 21 (0.512 
g; 1.27 mmol) in dry THF (10 ml). After stirring for 45 min. at -78°C, TLC analysis showed complete 
conversion of the starting material. Water (5 ml) and dichloromethane were added and after 
separation of the organic layer, drying (MgSO4) and concentration in vacuo, the residue was purified 
by column chromatography (SiO2, ethyl acetate/heptane 1:1), giving methylene compound 25 (4.0 
mg; 1%). 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.47 (s, 9H, C(CH3)3), 3.66 and 3.68 (qAB, JAB = 16.0 Hz, 2H, 
PhCH2), 5.04 (d, J = 11.3 Hz, 1H, CH=CHcHt),  5.08 (s, 1H, SCH=), 5.28 (d, J = 14.3 Hz, 1H, 
CH=CHcHt), 5.37 (d, J = 4.0 Hz, 1H, NHCHCHS), 5.66 (dd, J = 4.0 Hz J = 8.8 Hz, 1H, NHCHCHS), 6.15 
(d, J = 8.8 Hz, 1H, NH), 6.22 (dd, J = 14.3 Hz J = 11.3 Hz, 1H, CH=CH2), 6.23 (s, 1H, =CHCO2tBu), 7.26-
7.37 (m, 5H, PhH). 
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DIASTEREOSELECTIVE BARBIER TYPE 
ORGANOZINC ADDITIONS TO  
3-FORMYLCEPHALOSPORINS 
 
 
 
 
 
 
 
 
 
 
7.1 Introduction 
 
The addition of carbon nucleophiles to carbonyl groups is one of the most frequently 
used methods for constructing carbon-carbon bonds.[1] A typical example is the 
allylation of aldehydes and ketones applying appropriate organometallic 
compounds.[2] The Grignard and Barbier-type organometallic additions are 
illustrative in these transformations. Allylic halides, which are difficult to transform 
into the corresponding Grignard reagents, frequently give excellent results applying 
the Barbier procedure[3] in which the organometallic intermediate is generated in situ 
in the presence of the carbonyl group.[4] The possibility of conducting these Barbier-
Grignard type reactions in aqueous media has a great advance as no anhydrous 
organic solvents are needed. Moreover, the synthetic procedure does not require 
special safety precautions.[5],[6]  
 
So far, organometallic additions to 3-formylcephalosporins have been reported only 
for Grignard-type reactions affording the corresponding carbinols as mixtures of 
diastereomers without significant diastereoselectivity. The only examples reported 
are additions with methyl-, ethyl-, and phenyl-magnesium bromide,[7] and with 
Chapter 7 
 120 
vinyl-, ethynyl-, and propynyl-magnesium bromide.[8],[9] For a more detailed 
overview of Grignard reactions with 3-formylcephaloporins, see Chapter 2. So far, 
scarce attention was paid to Barbier-type additions to 3-formylcephalosporins.[10]  
 
As outlined in Scheme 1, the allylation of 3-formylcephalosporins offers attractive 
prospects for the synthesis of a variety of new 3-substituted cephalosporins. These 
types of alkenyl-substituted β-lactams are known to have potent anti-bacterial 
activity. 
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Starting from the readily available aldehydes 1 and 2, the initially formed addition 
products 3 can be used as precursor for more complex cephalosporins. Metathesis 
with Grubb's catalyst offers new opportunities for further functionalization to 4. In 
addition, the intermediate addition products 3 may be converted into cefprozil 
analogues 5 or cephalothin analogues 6 in a limited number of steps (Scheme 1). The 
parent antibiotics cefprozil (7) and cephalothin (8) are orally active antibiotics with 
desired properties (Figure 1).[11]  
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In this chapter, the results of organozinc additions to 3-formylcephalosporins using 
the Barbier methodology are described. A preliminary study on possible 
applications of the obtained allylic carbinols is included as well. 
 
 
7.2 Results and discussion 
 
The zinc Barbier procedure was first applied to the allylation of 3-
formylcephalosporin 1. The reaction of 1[12] with allyl bromide, non-activated zinc 
and saturated ammonium chloride in THF, resulted in homoallylic alcohol 9 in an 
excellent yield of 89% at room temperature (Scheme 2). At this temperature, two 
diastereomers were formed in a 25:75 ratio (fast-moving : slow-moving 
diastereomers on TLC). At 0°C, however, the reaction appeared to be highly 
diastereoselective. The ratio of homoallylic alcohols 9 now amounted to 10:90. In 
order to establish the scope of the reaction, other allylic bromides and also propargyl 
bromide were applied under similar conditions. In all cases the corresponding 
carbinols were produced in satisfactory yields, and with high diastereoselectivity 
(Table 1). Thus, the reaction of 1 with propargyl bromide afforded the 
homopropargyl alcohols 10 in 41% yield (diasteromeric ratio: 17:83 at ambient 
temperature). Again, the selectivity was improved to 10:90 when the reaction was 
performed at 0°C.  
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General reaction conditions: 2 equiv. bromide, 5 equiv. Zn dust, aqueous NH4Cl, THF, 0°C or r.t. 
Scheme 2. 
 
Table 1: Barbier-type reactions of 3-formylcephalosporin 1. 
a   reaction not performed 
b   ratio at C10 
c inseparable mixture (syn / anti) at C11 
d single isomer 
 
The reaction of 3-formylcephalosporin 1 with crotyl bromide under Barbier 
conditions gave the methyl substituted homoallyl alcohol 11 in 79% yield in a 1:1 
diastereomeric ratio. Clearly, the organozinc reagent derived from crotyl bromide 
has reacted in a different manner as initially expected. This product formation can be 
explained by an initial complexation of the organozinc reagent at the carbonyl 
 entry: bromide: product: yield (%): ratio (0°C): ratio (20°C): 
1 allyl 9 89 10:90 25:75 
2 propargyl 10 85 10:90 17:83 
3 crotyl 11 79 50:50b,c -a 
4 prenyl 12 80 33:67 -a 
5 cinnamyl 13 71 0:100b,d 10:90b 
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group, followed by a reaction at the carbonyl atom via a cyclic transition state as 
shown in Scheme 3. 
 
O
H
Zn Br ZnBr
O
 
Scheme 3. 
 
It is conceivable that the reaction with allylzinc bromide follows a similar pathway. 
However, the diastereomeric ratio would then be in the range of 1:1. Therefore, the 
direct conventional reaction of the organometallic reagent surely will play a role as 
well. The organozinc reagent derived from propargyl bromide clearly reacts directly 
with aldehyde 1, otherwise an allenic product would have been expected. The 
behavior of allylic organometallic reagents involving an attack resulting in a 
rearranged product have been encountered in the literature before.[13] 
 
Similarly, the reaction of 1 with prenyl- and cinnamyl bromide resulted in the 
corresponding rearrangement products with a good to excellent diastereoselectivity 
(Table 1). Usually, reactions at ambient temperature showed a lower yield and a 
lower diastereoselectivity, therefore the reactions are preferably performed at 0°C. 
The reaction with cinnamyl bromide proceeds in a complete stereoselective manner. 
This preferred product formation can readily be explained by assuming that 
cinnamylzinc bromide reacts with aldehyde 1 via a six-membered cyclic transition 
state as depicted in Scheme 4. Usually, substituted allyl bromides in organozinc 
reactions result in an anti-diastereoselectivity (with respect to the extra chiral center), 
which is independent of the stereochemistry of the double bond in the allyl bromide 
moiety (Schemes 2 and 5). The alcohol function in cinnamyl adduct 13 was thus 
expected to be in an anti-relationship with respect to the phenyl group, as was 
confirmed by in-depth 1H- and 13C-spectroscopy (Scheme 4). 
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With the aim to study the steric influence of a different ester group at C4, aldehyde 2, 
containing at C4 a diphenylmethyl ester, was synthesized.[14] Surprisingly, the 
reaction of aldehyde 2 with allyl bromide did not afford the expected homoallyl 
alcohols, but instead gave the corresponding lactones 14 in a good yield of 76% after 
purification. Even though TLC analysis showed the formation of the expected 
alcohols, the only products obtained after column chromatography were the lactones 
14 as a mixture of diastereomers (Scheme 5; Table 2).  
 
The formation of the lactones 14 is the result of an intramolecular transesterification 
of the initially formed homoallyl alcohols. Apparently, such transesterification does 
not take place with the tert-butyl ester products 10-13. This difference in chemical 
behavior of two related esters again points to the sensitivity of cephalosporin 
substrates to subtle structural differences. The lactonization of the initially formed 
diphenylmethyl esters could not be avoided, even not under neutral conditions. A 
related facile lactonization was reported for a cephalosporin diphenylmethyl ester 
containing an acetoxy methyl group at C3.[9] Lactone formation clearly is an easy 
process. 
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General reaction conditions: 2 equiv. bromide, 5 equiv. Zn dust, aqueous NH4Cl, THF, 0°C or r.t. 
Scheme 5. 
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Table 2: Barbier-type reactions of 3-formylcephalosporin 2. 
a inseparable mixture of 2 diastereomers (1:1) at C11 
b only trace amount of other isomer (TLC) 
c not performed 
d single isomer at C11 
 
The data in Table 2 reveal that in most cases the addition of the Barbier reagents to 2 
is a highly diastereoselective process. These results are fully in line with those 
obtained for aldehyde 1 (tert-butyl ester) and those reported for 3-bromo-4-
formylpyridine.[15] The relative configuration at C10 in the lactones was established 
by X-ray crystal structure analyses of the minor diastereomers of lactones 14 and 17 
(Figure 4). From these X-ray studies, and by comparison of the 1H-NMR structural 
characteristics, the configuration at C10 in other lactones 15, 16, and 18 could be 
established. 
 
In the discussion of the stereochemical course of the reaction first the relative 
stereochemistry of the newly formed stereochemical centers at C10 and C11 in the 
reaction with cinnamylzinc bromide will be addressed. Assuming that the actual 
carbon-carbon bond formation proceeds via a cyclic transition state as depicted in 
Scheme 4, the preferred conformation of the six-membered chair-like cyclic 
transition state will be strongly dictated by an equatorial position of the β-lactam 
nucleus and the phenyl ring. In this manner the anti product 13 will preferentially be 
formed. For crotylzinc bromide, the conformational preference in the transition state 
is much less outspoken, leading to a mixture of diastereomeric products derived 
from C11. Also the steric size of the substituent at the aldehyde has an influence on 
the anti/syn ratio. This ratio increases with an increasing size of the aldehyde R-
group.[6]  
 
The relative stereochemistry at the hydroxyl bearing carbon atom will be governed 
by the facial selectivity of the reaction at the aldehyde function. In principle, the 
aldehyde (e.g. 1) can react in four possible conformations (Figure 2). It was assumed 
 entry: bromide: product: yield (%): ratio (0°C): ratio (20°C): 
1 allyl 14 76 80:20 50:50 
2 propargyl 15 95 98:02 67:33 
3 crotyl 16 73 57:43a -c 
4 prenyl 17 87 70:30 -c 
5 cinnamyl 18 70 100:0b,d 85:15 
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that the π-orbitals of the ester carbonyl, the C3-C4 double bond, and the formyl 
carbonyl have an optimal overlap (preferably a planar structure). 
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Initially, a space-filling model was used to differentiate between the possible 
conformations. It is obvious that the bulky tert-butyl ester will escape from sterical 
hindrance, and therefore, the conformers A and C are energetically not very likely. 
However, using this simple model, it is more difficult to discriminate between 
conformers B and D. Therefore, information from an X-ray structure of aldehyde 1 
was introduced in order to provide insight in this conformational preference. The 
result of this X-ray analysis is shown in Figure 3 and clearly reveals the s-trans 
conformation for the aldehyde moiety with respect to the olefinic bond, thus 
conformation B. It should be realized that this structural analysis refers to the solid 
state, however, it may be taken as strongly suggestive for the preference 
conformation in solution.  
less favored
favored
 
Figure 3. PLUTON drawing of the X-ray structure of aldehyde 1. 
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In order to escape from sterical hindrance, the bulky tert-butyl ester will be slightly 
folded out of the plane. Assuming that conformation B predominates in solution, 
attack of the organozinc reagent from the least hindered face will be preferred. Such 
an attack leads to the stereochemistry at C10 as indicated in structure 13. This 
structural assignment was substantiated by an X-ray analysis of two products. The 
two major isomers of products 14 and 17 did not gave suitable crystalline material 
for an diffraction analysis. Fortunately, the minor diastereomers of these products 
gave crystals which could be subjected to an X-ray structure analysis. The resulting 
structures are shown in Figure 4.  
14 17
 
Figure 4. PLUTON drawings of the X-ray structures of allyl lactone 14 and prenyl lactone 17 (minor isomers). 
 
The stereochemistry at C10 of the major isomers is opposite to that shown in Figure 4, 
and is pictured in Figure 5. These results are fully consistent with those derived from 
the face selectivity of the organozinc reaction. This face selectivity is clearly the result 
of steric approach control, which is governed by the spatial encumbrance of the 
folded nucleus. 
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Figure 5. Structures of the major diastereomers of lactones 14 and 17. 
 
Chapter 7 
 128 
The high yields observed for the Barbier addition to the sensitive 3-
formylcephalosporins show the relative mildness of this addition reaction. It may 
therefore be concluded that the Barbier addition offers unique opportunities to the 
selective functionalization of cephalosporins.  
 
 
7.3 Some synthetic applications of allylated cephalosporins  
 
In principle, the allylated cephalosporins are interesting building blocks for the 
preparation of new or existing antibiotics. The synthesis of cefprozil analogues 5 
would be a nice illustration hereof. For this purpose, the synthesis of the vinyl 
analogues was attempted by dehydration of homoallyl alcohol 9 (Scheme 6). The 
results of the dehydration experiments are collected in Table 3. 
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Table 3: Attempted dehydration of homoallylic alcohol 9. 
a n.d. (not determined) 
b as a mixture of E/Z, together with starting material 9 
 
Acid catalyzed dehydration of 9 with p-toluenesulfonic acid in toluene using a Dean-
Stark apparatus (entry 1) did not lead to the desired conjugated alkene 19. Instead, 
the allyllactone 14 (see Scheme 5) was formed. Apparently, intramolecular 
transesterification to lactone 14 had taken place under these acidic conditions. The 
entry: conditions: result: yield (%): 
1 p-TsOH, benzene, Dean-Stark, reflux lactone 14 n.d.a 
2 pyridinium p-tosylate, 9 days lactone 14 62% 
3 mesyl chloride, pyridine, -20°C decomposition - 
4 Martin sulfurane dehydrating agent, -50°C 
SPh2
OC(CF3)2Ph
OC(CF3)2Ph
 
19 44%b 
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same lactone 14 was obtained in a yield of 62% by stirring alcohol 9 in 
dichloromethane in the presence of a catalytic amount of pyridinium p-tosylate[16] for 
9 days (entry 2). It should be noted that only one epimeric alcohol 9 had undergone 
this lactonization reaction, as was indicated by the fact that a single lactone was 
obtained. No epimerization of the chiral center at C10 was observed. 
 
Attempted conversion of the hydroxyl group of 9 into the corresponding mesylate 
by treatment with mesyl chloride in pyridine at -20°C only led to decomposition 
products (entry 3). Finally, Martin's sulfurane dehydration agent[17] was applied to 
enforce dehydration of homoallyl alcohol 9 (entry 4). After work-up without using 
water, the desired product 19 was obtained as an inseparable mixture of E- and Z-
alkenes, together with some starting material. As product separation was not 
possible, no further attention was given to the synthesis of 19. 
 
For the purpose of synthetically modifying substrate 14, a selective cross-
methathesis[18],[19] with an olefin containing functional groups is an interesting 
application. Thus, a mixture of allyl lactone 14, an excess of allyl acetate and Grubb's 
catalyst 20 was dissolved in dichloromethane and stirred at ambient temperature for 
24 hours (Scheme 7). After work-up and purification, the expected metathesis 
product 26 was obtained as an inseparable mixture of E- and Z-alkenes, along with 
some self-metathesis products. The presence of acetoxy groups in both compounds 
in the complex reaction mixture was confirmed by 1H-NMR (singlets at 2.05 and 2.06 
ppm). 
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a) Grubb's catalyst 20, dichloroethane, 24h, 13%. 
Scheme 7. 
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This preliminary experiment only gave a modest yield of the desired products. 
However, employing different functionalized olefins and various types of Grubb's 
catalyst, including those belonging to the second generation, gives ample 
opportunities to improve this result. Such experiments could not be carried out due 
to time constraints. 
 
 
7.4 Concluding remarks 
 
The results described in this chapter clearly demonstrate that zinc mediated Barbier 
type additions to 3-formylcephalosporins are efficient and highly stereoselective 
reactions, which allow, depending on the nature of the ester moiety at C4, the 
synthesis of a variety of 3-substituted homoallylic cephalosporins or the 
corresponding butenolides. The observed high diastereoselectivity can readily be 
explained by a steric approach control model by involving the hindrance of the β-
lactam moiety. 
  
Preliminary experiments suggest that further synthetic modifications of the allyl 
cephalosporins, e.g. by cross-metathesis, in order to obtain novel cephalosporin 
antibiotics, is a realistic option.  
 
 
7.5 Experimental part 
 
General remarks 
100 MHz 1H-NMR spectra were recorded on a Bruker AC 100 spectrometer and 300 MHz 1H-NMR 
spectra and all 13C-NMR spectra were recorded on a Bruker AC 300 using Me4Si as internal standard. 
All coupling constants are given as 3J in Hz, unless indicated otherwise. Melting points were 
measured with a Reichert Thermopan microscope and are uncorrected. IR spectra were recorded on a 
Bio-Rad FTS-25 instrument. For mass spectra a double focusing VG7070E mass spectrometer was 
used. For some samples, High Resolution FAB was carried out using a JEOL JMS SX/SX102A four-
sector mass spectrometer (JEOL Ltd. 1-2 Musashino  3-chome, Akishima Tokyo), coupled to a MS-MP 
9021D/UPD data system (University of Amsterdam). Elemental analyses were conducted on a Carlo 
Erba Instruments CHNSO EA 1108 element analyzer. For the determination of optical rotations a 
Perkin-Elmer 241MC polarimeter was used. Solvents were dried using the following methods: 
dichloromethane was distilled from P2O5; ethyl acetate was distilled from K2CO3; diethyl ether was 
distilled from NaH; hexane and heptane were distilled from CaH2; tetrahydrofuran was distilled from 
sodium just before use. All other solvents were of analytical grade. Thin layer chromatography (TLC) 
was carried out on a Merck precoated silica gel 60 F254 plates (0.25 mm). Spots were visualized with 
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UV or using a molybdate spray. Flash chromatography was carried out at a pressure of ca. 1.5 bar, 
using Merck Kieselgel 60H. Column chromatography at atmospheric pressure was performed with 
ACROS silicagel (0.035-0.070 mm; pore diameter ca. 6 nm). 
Systematic names were generated using the ACD/Name program provided by Advanced Chemistry 
Development Inc. (Toronto, Canada). 
 
 
General procedure for the organozinc addition reactions 
Zinc dust (5 equiv.) and the corresponding bromide (2 equiv.) were added to a solution of aldehyde 1 
or 2 in THF (10-20 ml)., Then, saturated aqueous ammonium chloride (5-10 ml) was added slowly at 
0°C. After completion, the zinc salts were removed by filtration and ethyl acetate and 2N HCl were 
added to the filtrate. The organic layer was washed with brine, dried (MgSO4) and concentrated in 
vacuo. The product was purified by column chromatography, followed by crystallization from ethyl 
acetate/heptane.   
 
Benzhydryl (7R,7aR)-3-formyl-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-dihydro-2H,6H-azeto[2,1- 
b][1,3]thiazine-4-carboxylate (2)  
Aldehyde 2 was synthesized according to the procedure of Frigerio et al.[14] in 95% yield. 
1H-NMR (100 MHz, CDCl3) δ (ppm) = 3.22 and 3.93 (qAB, JAB = 18.4 Hz, 2H, SCH2), 3.62 (s, 2H, 
PhCH2), 4.98 (1H, J = 5.2 Hz, NHCHCHS), 5.96 (dd, J = 5.2 Hz J = 9.3 Hz, 1H, NHCHCHS), 6.24 (d, J = 
9.3 Hz, 1H, NH), 7.05 (s, 1H, Ph2CH), 7.20-7.34 (m, 15H, PhH and PhH (ester)), 9.62 (s, 1H, CHO); All 
other analytical data were in complete agreement with those reported previously.[20] 
 
(1R) and (1S) tert-Butyl (7R,7aR)-3-[1-hydroxy-3-butenyl]-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-
dihydro-2H,6H-azeto[2,1-b][1,3]thiazine-4-carboxylate (9) 
The reaction was performed according to the general procedure, using aldehyde 1 (0.444 g; 1.10 
mmol), allyl bromide (0.266 g; ca. 2 equiv.) and zinc dust (0.36 g; ca. 5 equiv.). After work-up, the 
crude mixture was purified by column chromatography (SiO2, ethyl acetate / heptane 1:1) affording 
the allyl adducts 9 (0.430 g; 89%) as a mixture of diastereomers (ratio 10:90). Analytical samples were 
obtained by crystallization from ethyl acetate / heptane: off-white plates (fast-moving isomer) and 
colorless needles (slow-moving isomer). 
Fast-moving minor isomer (1R)-9 
Mp 128-130°C (dec.); [α]D = +73.0° (c = 0.61; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.48 (s, 
9H, C(CH3)3), 2.17-2.27 (mAB, 1H, CH2CH=CH2), 2.41-2.50 (mAB, 1H, CH2CH=CH2), 3.32 and 3.64 
(qAB, JAB = 17.9 Hz, 2H, SCH2), 3.56 (s, 2H, PhCH2), 3.51 (bs, 1H, OH), 4.87 (d, J = 4.8 Hz, 1H, 
NHCHCHS), 4.90 (t, J = 7.5 Hz, 1H, C(OH)HCH2), 5.05-5.11 (m, 2H, CH=CH2), 5.57-5.69 (m, 1H, 
CH=CH2), 5.74 (dd, J = 4.8 Hz J = 9.2 Hz, 1H, NHCHCHS), 7.19-7.34 (m, 6H, PhH and NH); 13C-NMR 
(75 MHz, CDCl3) δ (ppm) = 22.6 (SCH2), 27.7 (C(CH3)3), 38.0 (CH2CH=CH2), 43.3 (PhCH2), 57.9 
(CHNH), 58.8 (CHS), 68.4 (CHOH), 84.0 (C(CH3)3), 117.8 (CH=CH2), 125.5 (=CCHOH), 127.3, 128.8, 
129.4, and 134.0 (PhC), 129.6 (=CCO2tBu), 133.4 (CH=CH2), 161.2 (CO2 tBu), 165.1 (C=O, lactam), 171.4 
(PhCH2C(O)); IR (KBr): ν 3435 (broad, OH), 3272 (broad, NH), 1786 (C=O, lactam), 17157 (C=O, ester), 
1688 and 1514 (C=O, amide), 1391 (C-N), 1156 (C-O, ester) cm-1; MS (CI+): m/z (%) = 474 (1) 
[M+C2H5]+, 445 (1) [M+H]+, 459 (1), [M+H]+, 404 (1), 377 (2), 174 (15), 136 (6), 91 (19) [PhCH2+], 57 (100) 
[C4H9+]; HRMS (CI+, m/z): calculated for C23H28O5N2S [M+]: 444.1719 amu. Found: 444.17183 ± 
0.00133 amu. 
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Slow-moving major isomer (1S)-9 
Mp 221-223°C (dec.); [α]D = +10.0° (c = 0.13; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.50 (s, 
9H, C(CH3)3), 2.25-2.35 (mAB, 1H, CH2CH=CH2), 2.44-2.52 (mAB, 1H, CH2CH=CH2), 2.80 (d, J = 3.6 
Hz, 1H, CHOH), 3.40 and 3.52 (qAB, JAB = 18.6 Hz, 2H, SCH2), 3.62 (s, 2H, PhCH2), 4.81-4.87 (m, 1H, 
CHOH), 4.88 (d, J = 4.8 Hz, 1H, NHCHCHS), 5.14-5.19 (m, 2H, CH=CH2), 5.75 (dd, J = 4.8 Hz J = 8.9 
Hz, 1H, NHCHCHS), 5.78-5.92 (m, 1H, CH=CH2), 6.58 (d, 8.9 Hz, 1H, NH), 7.24-7.38 (m, 5H, PhH); 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 24.5 (SCH2), 27.7 (C(CH3)3), 40.4 (CH2CH=CH2), 43.1 (PhCH2), 
57.7 (CHNH), 58.8 (CHS), 69.6 (CHOH), 83.3 (C(CH3)3), 118.7 (CH=CH2), 123.8 (=CCHOH), 127.5, 
129.0, 129.2, and 133.7 (PhC), 133.0 (=CCO2tBu), 133.8 (CH=CH2), 160.7 (CO2 tBu), 164.3 (C=O, lactam), 
171.4 (PhCH2C(O)). 
 
(1R) and (1S) tert-Butyl (7R,7aR)-3-[(1S)-1-hydroxy-3-butynyl]-6-oxo-7-[(2-phenylacetyl)amino]-
7,7a-dihydro-2H,6H-azeto[2,1-b][1,3]thiazine-4-carboxylate (10) 
Aldehyde 1 (0.805 g; 2.0 mmol) was treated according to the general procedure (propargyl bromide) 
to give, after column chromatography (SiO2, ethyl acetate / heptane 1:1), both propargyl adducts 10 
(0.708 g; 85%) as two separable diastereomers in a ratio of 10:90. Analytical samples were obtained by 
crystallization from ethyl acetate / heptane. 
Fast-moving minor isomer (1R)-10 
Mp 123-125°C (dec.); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.50 (s, 9H, C(CH3)3), 1.98 (t, 4J = 2.6 Hz, 
1H, C≡CH), 2.41 (m (part of AB), JAB = 17.7 Hz J = 9.2 Hz J = 2.6 Hz, 1H, CHCH2C≡CH), 2.58 (m (part 
of AB), JAB = 17.7 Hz J = 6.0 Hz J = 2.6 Hz, 1H, CHCH2C≡CH), 3.43 and 3.63 (qAB, JAB = 17.9 Hz, 2H, 
SCH2), 3.56 and 3.58 (qAB, J = 15.7 Hz, 2H, PhCH2), 3.72 (bs, 1H, OH), 4.91 (d, J = 4.8 Hz, 1H, 
NHCHCHS), 5.04 (dd, J = 6.0 Hz J = 9.2, 1H, CH(OH)CH2), 5.76 (dd, J = 4.8 Hz J = 9.2 Hz, 1H, 
NHCHCHS), 7.13 (d, J = 9.2 Hz, 1H, NH), 7.20-7.34 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) 
= 22.2 (CH2C≡CH), 23.8 (SCH2), 27.8 (C(CH3)3), 43.4 (PhCH2), 57.8 (CHNH), 58.9 (CHS), 67.5 (CHOH), 
70.8 (C≡CH), 79.5 (C≡CH), 84.2 (C(CH3)3), 126.3 (=CCHOH), 127.3, 128.9, 129.4 and 133.9 (PhC), 128.5 
(=CCO2), 161.2 (CO2 tBu), 165.2 (C=O, lactam), 171.4 (PhCH2C(O)); IR (KBr): ν 3418 (broad, OH), 3377 
(broad, NH), 1771 (C=O, lactam), 1692 (C=O, ester), 1667 and 1538 (C=O, amide), 1365 (C-N), 1155 (C-
O, ester) cm-1; MS (CI+): m/z (%) = 443 (1), [M+H]+, 425 (1) [M+H-H2O]+, 404 (1), 377(1) [M+H-C4H8]+, 
349 (1), 331 (1), 230 (8), 174 (15), 91 (16) [PhCH2+], 57 (100) [C4H9+]; HRMS (CI+, m/z): calculated for 
C23H26O5N2S [M+]: 442.1562 amu. Found: 442.15617 ± 0.00133 amu. 
Slow-moving major isomer (1S)-10 
Mp 139-141°C (dec.); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.50 (s, 9H, C(CH3)3), 2.12 (t, 4J = 2.6 Hz, 
1H, C≡CH), 2.55 (m (part of AB), JAB = 16.7 Hz J = 7.9 Hz J = 2.6 Hz, 1H, CHCH2C≡CH),  2.66 (m (part 
of AB), JAB = 16.7 Hz J = 4.1 Hz J = 2.6 Hz, 1H, CHCH2C≡CH), 3.13 (d, J = 3.9 Hz, 1H, OH), 3.57 (s, 2H, 
PhCH2), 3.56 (s, 2H, SCH2), 4.89 (d, J = 4.9 Hz, 1H, NHCHCHS), 4.88-4.95 (m, 1H, CH(OH)CH2), 5.78 
(dd, J = 4.9 Hz J = 8.9 Hz, 1H, NHCHCHS), 6.41 (d, J = 8.9 Hz, 1H, NH), 7.25-7.38 (m, 5H, PhH); 13C-
NMR (75 MHz, CDCl3) δ (ppm) = 24.6 (CH2C≡CH), 26.6 (SCH2), 27.8 (C(CH3)3), 43.1 (PhCH2), 57.5 
(CHNH), 58.9 (CHS), 68.8 (CHOH), 71.7 (C≡CH), 80.1 (C≡CH), 83.6 (C(CH3)3), 124.4 (=CCHOH), 127.5, 
129.0, 129.1 and 133.6 (PhC), 131.9 (=CCO2), 160.6 (CO2 tBu), 164.4 (C=O, lactam), 171.3 (PhCH2C(O)). 
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(1R,2R), (1R,2S), (1S,2R), and (1S,2S) tert-Butyl (7R,7aR)-3-[-1-hydroxy-2-methyl-3-butenyl]-6-oxo-7-
[(2-phenylacetyl)amino]-7,7a-dihydro-2H,6H-azeto[2,1-b][1,3]thiazine-4-carboxylate (11)  
Aldehyde 1 (0.810 g; 2.01 mmol) was treated according to the general procedure (crotyl bromide) to 
give, after column chromatography (SiO2, ethyl acetate / heptane 1:1), the adducts 11 (0.729 g; 79%) as 
two separable diastereomers (50:50 ratio), both containing an inseparable mixture of syn / anti 
isomers. Analytical samples were obtained by crystallization from ethyl acetate / heptane. 
Fast-moving minor isomers (1R,2S)-11 and (1R,2R)-11 (ratio 5:2) 
(1R,2S)-11: 1H-NMR (300 MHz, CDCl3) δ (ppm) = 0.81 (d, J = 6.8 Hz, 1H, CH3), 1.48 (s, 9H, C(CH3)3), 
2.25-2.35 (m, 1H, CHCH3), 3.29 and 3.74 (qAB, JAB = 17.8 Hz, 2H, SCH2), 3.56 (s, 2H, PhCH2), ~3.5 (bs, 
OH, 1H), 4.64 (d, J = 9.7 Hz, 1H, CHOH), 4.91 (d, J = 4.7 Hz, 1H, NHCHCHS), 5.12 (d, J = 11.2 Hz, 1H, 
CH=CHtHc), 5.13 (d, J = 16.2 Hz, 1H, CH=CHtHc), 5.41-5.51 (m, 1H, CHOCH(CH3)), 5.68-5.76 (m, 1H, 
NHCHCHS), 5.81 (d, J = 9.3 Hz, 1H, NH), 7.20-7.33 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) 
= 16.7 (CHCH3), 22.5 (SCH2), 27.8 (C(CH3)3), 41.4 (CHCH3), 43.4 (PhCH2), 58.2 (CHNH), 58.8 (CHS), 
72.5 (CHOH), 83.9 (C(CH3)3), 115.7 (CH=CH2), 125.8 (=CCHOH), 127.3, 128.9, 129.4, and 133.9 (PhC), 
139.4 (=CCO2tBu), 140.9 (CH=CH2), 162.5 (CO2 tBu), 165.0 (C=O, lactam), 171.6 (PhCH2C(O)); IR (KBr): 
ν 3449 (broad, OH), 3326 (broad, NH), 1757 (C=O, lactam), 1711 (C=O, ester), 1669 and 1536 (C=O, 
amide), 1368 (C-N), 1156 (C-O, ester) cm-1; MS (CI+): m/z (%) = 487 (1) [M+C2H5]+, 459 (1), [M+H]+, 403 
(4) [M+H-C4H8]+, 385 (16), 347 (12), 210 (27), 194 (15), 136 (10), 91 (60) [PhCH2+], 57 (100) [C4H9+]. 
(1R,2R)-11:1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.13 (d, J = 6.4 Hz, 1H, CH3), 1.48 (s, 9H, C(CH3)3), 
1.90-2.05 (m, 1H, CHCH3), 3.50-3.69 (qAB, JAB = 18.0 Hz, 2H, SCH2), 3.56 (s, 2H, PhCH2), ~3.5 (bs, OH, 
1H), 4.59 (d, J = 9.7 Hz, 1H, CHOH), 4.85 (d, J = 4.7 Hz, 1H, NHCHCHS), 4.90-5.05 (m, CH=CHtHc), 
5.41-5.51 (m, 1H, CHOCH(CH3)), 5.68-5.76 (m, 1H, NHCHCHS), 5.87 (d, J = 9.3 Hz, 1H, NH), 7.20-7.33 
(m, 5H, PhH). 
Slow-moving major isomers (1S,2R)-11 and (1S,2S)-11 (ratio 7:3) 
(1S,2R)-11: 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.11 (d, J = 6.6 Hz, 1H, CH3), 1.50 (s, 9H, C(CH3)3), 
2.50-2.55 (m, 1H, CHCH3), 3.37 and 3.48 (qAB, JAB = 18.5 Hz, 2H, SCH2), 3.62 (s, 2H, PhCH2), ~3.6 (bs, 
OH, 1H), 4.46 (d, J = 7.3 Hz, 1H, CHOH), 4.89 (d, J = 4.8 Hz, 1H, NHCHCHS), 4.96-5.19 (m, 3H, 
CH=CH2), 5.71-5.80 (m, 2H, CHOCH(CH3) and NHCHCHS), 6.31 (d, J = 9.0 Hz, 1H, NH), 7.25-7.38 (m, 
5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 16.1 (CHCH3), 25.6 (SCH2), 27.8 (C(CH3)3), 43.3 
(CHCH3)*, 44.2 (PhCH2)*, 57.7 (CHNH), 58.9 (CHS), 74.8 (CHOH), 83.4 (C(CH3)3), 115.7 (CH=CH2), 
125.1 (=CCHOH), 127.6, 129.1, 129.4, and 133.8 (PhC), 139.7 (CH=CH2), 140.3 (=CCO2tBu), 161.5 
CO2tBu), 164.4 (C=O, lactam), 171.3 (PhCH2C(O)) (*: signals may have interchanged). 
(1S,2S)-11: 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.00 (d, J = 6.9 Hz, 1H, CH3), 1.50 (s, 9H, C(CH3)3), 
2.40-2.45 (m, 1H, CHCH3), 3.40-3.56 (qAB, JAB = 18.3 Hz, 2H, SCH2), 3.62 (s, 2H, PhCH2), ~3.6 (bs, OH, 
1H), 4.67 (d, J = 7.6 Hz, 1H, CHOH), 4.94 (d, J = 4.8 Hz, 1H, NHCHCHS), 4.96-5.19 (m, 3H, CH=CH2), 
5.71-5.80 (m, 2H, CHOCH(CH3) and NHCHCHS), 6.24 (d, J = 9.0 Hz, 1H, NH), 7.25-7.38 (m, 5H, PhH). 
 
(1R) and (1S) tert-Butyl (7R,7aR)-3-[1-hydroxy-2,2-dimethyl-3-butenyl]-6-oxo-7-[(2-
phenylacetyl)amino]-7,7a-dihydro-2H,6H-azeto[2,1-b][1,3]thiazine-4-carboxylate (12)  
Prenyl adducts 12 were synthesized from aldehyde 1 (0.750 g; 1.86 mmol) according to the general 
procedure (prenyl bromide). After column chromatography (SiO2, ethyl acetate / heptane 4:6), 
adducts 12 (0.698 g; 80%) were obtained in a diasteromeric ratio of 33:67. Analytical samples were 
obtained by crystallization from ethyl acetate / heptane: colorless plates (fast-moving isomer) and 
colorless needles (slow-moving isomer). 
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Fast-moving minor isomer (1R)-12  
Mp 170-172°C (dec.); [α]D = +52.0° (c = 0.46; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 0.96 (s, 
3H, CH3), 1.08 (s, 3H, CH3), 1.49 (s, 9H, C(CH3)3), 3.22 (d, J = 3.2 Hz, 1H, OH), 3.29 and 3.67 (qAB, JAB = 
17.6 Hz, 2H, SCH2), 3.56 (s, 2H, PhCH2), 4.93 (d, J = 4.7 Hz, 1H, NHCHCHS), 4.95-5.04 (m, 3H, 
CH=CH2 and CHOH), 5.71 (dd, J = 4.7 Hz J = 9.2 Hz, 1H, NHCHCHS), 6.02 (dd, J = 17.4 Hz J = 11.0 
Hz, 1H, CH=CHtHc), 7.12 (d, J = 9.2 Hz, 1H, NH), 7.20-7.34 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ 
(ppm) = 22.9 (CH3)*, 25.9 (CH3)*, 23.8 (SCH2)*, 27.8 (C(CH3)3), 42.0 (CHCH3), 43.4 (PhCH2), 58.7 
(CHNH)#, 58.9 (CHS)#, 75.1 (CHOH), 83.8 (C(CH3)3), 112.7 (CH=CH2), 125.8 (=CCHOH), 127.3, 128.9, 
129.4, and 134.0 (PhC), 130.1 (=CCO2tBu), 144.3 (CH=CH2), 161.5 (CO2 tBu), 165.3 (C=O, lactam), 171.4 
(PhCH2C(O)) (*,#: signals may have interchanged); IR (KBr): ν 3415 (broad, OH), 3292 (broad, NH), 
1775 (C=O, lactam), 1717 (C=O, ester), 1668 and 1539 (C=O, amide), 1368 (C-N), 1153 (C-O, ester) cm-1; 
MS (FAB+, NOBA): m/z (%) = 495 (2) [M+Na]+, 473 (1) [M+H]+, 439 (1) [M+Na-C4H8]+, 413 (2) [M+H-
C4H8]+, 399 (5), 298 (7), 253 (20), 242 (39), 224 (55), 176 (93), 91 (100) [PhCH2+], 57 ( 95) [C4H9+]; HRMS 
(FAB, m/z): calculated for C25H33O5N2S+: 473.2110 amu. Found: 473.2141 ± 0.0047 amu. 
Slow-moving major isomer (1S)-12 
Mp 213-215°C (dec.); [α]D = +69.4° (c = 0.89; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.04 (s, 
3H, CH3), 1.12 (s, 3H, CH3), 1.50 (s, 9H, C(CH3)3), 3.24 (d, J = 5.6 Hz, 1H, OH), 3.36 and 3.40 (qAB, JAB = 
17.1 Hz, 2H, SCH2), 3.61 (s, 2H, PhCH2), 4.81 (d, J = 5.6 Hz, 1H, CHOH), 4.89 (d, J = 4.7 Hz, 1H, 
NHCHCHS), 5.04 (d, J = 17.6 Hz, 1H, CH=CHcHt), 5.08 (d, J = 10.8 Hz, 1H, CH=CHcHt), 5.66 (dd, J = 
4.7 Hz J = 8.7 Hz, 1H, NHCHCHS), 6.05 (dd, J = 17.6 Hz J = 10.8 Hz, 1H, CH=CHtHc), 6.55 (d, J = 8.7 
Hz, 1H, NH), 7.25-7.36 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 22.6 (CH3)*, 25.9 (CH3)*, 
26.2 (SCH2)*, 27.7 (C(CH3)3), 42.5 (CHCH3), 43.1 (PhCH2), 58.5 (CHNH)#, 59.2 (CHS)#, 76.6 (CHOH), 
83.4 (C(CH3)3), 113.6 (CH=CH2), 126.0 (=CCHOH), 127.4, 128.9, 129.3, and 133.8 (PhC), 136.9 
(=CCO2tBu), 144.3 (CH=CH2), 161.2 (CO2 tBu), 164.6 (C=O, lactam), 171.3 (PhCH2C(O)) (*,#: signals may 
have interchanged). 
 
tert-Butyl (7R,7aR)-3-[(1S,2R)-1-hydroxy-2-phenyl-3-butenyl]-6-oxo-7-[(2-phenylacetyl)amino]-7,7a-
dihydro-2H,6H-azeto[2,1-b][1,3]thiazine-4-carboxylate (13) 
Aldehyde 1 (0.810 g; 2.01 mmol) was reacted with cinnamyl bromide according to the general 
procedure to give, after column chromatography (SiO2, ethyl acetate / heptane 1:1), adduct 13 (0.743 
g; 71%) as one single stereoisomer. An analytical sample was obtained by crystallization from ethyl 
acetate / heptane. 
Mp 87-90°C (dec.); [α]D = +46.9° (c = 1.02; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.45 (s, 9H, 
C(CH3)3), 3.18 and 3.68 (qAB, JAB = 17.7 Hz, 2H, SCH2), 3.38-3.54 (m, 1H, CHPh), 3.46 and 3.51 (qAB, 
JAB = 15.6 Hz, 2H, PhCH2), 3.63 (d, J = 2.0 Hz, 1H, OH), 4.47 (d, J = 4.8 Hz, 1H, NHCHCHS), 5.03 (d, J = 
17.0 Hz, 1H, CH=CHtHc), 5.16 (d, J = 10.3 Hz, 1H, CH=CHtHc), 5.27 (dd, J = 10.4 Hz J = 1.6 Hz, 1H, 
CHOH), 5.53 (dd, J = 4.8 Hz J = 9.2 Hz, 1H, NHCHCHS), 7.05 (d, J = 9.2 Hz, 1H, NH), 6.99-7.36 (m, 
10H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 22.7 (SCH2), 27.8 (C(CH3)3), 43.4 (PhCH2), 54.0 
(CHPh), 57.8 (CHNH), 68.9 (CHS), 71.3 (CHOH), 83.7 (C(CH3)3), 116.9 (=CH2), 126.1 (=CCHO), 125.9, 
127.0, 127.3, 127.7, 128.0, 128.5, 128.7, 128.8, 128.9, 129.4, 133.8 (PhC, CHPhCH=CH2, =CCO2CH), 139.2 
(CH=CH2), 140.0 (=CCO2tBu), 160.9 (CO2 tBu), 164.7 (C=O, lactam), 171.3 (PhCH2C(O)); IR (KBr): ν 
3508 (broad, OH), 3310 (broad, NH), 1775 (C=O, lactam), 1713 (C=O, ester), 1665 and 1537 (C=O, 
amide), 1368 (C-N), 1154 (C-O, ester) cm-1; MS (FAB+, NOBA): m/z (%) = 543 (2) [M+Na]+, 521 (2) 
[M+H]+, 463 (3) [M+H-C4H8]+, 447 (9) [M+H-C4H8-H2O]+, 347 (10), 290 (18), 272 (39), 176 (100), 154 (45) 
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[NOBA]*, 136 (54), 91 (67) [PhCH2+] (* defragmentation of NOBA matrix); HRMS (FAB, m/z): 
calculated for C29H32O5N2SNa+: 543.1930 amu. Found: 543.1917 ± 0.0054 amu.; HRMS (FAB, m/z): 
calculated for C29H32O5N2SNa+ [M-H2O]+: 503.2005 amu. Found: 503.2037 ± 0.0050 amu. 
 
 (3S) and (3R) N1-[(5aR,6R)-3-Allyl-1,7-dioxo-1,4,6,7-tetrahydro-3H,5aH-azeto[2,1-b]furo[3,4-
d][1,3]thiazin-6-yl]-2-phenylacetamide (14) 
Aldehyde 2 (0.77 g; 1.5 mmol) was converted in the corresponding allyl-lactones 14 according to the 
general procedure (allyl bromide). After column chromatography (SiO2, ethyl acetate / heptane 4:6) 
and crystallization from ethyl acetate / heptane, lactones 14 (0.423 g; 76%) were obtained as a white 
solid (fast-moving isomer) and colorless needles (slow-moving isomer) in a ratio of 80:20.  
Fast-moving major isomer (3S)-14 
Mp 188-190°C (dec.); [α]D = +89.1° (c = 0.53; acetone); 1H-NMR (300 MHz, acetone-d6) δ (ppm) = 2.49-
2.59 (mAB, 1H, CH2CH=CH2), 2.73-2.82 (mAB, 1H, CH2CH=CH2), 3.68 and 3.73 (qAB, JAB = 14.4 Hz, 
2H, PhCH2), 3.77 and 3.90 (qAB, JAB = 18.3 Hz, 2H, SCH2), 5.16 (d, J = 5.0 Hz, 1H, NHCHCHS), 5.16-
5.30 (m, 2H, =CH2), 5.33 (t, J = 5.2 Hz, 1H, OCHCH2), 5.74-5.86 (m, 1H, CH=CH2), 6.00 (dd, J = 5.0 Hz J 
= 8.7 Hz, 1H, NHCHCHS), 7.29-7.42 (m, 5H, PhH), 8.13 (d, J = 8.7 Hz, 1H, NH); 13C-NMR (75 MHz, 
acetone-d6) δ (ppm) = 23.3 (SCH2), 37.1 (CH2CH=CH2), 42.9 (PhCH2), 58.4 (CHNH), 60.9 (CHS), 82.2 
(OCHCHCH3), 119.8 (=CH2), 125.4 (=CCHO), 127.5, 129.1, 130.0, and 136.4 (PhC), 132.1 (CH=CH2), 
143.2 (=CCO2), 164.9 (C=O, lactam), 166.2 (CO2CH2), 171.6 (PhCH2C(O)); IR (KBr): ν 3258 (broad, NH), 
1787 (C=O, lactam), 1760 (C=O, lactone), 1667 and 1546 (C=O, amide), 1412 (C-N), 1156 (C-O, lactone) 
cm-1; MS (FAB+, NOBA): m/z (%) = 393 (65) [M+Na]+, 371 (64) [M+H]+, 196 (22), 176 (48), 154 (100) 
[NOBA]*, 91 (22) [PhCH2+] (* defragmentation of NOBA matrix); HRMS (FAB, m/z): calculated for 
C19H19O4N2S+: 371.1066 amu. Found: 371.1096 ± 0.0037 amu. 
Slow-moving minor isomer (3R)-14 
Mp 215-217°C (dec.); [α]D = +173.0° (c = 0.30; acetone); 1H-NMR (300 MHz, CDCl3 and acetone-d6) δ 
(ppm) = 2.41-2.50 (mAB, 1H, CH2CH=CH2), 2.70-2.79 (mAB, 1H, CH2CH=CH2), 3.56 and 3.73 (qAB, JAB 
= 18.5 Hz, 2H, SCH2), 3.60 and 3.65 (qAB, JAB = 14.5 Hz, 2H, PhCH2), 5.02 (d, J = 5.1 Hz, 1H, 
NHCHCHS), 5.06-5.18 (m, 3H, CH=CH2 and OCHCH2), 5.54-5.67 (m, 1H, CH=CH2), 5.88 (dd, J = 5.0 
Hz J = 8.7 Hz, 1H, NHCHCHS), 7.16-7.31 (m, 5H, PhH), 7.64 (d, J = 8.7 Hz, 1H, NH); 13C-NMR (75 
MHz, CDCl3 and acetone-d6) δ (ppm) = 21.6 (SCH2), 35.0 (CH2CH=CH2), 41.6 (PhCH2), 56.8 (CHNH), 
69.3 (CHS), 80.2 (OCHCHCH3), 118.6 (=CH2), 124.2 (=CCHO), 126.0, 127.6, 128.4, and 134.2 (PhC), 
129.8 (CH=CH2), 141.1 (=CCO2), 163.0 (C=O, lactam), 164.7 (CO2CH2), 170.5 (PhCH2C(O)); IR (KBr): ν 
3278 (broad, NH), 1789 (C=O, lactam), 1764 (C=O, lactone), 1662 and 1536 (C=O, amide), 1422 (C-N), 
1142 (C-O, lactone) cm-1; MS (FAB+, NOBA): m/z (%) = 393 (37) [M+Na]+, 371 (28) [M+H]+, 196 (9), 176 
(31), 154 (100) [NOBA]*, 91 (18) [PhCH2+] (* defragmentation of NOBA matrix). 
 
(3R) and (3S) N1-[(5aR,6R)-1,7-Dioxo-3-(2-propynyl)-1,4,6,7-tetrahydro-3H,5aH-azeto[2,1-b]furo[3,4-
d][1,3]thiazin-6-yl]-2-phenylacetamide (15)  
Aldehyde 2 (1.025 g; 2.0 mmol) was treated according to the general procedure (propargyl bromide) 
to give 15 (0.699 g; 95%) as colorless plates (fast-moving isomer) and traces of a yellowish solid (slow-
moving isomer) after purification by column chromatography (SiO2, ethyl acetate/heptane 2:1), and 
subsequent crystallization from ethyl acetate / heptane. 
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Fast-moving major isomer (3S)-15 
Mp 212-214°C (dec.); [α]D = +120.0° (c = 0.35; acetone); 1H-NMR (300 MHz, acetone-d6) δ (ppm) = 2.67 
(t, 4J = 2.6 Hz, 1H, C≡CH), 2.95 and 3.06 (q(dd)AB, JAB = 17.3 Hz J = 5.1 Hz J = 2.6 Hz, 2H, 
CHCH2C≡CH), 3.77 and 3.82 (qAB, JAB = 14.4 Hz, 2H, PhCH2), 3.91 and 3.98 (qAB, JAB = 18.3 Hz, 2H, 
SCH2), 5.25 (d, J = 5.1 Hz, 1H, NHCHCHS), 5.48 (t, J = 5.1 Hz, 1H, OCHCH2), 6.11 (dd, J = 5.1 Hz J = 
8.6 Hz, 1H, NHCHCHS), 7.35-7.50 (m, 5H, PhH), 8.22 (d, J = 8.6 Hz, 1H, NH); 13C-NMR (75 MHz, 
acetone-d6) δ (ppm) = 23.2 (SCH2 and CH2C≡CH), 42.9 (PhCH2), 58.4 (CHNH), 60.9 (CHS), 73.5 
(C≡CH), 77.9 (C≡CH), 80.2 (OCHCH2), 127.5, 129.2,  130.0, and 136.4 (PhC and =CCHO), 142.3 
(=CCO2), 165.0 (C=O, lactam), 165.9 (CO2CH2), 171.6 (PhCH2C(O)); MS (CI+): m/z (%) = 369 (3) 
[M+H]+, 337 (5), 203 (30), 136 (66), 91 (100) [PhCH2+], 57 (52); HRMS (CI+, m/z): calculated for 
C19H16O4N2S: 368.08310 amu. Found: 368.08238 ± 0.00110 amu. 
Slow-moving minor isomer (3R)-15 
Mp >150°C (slow dec.); [α]D = +145.3° (c = 0.17; acetone); 1H-NMR (300 MHz, acetone-d6) δ (ppm) = 
2.54 (t, 4J = 2.6 Hz, 1H, C≡CH), 2.92 and 3.05 (q(dd)AB, JAB = 17.6 Hz J = 4.9 Hz J = 2.6 Hz, 2H, 
CHCH2C≡CH), 3.71 and 3.76 (qAB, JAB = 14.2 Hz, 2H, PhCH2), 3.82 and 3.89 (qAB, JAB = 18.6 Hz 4J < 
1.5 Hz, 2H, SCH2), 5.17 (d, J = 5.1 Hz, 1H, NHCHCHS), 5.37 (t, J = 4.8 Hz, 1H, OCHCH2), 6.03 (dd, J = 
5.1 Hz J = 8.8 Hz, 1H, NHCHCHS), 7.27-7.43 (m, 5H, PhH), 8.17 (d, J = 8.8 Hz, 1H, NH); 13C-NMR (75 
MHz, acetone-d6) δ (ppm) = 22.7 (CH2C≡CH)*, 23.0 (SCH2)*, 42.9 (PhCH2), 58.2 (CHNH), 60.8 (CHS), 
73.5 (C≡CH), 77.9 (C≡CH), 79.9 (OCHCH2), 127.5, 129.1, 130.0, and 136.5 (PhC), 127.3 (=CCHO), 142.5 
(=CCO2), 164.9 (C=O, lactam), 166.0 (CO2CH2), 171.6 (PhCH2C(O)) (*: signals may have interchanged). 
 
(1R, 3R), (1R, 3S), (1S, 3R), and (1S, 3S) N1-(5aR,6R)-3-[1-Methyl-2-propenyl]-1,7-dioxo-1,4,6,7-
tetrahydro-3H,5aH-azeto[2,1-b]furo[3,4-d][1,3]thiazin-6-yl-2-phenylacetamide (16) 
Aldehyde 2 (0.50 g; 0.975 mmol) was treated according to the general procedure (crotyl bromide) to 
give, after column chromatography (SiO2, ethyl acetate/heptane 2:1) and crystallization from 
heptane/ethyl acetate, lactones 16 (0.275 g; 73%) as an inseparable mixture consisting of 2 isomers 
(ratio 4:3). 
Major isomer 16 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.06 (d, J = 6.9 Hz, 3H, CH3), 2.55 (m, 1H, CHCH3), 3.35 and 
3.59 (qAB, JAB = 18.3 Hz, 2H, SCH2), 3.61 and 3.65 (qAB, JAB = 16.0 Hz, 2H, PhCH2), 4.92 (d, J = 5.0 Hz, 
1H, NHCHCHS), 4.96 (d, J = 5.1 Hz, 1H, OCHCHCH3), 5.14 (d, J = 17.3 Hz, 1H, CH=CHtHc), 5.21 (d, J 
= 10.0 Hz, 1H, CH=CHtHc), 5.69-5.80 (m, 1H, CH=CHtHc), 5.90 (dd, J = 5.0 Hz J = 8.9 Hz, 1H, 
NHCHCHS), 6.44 (d, J = 8.9 Hz, 1H, NH), 7.24-7.37 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) 
= 14.9 (CH3), 23.7 (SCH2), 41.3 (CHCH3), 43.2 (PhCH2), 57.7 (CHNH), 60.0 (CHS), 85.7 (OCHCHCH3), 
117.8 (=CH2), 125.5 (=CCHO), 127.7, 129.1, 129.5, and 137.1 (PhC), 139.7 (=CCO2), 163.8 (C=O, lactam), 
165.5 (CO2CH), 171.3 (PhCH2C(O)); IR (both isomers, KBr): ν 3385 (broad, NH), 1765 (broad, C=O, 
lactam and lactone), 1662, 1679 and 1505 (C=O, amide), 1423 (C-N), 1157 (C-O, lactone) cm-1; MS 
(FAB+, NOBA): m/z (%) = 407 (9) [M+Na]+, 385 (36), 210 (62), 176 (100), 154 (54), [NOBA+], 91 (58) 
[PhCH2+]; HRMS (FAB, m/z): calculated for C20H21O4N2S+: 385.1222 amu. Found: 385.1237 ± 0.0039 
amu. 
Minor isomer 16 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 1.16 (d, J = 6.9 Hz, 3H, CH3), 2.73 (m, 1H, CHCH3), 3.34 and 
3.54 (qAB, JAB = 18.3 Hz, 2H, SCH2), 3.61 and 3.65 (qAB, JAB = 16.0 Hz, 2H, PhCH2), 4.92 (d, J = 5.0 Hz, 
1H, NHCHCHS), 4.96 (d, J = 5.1 Hz, 1H, OCHCHCH3), 5.14 (d, J = 17.3 Hz, 1H, CH=CHtHc), 5.21 (d, J 
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= 10.0 Hz, 1H, CH=CHtHc), 5.53-5.65 (m, 1H, CH=CHtHc), 5.90 (dd, J = 5.0 Hz J = 8.9 Hz, 1H, 
NHCHCHS), 6.44 (d, J = 8.9 Hz, 1H, NH), 7.24-7.37 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) 
= 15.2 (CH3), 23.3 (SCH2), 40.0 (CHCH3), 43.2 (PhCH2), 57.5 (CHNH), 60.0 (CHS), 85.6 (OCHCHCH3), 
118.2 (=CH2), 125.4 (=CCHO), 127.7, 129.1, 129.5, and 137.1 (PhC), 139.9 (=CCO2), 163.8 (C=O, lactam), 
165.7 (CO2CH), 171.3 (PhCH2C(O)). 
 
(3R) and (3S) N1-[(5aR,6R)-3-(1,1-dimethylallyl)-1,7-dioxo-1,4,6,7-tetrahydro-3H,5aH-azeto[2,1-
b]furo[3,4-d][1,3]thiazin-6-yl]-2-phenylacetamide (17)  
Aldehyde 2 (1.025 g; 2.0 mmol) was treated according to the general procedure (prenyl bromide) to 
give, after column chromatography (SiO2, ethyl acetate/heptane 2:1), lactones 17 (0.606 g; 87%) as a 
70:30 mixture of 2 diastereomers. Analytical samples were obtained by crystallization from ethyl 
acetate / heptane: white solid (fast-moving isomer) and transparent cubic crystals (slow-moving 
isomer).  
Fast-moving major isomer (3R)-17  
Mp 222-224°C (dec.); [α]D = +84.0° (c = 0.53; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 0.97 (s, 
3H, CH3), 1.20 (s, 3H, CH3), 3.31 and 3.52 (qAB, JAB = 18.3 Hz, 2H, SCH2), 3.59 (s, 2H, PhCH2), 4.80 (s, 
1H, CHOC), 4.92 (d, J = 5.0 Hz, 1H, NHCHCHS), 5.16 (d, J = 17.3 Hz, 1H, CH=CHtHc), 5.17 (d, J = 10.7 
Hz, 1H, CH=CHtHc), 5.80 (dd, J = 17.3 Hz J = 10.7 Hz, 1H, CH=CHtHc), 5.87 (dd, J = 5.0 Hz J = 8.8 Hz, 
1H, NHCHCHS), 6.90 (d, J = 8.8 Hz, 1H, NH), 7.23-7.34 (m, 5H, PhH); 13C-NMR (75 MHz, CDCl3) δ 
(ppm) = 19.8 (CH3), 25.0 (CH3)*, 25.1 (SCH2)*, 41.3 (C(CH3)2), 42.9 (PhCH2), 57.7 (CHNH), 59.9 (CHS), 
88.9 (OCHC(CH3)2), 115.5 (=CH2), 125.6 (=CCHO), 127.4, 128.9, 129.4, and 134.0 (PhC), 139.5 (=CCO2), 
141.4 (CH=CH2), 163.8 (C=O, lactam), 166.0 (CO2CH), 171.5 (PhCH2C(O)) (*: signals may have 
interchanged). 
Slow-moving minor isomer (3S)-17 
Mp 207-209°C (dec.); [α]D = +144.6° (c = 0.18; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 0.94 (s, 
3H, CH3), 1.28 (s, 3H, CH3), 3.52 and 3.75 (qAB, JAB = 18.3 Hz J < 1.5 Hz, 2H, SCH2), 3.63 and 3.67 
(qAB, JAB = 16.1 Hz, 2H, PhCH2), 4.86 (s, 1H, CHOC), 4.95 (d, J = 5.0 Hz, 1H, NHCHCHS), 5.24 (d, J = 
17.5 Hz, 1H, CH=CHtHc), 5.28 (d, J = 10.7 Hz, 1H, CH=CHtHc), 5.91 (dd, J = 17.5 Hz J = 10.7 Hz, 1H, 
CH=CHtHc), 5.97 (dd, J = 5.0 Hz J = 8.8 Hz, 1H, NHCHCHS), 6.20 (d, J = 8.8 Hz, 1H, NH), 7.30-7.41 (m, 
5H, PhH); 13C-NMR (75 MHz, CDCl3) δ (ppm) = 18.8 (CH3), 23.9 (CH3)*, 27.2 (SCH2)*, 41.3 (C(CH3)2), 
43.3 (PhCH2), 57.0 (CHNH), 60.3 (CHS), 87.8 (OCHC(CH3)2), 115.5 (=CH2), 128.5 (=CCHO), 127.8, 
129.2, 129.5, and 133.5 (PhC), 140.8 (=CCO2), 142.8 (CH=CH2), 163.7 (C=O, lactam), 166.0 (CO2CH), 
171.2 (PhCH2C(O)) (*: signals may have interchanged); IR (KBr): ν 3248 (broad, NH), 1770 (C=O 
(broad), lactam and ester), 1654 and 1554 (C=O, amide), 1415 (C-N) cm-1; MS (CI+): m/z (%) = 399 (17) 
[M+H]+, 367 (15), 224 (38), 176 (45), 136 (37), 91 (100) [PhCH2+]; HRMS (CI+, m/z): calculated for 
C21H22O4N2S [M+]: 398.1300 amu. Found: 398.13026 ± 0.00119 amu. 
 
N1-(3S,5aR,6R)-1,7-Dioxo-3-[(1S)-1-phenyl-2-propenyl]-1,4,6,7-tetrahydro-3H,5aH-azeto[2,1-
b]furo[3,4-d][1,3]thiazin-6-yl-2-phenylacetamide (18) 
Aldehyde 2 (1.025 g; 2.0 mmol) was treated according to the general procedure (cinnamyl bromide) 
yielding, after column chromatography (SiO2, ethyl acetate/ heptane 2:1) and crystallization from 
ethyl acetate / heptane, lactone 18 (0.631 g; 70%) as colorless plates. 
Mp 101-103°C (dec.); [α]D = +200.7° (c = 0.28; acetone); 1H-NMR (300 MHz, CDCl3) δ (ppm) = 3.00 and 
3.44 (qAB, JAB = 18.4 Hz 5J <1.5 Hz, 2H, SCH2), 3.60 (m, 1H, PhCHCH=), 3.63 and 3.65 (qAB, JAB = 14.5 
Hz, 2H, PhCH2), 4.93 (d, J = 5.0 Hz, 1H, NHCHCHS), 5.07 (d, J = 17.1 Hz, 1H, CH=CHtHc), 5.20 (d, J = 
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10.3 Hz, 1H, CH=CHtHc), 5.29 (d, J = 4.5 Hz, 1H, OCHCHPh), 5.92 (dd, J = 5.0 Hz J = 8.7 Hz, 1H, 
NHCHCHS), 5.90-6.00 (m, 1H, CH=CHtHc), 6.11 (d, J = 8.7 Hz, 1H, NH), 7.29-7.41 (m, 10H, PhH); 13C-
NMR (75 MHz, CDCl3) δ (ppm) = 23.0 (SCH2), 43.3 (PhCH2), 52.4 (CHPh), 57.3 (CHNH), 60.2 (CHS), 
84.3 (OCHCHPh), 119.2 (=CH2), 126.1 (=CCHO), 127.8, 128.0, 128.3, 129.2, 129.3, 129.5, 133.5 134.3, 
138.3 and 140.2 (PhC, CHPhCH=CH2, =CCO2CH), 163.7 (C=O, lactam), 165.5 (CO2CH), 171.0 
(PhCH2C(O)); IR (KBr): ν 3260 (broad, NH), 1795 (broad, C=O, lactam and lactone), 1670 and 1525 
(C=O, amide), 1454 (C-N) cm-1; MS (CI+): m/z (%) = 447 (78) [M+], 415 (71), 272 (100), 176 (76), 117 (44), 
91 (45) [PhCH2+]; HRMS (CI+, m/z): calculated for C25H22O4N2S: 446.13000 amu. Found: 446.13066 ± 
0.00133 amu. 
 
Dehydration experiment with allyl alcohol 9 
To a solution of allyl alcohol 9 (0.10 g; 0.22 mmol) in chloroform (5 ml) Martin's dehydrating agent 
(0.142 g; 0.25 mmol) was added at -50°C and under a nitrogen atmosphere. The reaction was 
monitored by TLC analysis (ethyl acetate / heptane 1:1). After completion, the reaction mixture was 
concentrated to dryness under reduced pressure and the resulting residue was purified by column 
chromatography (SiO2, ethyl acetate/heptane 1:1), to afford 19 (0.044 g; 46%). 1H-NMR showed 19 as 
a mixture of E- and Z-isomers, together with starting material 9. 
 
Metathesis with allyl lactone 14 employing Grubb's catalyst 
Allyl lactone 14 (0.050 g; 0.13 mmol) was subjected to a metathesis reaction with allylacetate (0.1 ml) 
and Grubb's catalyst 20 (22.1 mg) in dichloroethane (5 ml) at room temperature. After 24h, the 
reaction mixture was concentrated in vacuo. The residue was purified by column chromatography 
(SiO2, ethyl acetate/heptane 2:1), to afford 26 (8.0 mg; 13%) as an inseparable mixture of E- and Z-
isomers (1H-NMR analysis), indicated by the presence of olefinic protons (multiplets between 4.8 and 
5.8 ppm). 
 
 
7.6 Crystal structure data 
 
(3R) N1-[(5aR,6R)-3-Allyl-1,7-dioxo-1,4,6,7-tetrahydro-3H,5aH-azeto[2,1-b]furo[3,4-d][1,3]thiazin-6- 
yl]-2-phenylacetamide (14) 
Crystals of 14 (slow-moving diastereomer) suitable for X-ray diffraction studies were obtained from 
heptane-ethyl acetate by diffusion. A single crystal was mounted in air on a glass fibre. Intensity data 
were collected at room temperature. An Enraf-Nonius CAD4 single-crystal diffractometer was used, 
Mo-Kα radiation, θ-2θ  scan mode. Unit cell dimensions were determined from the angular setting of 
25 reflections. Intensity data were corrected for Lorentz and polarization effects. Semi-empirical 
absorption correction (ψ-scans) was applied.[21] The structure was solved by the program system 
DIRDIF[22] using the program PATTY[23] to locate the sulfur atom and was refined with standard 
methods (refinement against F2 of all reflections with SHELXL97[24] with anisotropic parameters for 
the non-hydrogen atoms. All hydrogens, excepted the hydrogen attached to C(16), were initially 
placed at calculated positions and were freely refined subsequently. The hydrogen attached to C(16) 
was refined riding on the parent atom. A structure determination summary, a list of atom 
coordinates, a list of bond lengths and angles, a list of hydrogen coordinates, and a list of anisotropic 
displacement parameters are given in Table 4. 
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A PLUTON drawing[25] is shown in Figure 4.  
 
Table 4: Crystal data and structure refinement for compound 14 (slow-moving diastereomer) 
Crystal color transparent colorless 
Crystal shape regular 
Size [mm] 0.53 x 0.29 x 0.21 mm 
Empirical formula C19H18N2O4S 
Molecular weight 370.41  g.mol-1 
Temperature 293(2) K 
Radiation / wavelength MoKα (graphite mon.) / 0.71073 Å 
Crystal system Orthorhombic 
Space group P212121 
Unit cell dimensions a = 9.6929(8) Å  α = 90° 
(25 reflections, 18.431 < θ < 21.309) b =  11.8524(12) Å β = 90° 
 c = 15.5755(11) Å γ = 90° 
Volume 1789.4(3) Å3 
Z 4 
Calculated density 1.375 Mg.m-3 
Absorption coefficient 0.208 mm-1 
Diffractometer / scan Enraf-Nonius CAD4 / θ-2θ 
F(000) 776 
θ-range for data collection 2.62 - 27.48° 
Index ranges 0 ≤ h ≤ 12, 0 ≤ k ≤ 15, 0 ≤ l ≤ 20 
Reflections collected / unique 2337 / 2337  
Reflections observed 1830 ([Io > 2σ (Io)]) 
Absorption correction Semi-empirical from ψ-scans 
Range of rel. transm. factors 1.039 and 0.964 
Refinement method Full-matrix least-squares on F2 
Computing SHELXL-97 (Sheldrick, 1997)  
Data / restraints / parameters 2337 / 0 / 303 
Goodness-of-fit on F2 1.054 
SHELXL-97 weight parameters 0.091800    0.252700 
Final R indices [I > 2σ(I)] R1 = 0.0517, wR2 = 0.1303 
R indices (all data) R1 = 0.0703, wR2 = 0.1436 
Largest difference peak and hole 0.483 and -0.325 e.Å-3 
 
 
 
(3S) N1-[(5aR,6R)-3-(1,1-dimethylallyl)-1,7-dioxo-1,4,6,7-tetrahydro-3H,5aH-azeto[2,1-b]furo[3,4- 
d][1,3]thiazin-6-yl]-2-phenylacetamide (17) 
Crystals of 17 (slow-moving diastereomer) suitable for X-ray diffraction studies were obtained from 
heptane-ethyl acetate. A single crystal was mounted in air on a glass fibre. Intensity data were 
collected at room temperature. An Enraf-Nonius CAD4 single-crystal diffractometer was used, Mo-
Kα radiation, Ω-scan mode. Unit cell dimensions were determined from the angular setting of 25 
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reflections. Intensity data were corrected for Lorentz and polarization effects. Semi-empirical 
absorption correction (ψ-scans)[21] was applied. The structure was solved by the program system 
DIRDIF[22] using the program PATTY[23] to locate the sulfur atom, and was refined with standard 
methods (refinement against F2 of all reflections with SHELXL97[24] with anisotropic parameters for 
the non-hydrogen atoms. All hydrogens were placed at calculated positions and were refined riding 
on the parent atoms. A structure determination summary, a list of atom coordinates, a list of 
bond lengths and angles, a list of hydrogen coordinates and a list of anisotropic displacement 
parameters are given in Table 5.  
A PLUTON drawing[25] is shown in Figure 4. 
 
Table 5: Crystal data and structure refinement for compound 17 (slow-moving diastereomer) 
Crystal color transparent colorless 
Crystal shape regular 
Size [mm] 0.31 x 0.22 x 0.18 mm 
Empirical formula C21H22N2O4S 
Molecular weight 398.47  g.mol-1 
Temperature 293(2) K 
Radiation / wavelength MoKα (graphite mon.) / 0.71073 Å 
Crystal system Orthorhombic 
Space group P212121 
Unit cell dimensions a = 9.1629(13) Å  α = 90° 
(25 reflections, 18.431 < θ < 21.309) b =  12.237(3) Å β = 90° 
 c = 18.108(3) Å γ = 90° 
Volume 2030.4(6) Å3 
Z 4 
Calculated density 1.304 Mg.m-3 
Absorption coefficient 0.188 mm-1 
Diffractometer / scan Enraf-Nonius CAD4 / Ω 
F(000) 840 
θ-range for data collection 3.00 - 27.49° 
Index ranges 0 ≤ h ≤ 11, -15 ≤ k ≤ 0, -23 ≤ l ≤ 0 
Reflections collected / unique 2630 / 2630 
Reflections observed 1207 ([Io > 2σ (Io)]) 
Absorption correction Semi-empirical from ψ-scans 
Range of rel. transm. factors 1.005 and 0.991 
Refinement method Full-matrix least-squares on F2 
Computing SHELXL-97 (Sheldrick, 1997)  
Data / restraints / parameters 2260 / 0 / 255 
Goodness-of-fit on F2 1.084 
SHELXL-97 weight parameters 0.038000    0.942500 
Final R indices [I > 2σ(I)] R1 = 0.0724, wR2 = 0.1119 
R indices (all data) R1 = 0.1865, wR2 = 0.1425 
Largest difference peak and hole 0.281 and -0.240 e.Å-3 
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SUMMARY 
 
The history of the life-saving β-lactam antibiotics started with the serendipitous 
discovery of penicillin G (1) by Alexander Fleming in 1928 (Figure 1). Important 
other milestones are the completion of the total synthesis of penicillin V (2) in 1957, 
and the discovery of the cephalosporins, e.g. cephalosporin C (3), a new family of β-
lactam antibiotics with a broad-spectrum activity. This new class of β-lactams 
opened a new field of research aimed at the search for and exploration of more 
active anti-bacterial compounds. As a result, numerous new penicillins and 
cephalosporins were developed, of which several have successively been brought 
onto the market. 
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Figure 1. 
 
Despite these successes, the worldwide incidence of antibiotic resistance among 
certain bacteria has increased. Therefore, much interest is still focused on the 
development of novel cephalosporin antibiotics in order to improve anti-bacterial 
activity against resistant bacterial strains. In this respect, the development of new 
synthetic methodologies and new reactions in the field of penicillin and 
cephalosporin chemistry is of extreme importance. This thesis deals with the 
syntheses of new β-lactam antibiotics from 3-formylcephalosporins as the key-
intermediates (Figure 2). The research is mainly focused on the development of new 
synthetic methodologies and reactions for chemical transformations in 
cephalosporins. In view of the fact that 3-formylcephalosporins may become 
available from fermentation processes in the future, the chemistry concerning these 
3-formyl derivatives falls well in the objectives of the cluster project "fine chemistry", 
which aims at clean, (bio)catalytic, efficient routes for β-lactam antibiotics.  
 
In Chapter 1, relevant background information of the research is given. Attention is 
paid to the history of the β-lactam antibiotics, the mode of action of these anti-
bacterial compounds, and the problem of increasing resistance of bacteria toward β-
lactam antibiotics. 
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An overview of relevant literature of 3-formylcephalosporins is presented in 
Chapter 2. In this review, various aspects of the chemistry of 3-
formylcephalosporins, the key-intermediates in this thesis, are covered. First, all 
reported syntheses of 3-formylcephalosporins are briefly summarized. The second 
part deals with applications and reactions of 3-formylcephalosporins. In this respect, 
the chemical behavior of the 3-formylgroup has been given special attention (Figure 
2).  
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Figure 2. 
 
The development of a new and generally applicable synthetic methodology for the 
preparation of 3-formylcephalosporins from cheap and readily available starting 
materials, is described in Chapter 3. Starting from the phenylacetyl protected 7-
aminodesacetylcephalosporanic acid, (7-phenylacetyl-ADCA) 4, 7-amino-
cephalosporanic acid (7-ACA) (5), and cephalolactone 6, 3-formylcephalosporins 7-9 
are synthesized in high overall yields (Scheme 1). Important aspects are the choice of 
the protecting groups, the chemical behavior in connection with the position of the 
double bond in the six-membered heteroatom ring, and the oxidation state of the 
sulfur atom.  
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Scheme 1. 
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Although 7-phenylacetyl-ADCA 4 and cephalolactone 6 are suitable as starting 
material, the overall synthetic efficiency of the routes to 3-formylcephalosporins 
starting from these two compounds is inferior to that using 7-ACA (5). 
 
In Chapter 4, a study towards the synthesis of 3-norcephalosporins is presented 
(Scheme 2).  
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Scheme 2. 
 
Non-radical as well as radical approaches to accomplish a (halo)-decarboxylation 
reaction on the model compound 7-phenylacetyl-ADCA 4 are described. Using 
Barton’s radical decarboxylation reaction, a variety of 4-functionalized 
cephalosporins 11 has been synthesized via Barton ester 10 (Scheme 3). Moderate to 
good yields were obtained for the conversion of the carboxyl function into a 
hydrogen, chlorine, bromine or iodine substituent, as well as for the introduction of 
selenium- and sulfur-containing groups at the 4-position.   
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Scheme 3. 
 
A new and improved method for the preparation of 3-carboxycephalosporins 12-14 
from 3-formylcephalosporins has been developed (Chapter 5). These compounds 
can be used for further synthetic elaboration at C3. As an example, 3-
carboxycephalosporin 12-14 have been used as key-intermediates for a new 
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synthesis of 3-norcephalosporins 16 using the Barton radical decarboxylation 
reaction. A remarkable difference was encountered in the reactivity and stability of 
the ∆2- and ∆3-isomers. Several non-carbon substituents (chloride, bromide, iodide, 
and hydrogen) were introduced at C3 in modest to good yields via Barton ester 15 
(Scheme 4). The (halo)-decarboxylation reactions represent for the first time the use 
of radical chemistry in the synthesis of 3-norcephalosporins. 
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Scheme 4. 
 
In Chapter 6, some Wittig olefination reactions of 3-formylcephalosporins 8 and 17 
are described. Moderate yields of the corresponding alkenyl products 18 were 
obtained with phosphorous ylides stabilized by conjugation, viz. for ester and cyano 
substituted ylides. The direct olefination of 3-hydroxymethylcephalosporins 19 and 
20, employing an oxidative Wittig process, was accomplished with the same type of 
ylides, again in reasonable yields (Scheme 5). 
 
Disappointingly, the olefination of 3-formylcephalosporins with non-stabilized 
ylides was not met with success, only decomposition of the cephalosporin nucleus 
was observed. Alternative routes to 3-alkenylcephalosporins also failed to give the 
desired products. 
 
Summary 
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Scheme 5. 
 
The allylation and propargylation of 3-formylcephalosporins 8 and 17 under zinc-
mediated Barbier conditions are described in Chapter 7. The corresponding 
homoallylic and homopropargylic alcohols 21-24 were produced in good yields and 
with good to excellent diastereoselectivity (Scheme 6). Preliminary synthetic studies 
directed to cephalothin and cefprozil analogues conclude this chapter.  
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In summary, this thesis describes the synthesis and exploration of 3-
formylcephalosporins. Novel chemistry of 3-formylcephalosporins is highlighted by 
their use in a new convenient synthesis of 3-carboxycephalosporins, key-
intermediates for the preparation of 3-norcephalosporins, and their use in a highly 
diastereoselective zinc-mediated Barbier-type allylation and propargylation reaction. 
The Barton radical decarboxylation reaction was successfully used for the synthesis 
of various 3- and 4-norcephalosporins. A summary in English and Dutch concludes 
this thesis. 
149 
SAMENVATTING 
 
De geschiedenis van de levensreddende β-lactam antibiotica begon in 1928 door de 
toevallige ontdekking van penicilline G (1) door Alexander Fleming (Figuur 1). 
Enkele belangrijke andere mijlpalen in deze geschiedenis zijn de voltooiing van de 
totaalsynthese van penicilline V (2) in 1957, de ontdekking van de cefalosporines, 
een nieuwe familie van antibiotica met een breed spectrum activiteit, geïnitieerd 
door de vondst van cefalosporine C (3). Deze nieuwe klasse van β-lactam antibiotica 
opende een geheel nieuw onderzoeksgebied, met als doel het zoeken naar en 
bestuderen van actievere antibacteriële verbindingen. Het gevolg  hiervan was, dat 
talrijke nieuwe penicilline en cefalosporines werden ontwikkeld, waarvan vele met 
succes op de markt gebracht zijn. 
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Ondanks deze successen is het aantal incidenten met betrekking tot de resistentie 
van bepaalde bacteriën voor antibiotica fors toegenomen. Daarom gaat 
tegenwoordig nog steeds veel aandacht uit naar de ontwikkeling van nieuwe 
cefalosporine antibiotica met verbeterde antibacteriële werking tegen resistente 
bacteriestammen. In deze context is de ontwikkeling van nieuwe 
synthesemethodieken en reacties buitengewoon belangrijk. Dit proefschrift handelt 
over de syntheses van nieuwe β-lactam antibiotica uit 3-formylcefalosporines als 
belangrijke intermediairen (Figuur 2). Het onderzoek is vooral toegespitst op de 
ontwikkeling van nieuwe synthesemethodieken en reacties om chemische 
omzettingen te bewerkstelligen in cefalosporine moleculen. Met in het achterhoofd 
dat 3-formylcefalosporines in de toekomst mogelijk beschikbaar komen uit 
fermentatieprocessen, past de ontwikkeling van nieuwe chemie rond deze 3-formyl 
derivaten uitstekend in het clusterproject "fijn chemie", dat zich tot doel stelt 
efficiënte schone (bio)katalytische routes voor β-lactam antibiotica te ontwikkelen. 
 
In Hoofdstuk 1 wordt relevante achtergrondinformatie gegeven over het onderzoek. 
Er wordt vooral aandacht besteed aan de ontstaansgeschiedenis van de β-lactam 
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antibiotica, het werkingsmechanisme van deze antibacteriële verbindingen en het 
probleem van de toenemende resistentie van bepaalde bacteriën voor β-lactam 
antibiotica. 
 
Een overzicht van relevante literatuur over 3-formylcephalosporines wordt 
behandeld in Hoofdstuk 2. In dit overzicht komen verschillende aspecten van de 
chemie van 3-formylcefalosporines, de belangrijke intermediairen in dit proefschrift, 
aan bod. Allereerst worden alle gerapporteerde syntheses van 3-formyl-
cefalosporines in het kort samengevat. Het tweede deel handelt over de 
toepassingen en reacties van 3-formylcefalosporines. In dit kader wordt speciaal 
aandacht geschonken aan het chemische gedrag van de 3-formylgroep (Figuur 2). 
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Figuur 2. 
 
De ontwikkeling van een nieuwe algemeen toepasbare synthesemethodiek voor de 
bereiding van 3-formylcefalosporines uit goedkope en eenvoudig verkrijgbare 
grondstoffen wordt beschreven in Hoofdstuk 3.  
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Uitgaande van fenylacetyl beschermd 7-aminodesacetylcefalosporaanzuur, (7-
fenylacetyl-ADCA) 4, 7-amino-cefalosporaanzuur (7-ACA) (5) en cefalolacton 6, 
werden 3-formylcefalosporines 7-9 gesynthetiseerd in hoge opbrengsten (Schema 1). 
De keuze van de beschermgroepen, het chemische gedrag in relatie met de positie 
van de dubbele binding in de zesring, alsmede de oxidatietoestand van het zwavel 
atoom zijn hierin belangrijke aspecten. Hoewel 7-fenylacetyl-ADCA 4 en 
cefalolacton 6 bruikbaar zijn als uitgangsstoffen, is de efficiëntie van de routes voor 
3-formylcefalosporines uitgaande van deze twee verbindingen inferieur aan de route 
die gebruikmaakt van 7-ACA (5). 
 
In Hoofdstuk 4 wordt een studie naar de synthese van 3-norcefalosporines 
beschreven (Schema 2). 
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Er worden zowel ionogene als radicalaire benaderingen behandeld om een (halo)-
decarboxylering in de modelverbinding 7-fenylacetyl-ADCA 4 te bewerkstelligen. 
Door gebruik te maken van de radicalaire decarboxylatie reactie van Barton, werd 
een verscheidenheid aan 4-gefunctionaliseerde cefalosporines 11 gesynthetiseerd via 
Barton ester 10 (Schema 3).  
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In de omzettingsreactie van de carboxylfunctie in een waterstof-, chloor-, broom- of 
jood-substituent, alsmede voor de introductie van selenium- en zwavelbevattende 
groepen op de 4-positie werden matige tot goede opbrengsten verkregen.   
 
Een nieuwe verbeterde methode voor de bereiding van 3-carboxycefalosporines 12-
14 uit 3-formylcefalosporines werd ontwikkeld (Hoofdstuk 5). Deze verbindingen 
kunnen gebruikt worden voor verder functionalisering op de C3 positie. De 3-
carboxycefalosporines 12-14 kunnen worden gebruikt als belangrijke intermediairen 
voor de ontwikkeling van een nieuwe syntheseroute voor 3-norcefalosporines 16, 
door gebruik te maken van de Barton radicalaire decarboxyleringsreactie. In deze 
reactie was een opvallend verschil waar te nemen in de reactiviteit en stabiliteit 
tussen de ∆2- en ∆3-isomeren. Verschillende niet-koolstofsubstituenten (chloor, 
broom, jood en waterstof) werden geïntroduceerd op de C3-positie in matige tot 
goede opbrengsten via Barton ester 15 (Schema 4). De (halo)-
decarboxyleringsreacties laten voor het eerst het gebruik zien van radicaalchemie 
voor de synthese van 3-norcefalosporines.  
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In Hoofdstuk 6 worden enkele Wittig olefineringsreacties van 3-
formylcefalosporines 8 en 17 beschreven. Met door conjugatie gestabiliseerde 
fosforylides werden in redelijke opbrengsten de overeenkomstige alkenylproducten 
18 verkregen. Door een oxidatieve Wittig procedure toe te passen, gebruikmakend 
Samenvatting 
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van hetzelfde type ylides, konden 3-hydroxymethylcefalosporines 19 en 20 direct 
worden omgezet in de overeenkomstige alkenyl producten 18 in redelijke 
opbrengsten (Schema 5). 
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Schema 5. 
 
De olefinering van 3-formylcefalosporines met niet-gestabiliseerde ylides was helaas 
geen succes. Er werd slechts ontleding van de cefalosporine-kern waargenomen. 
Alternatieve routes naar 3-alkenylcefalosporines leverden ook niet de gewenste 
resultaten op. 
 
De reacties van 3-formylcefalosporines 8 en 17 met (gesubstitueerde) allylbromides 
en propargylbromide onder Barbier condities worden beschreven in Hoofdstuk 7. 
De overeenkomstige homoallyl- en homopropargyl-alcoholen 21-24 werden 
gevormd in goede opbrengsten en met een goede tot excellente diastereoselectiviteit 
(Schema 6). Een eerste aanzet voor de synthese van cefalothin en cefprozil analoga 
besluit dit hoofdstuk.  
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Schema 6. 
 
Samenvattend kan worden gesteld, dat het onderzoek beschreven in dit proefschrift 
nieuwe chemie omtrent 3-formylcefalosporines heeft opgeleverd. Deze nieuwe 
chemie komt naar voren bij het gebruik van 3-formylcefalosporines in een nieuwe 
efficiënte synthese van 3-carboxycefalosporines, belangrijke intermediairen  in de 
bereiding van 3-norcefalosporines, en bij het gebruik van 3-formylcefalosporines in 
de diastereoselectieve Barbiertype organozink allylerings- en propargyleringsreactie. 
De Barton radicalaire decarboxyleringsreactie werd met succes toegepast in de 
synthese van verschillende 3- en 4-norcefalosporines.  
 
Samenvattingen in het Engels en Nederlands besluiten dit proefschrift. 
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